

# Saxagliptin and Cardiovascular Outcomes in Patients w

New England Journal of Medicine

369, 1317-1326

DOI: 10.1056/nejmoa1307684

Citation Report

#	ARTICLE	IF	CITATIONS
2	Hyaline Cartilage Tissue Is Formed through the Co-culture of Passaged Human Chondrocytes and Primary Bovine Chondrocytes. Journal of Histochemistry and Cytochemistry, 2012, 60, 576-587.	2.5	10
4	The Cardiovascular Safety of Diabetes Drugs “ Insights from the Rosiglitazone Experience. New England Journal of Medicine, 2013, 369, 1285-1287.	27.0	163
5	Resumen de estudios clínicos presentados en el Congreso de 2013 de la Sociedad Europea de Cardiología (31 de agosto-4 de septiembre de 2013, Ámsterdam, Países Bajos). Revista Española De Cardiología, 2013, 66, 879.e1-879.e9.	1.2	9
6	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2013 (31 Tj ETQq1 1 0.784314 rgBT /Overlo 0.6 0	0.6	0
7	The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice, 2013, 19, 1050-1061.	2.1	29
8	Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA - Journal of the American Medical Association, 2013, 310, 2510-22.	7.4	513
9	The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups. Advances in Therapy, 2013, 30, 1067-1085.	2.9	10
10	Cardiovascular safety of 'gliptin' therapy. Nature Reviews Cardiology, 2013, 10, 616-616.	13.7	0
11	Dipeptyl peptidase “ 4 inhibitors in type 2 diabetes: Cardiovascular risk reduction?. Geriatric Nursing, 2013, 34, 498-499.	1.9	0
12	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 143.	6.8	24
13	The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovascular Diabetology, 2013, 12, 130.	6.8	36
14	Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetologica, 2013, 51, 491-7.	2.5	55
15	Diabetes Treatment: Recent Developments. Advances in Therapy, 2013, 30, 1031-1032.	2.9	1
16	Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy, 2013, 4, 221-238.	2.5	13
18	DTB Select: 11   November 2013. Drug and Therapeutics Bulletin, 2013, 51, 122.2-125.	0.3	0
19	How safe are DPP“4 inhibitors?. Practical Diabetes, 2013, 30, 352.	0.3	2
21	Gliptins neither benefit nor harm T2DM cardiovascular outcomes. Reactions Weekly, 2013, 1471, 4-4.	0.0	0
22	New oral hypoglycaemics fail to show cardiovascular benefits. BMJ, The, 2013, 347, f5458-f5458.	6.0	2

#	ARTICLE	IF	CITATIONS
23	ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes, 2013, 30, 388-391.	0.3	1
24	Use of Non-Insulin Therapies for Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 901-908.	4.4	11
25	CHALLENGES TO ADVANCING THE EVIDENCE BASE FOR NEPHROLOGY: THE TIME IS RIGHT FOR COLLABORATION. Journal of Renal Care, 2013, 39, 191-193.	1.2	0
26	The potential risks of pancreatitis and pancreatic cancer with GLP-1 based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine, 2013, 30, 1148-1155.	2.3	32
27	Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus. Nature Reviews Endocrinology, 2013, 9, 625-625.	9.6	0
28	Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects. Diabetes Technology and Therapeutics, 2013, 15, 909-913.	4.4	3
30	Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones, 2013, 12, 483-494.	1.9	15
31	Research roundup: October 2013. NursePrescribing, 2013, 11, 478-478.	0.1	0
32	Dipeptidyl peptidase-4 inhibitors and cardiovascular safety. Medical Journal of Australia, 2014, 200, 450-451.	1.7	3
33	The durability of sitagliptin in elderly patients with type 2 diabetes. Clinical Interventions in Aging, 2014, 9, 1905.	2.9	11
34	Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Therapeutics and Clinical Risk Management, 2014, 10, 547.	2.0	7
35	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 169.	2.4	135
36	DPP4 Deficiency Preserved Cardiac Function in Abdominal Aortic Banding Rats. PLoS ONE, 2014, 9, e85634.	2.5	17
37	The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors. BioMed Research International, 2014, 2014, 1-10.	1.9	54
38	Treating the elderly diabetic patient: special considerations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 391.	2.4	10
39	Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 15.	2.4	42
40	Tubulointerstitial disease in diabetic nephropathy. International Journal of Nephrology and Renovascular Disease, 2014, 7, 107.	1.8	44
41	The Treatment of Type 2 Diabetes. Deutsches Arzteblatt International, 2014, 111, 69-81; quiz 82.	0.9	77

#	ARTICLE	IF	CITATIONS
42	Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged &ge;65) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	17
43	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. Journal of Diabetes & Metabolism, 2014, 05, .	0.2	2
44	Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance. Endocrinology and Metabolism, 2014, 29, 536.	3.0	19
45	Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin. Patient Preference and Adherence, 2014, 8, 473.	1.8	1
46	Antidiabetic treatment, stroke severity and outcome. World Journal of Diabetes, 2014, 5, 84.	3.5	22
47	Advances in managing type 2 diabetes: challenging old paradigms and developing new ones. F1000prime Reports, 2014, 6, 42.	5.9	9
49	Gut hormones and Type 2 diabetes mellitus. Diabetes Management, 2014, 4, 501-513.	0.5	2
50	Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone, 2014, 68, 124-130.	2.9	61
51	The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes. Diabetes Spectrum, 2014, 27, 75-77.	1.0	3
52	Bariatric Surgery versus Intensive Medical Therapy for Diabetes. New England Journal of Medicine, 2014, 371, 680-682.	27.0	63
54	Canagliflozin â€“ something new for type 2 diabetes, but is it safe and efficacious?. Expert Opinion on Pharmacotherapy, 2014, 15, 437-441.	1.8	7
55	The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 787-812.	3.3	59
56	Insulin, Other Hypoglycaemic Drugs, and Glucagon. Side Effects of Drugs Annual, 2014, 36, 645-657.	0.6	0
57	Diabetes, impaired fasting glucose, and heart failure: Its not all about the sugar. European Journal of Heart Failure, 2014, 16, 1153-1156.	7.1	18
58	Insulin for the uninitiated. Clinical Medicine, 2014, 14, 623-629.	1.9	4
59	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. European Journal of Clinical Pharmacology, 2014, 70, 1277-1289.	1.9	6
60	Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovascular Diabetology, 2014, 13, 142.	6.8	94
62	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetologica, 2014, 51, 1015-1023.	2.5	35

#	ARTICLE	IF	CITATIONS
63	DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovascular Diabetology, 2014, 13, 157.	6.8	47
64	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovascular Disorders, 2014, 14, 129.	1.7	62
65	Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study. Diabetology and Metabolic Syndrome, 2014, 6, 103.	2.7	21
66	Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2014, 9, 547-559.	2.4	1
68	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	8.6	141
69	Drug-eluting stent outcomes in diabetes. Expert Review of Cardiovascular Therapy, 2014, 12, 95-109.	1.5	10
70	Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial?. Hospital Pharmacy, 2014, 49, 697-701.	1.0	0
71	Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997-2012. Diabetes Care, 2014, 37, 985-992.	8.6	119
72	Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ, The, 2014, 348, g2780-g2780.	6.0	65
73	Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?. International Journal of Molecular Sciences, 2014, 15, 18381-18406.	4.1	136
74	Evidence Based Medicine; are we on the same page?. Bangladesh Journal of Medical Science, 2014, 13, 110-113.	0.2	2
75	A protocol for a randomised, double-blind, placebo-controlled study of the effect of Liraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq1 1 0.784314 rg81 /Over	0.2	0
81	Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open, 2014, 4, e005752.	1.9	31
82	Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. Postgraduate Medicine, 2014, 126, 161-171.	2.0	2
83	European Society of Cardiology Congress 2013 highlights. Future Cardiology, 2014, 10, 23-26.	1.2	0
84	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1346-1353.	2.6	39
87	Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?. Clinical Therapeutics, 2014, 36, 2072-2079.	2.5	47
88	Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectrum, 2014, 27, 180-188.	1.0	32

#	ARTICLE	IF	CITATIONS
89	Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H477-H492.	3.2	92
90	Early therapy for type 2 diabetes in China. Lancet Diabetes and Endocrinology,the, 2014, 2, 992-1002.	11.4	54
91	Incretin-mimetic therapies and pancreatic disease: a review of observational data. Current Medical Research and Opinion, 2014, 30, 2471-2481.	1.9	16
92	New insights into insulin action and resistance in the vasculature. Annals of the New York Academy of Sciences, 2014, 1311, 138-150.	3.8	100
94	GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe. American Journal of Kidney Diseases, 2014, 64, 838-840.	1.9	12
95	Heart failure and dipeptidyl peptidaseâ€4 inhibitors. European Journal of Heart Failure, 2014, 16, 603-607.	7.1	23
96	Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2014, 30, 556-569.	4.0	48
97	Saxagliptin, Alogliptin, and Cardiovascular Outcomes. New England Journal of Medicine, 2014, 370, 483-484.	27.0	25
98	Combination therapy with metformin plus sulphonylureas versus metformin plus <sc>DPP</sc>â€4 inhibitors: association with major adverse cardiovascular events and allâ€cause mortality. Diabetes, Obesity and Metabolism, 2014, 16, 977-983.	4.4	62
99	Journal of Diabetes <sc>NEWS</sc>. Journal of Diabetes, 2014, 6, 96-99.	1.8	0
100	Cardiovascular safety trials: Be careful what you wish for (â¿fè¡€ç®¡â®%ã...~æ€Œç”ç©ŒŒ1/4šâ1/2“â¿fä1/2è®,çš,,æ,,j). Journal of Diabetes, 2014, 6, 96-99.	1.8	0
101	Something old, something new and something very old: drugs for treating type 2 diabetes. British Journal of Pharmacology, 2014, 171, 2940-2950.	5.4	13
102	Incidence and precipitants of hospitalization for pancreatitis in people with diabetes: the Fremantle Diabetes Study. Diabetic Medicine, 2014, 31, 913-919.	2.3	4
103	The extraâ€pancreatic effects of <sc>GLPâ€1</sc> receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes, Obesity and Metabolism, 2014, 16, 673-688.	4.4	103
104	Pancreatic Safety of Incretin-Based Drugs â€” FDA and EMA Assessment. New England Journal of Medicine, 2014, 370, 794-797.	27.0	441
105	Noncardiac Comorbidities in Heartâ€Failureâ€With Reduced Versus Preservedâ€Ejection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
106	GLPâ€1 receptor agonists vs. DPPâ€4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. International Journal of Clinical Practice, 2014, 68, 557-567.	1.7	89
107	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety, 2014, 5, 138-146.	2.4	96

#	ARTICLE	IF	CITATIONS
108	Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin. <i>Diabetes Care</i> , 2014, 37, 2435-2441.	8.6	61
109	Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes. <i>Clinical Diabetes</i> , 2014, 32, 170-177.	2.2	5
110	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 306-323.	2.0	55
111	Effect of Alogliptin on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	7.4	206
112	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 395-409.	2.0	15
113	Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition. <i>Hypertension</i> , 2014, 63, 951-957.	2.7	62
114	Cardiovascular disease prevention in diabetes: uncertainties and ethics. <i>Diabetes Management</i> , 2014, 4, 285-292.	0.5	0
115	Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 162.	1.7	6
116	Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. <i>Cardiovascular Diabetology</i> , 2014, 13, 148.	6.8	296
117	Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. <i>Cardiovascular Diabetology</i> , 2014, 13, 154.	6.8	44
118	Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 641-658.	2.4	1
119	Glycemic Management in Patients With Coronary Artery Disease and Prediabetes or Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 2567-2573.	1.6	12
120	Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2014, 126, 56-65.	2.0	11
121	Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. <i>BMJ Open</i> , 2014, 4, e005442-e005442.	1.9	56
122	Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes. <i>Clinical Diabetes</i> , 2014, 32, 121-126.	2.2	8
123	Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. <i>Clinical Drug Investigation</i> , 2014, 34, 763-772.	2.2	3
125	Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist's paradox. <i>Cardiovascular Endocrinology</i> , 2014, 3, 111-116.	0.8	2
126	Pioglitazone Prevents the Endothelial Dysfunction Induced by Ischemia and Reperfusion in Healthy Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 326-331.	1.9	5

#	ARTICLE	IF	CITATIONS
127	Heart Failure and Loss of Metabolic Control. Journal of Cardiovascular Pharmacology, 2014, 63, 302-313.	1.9	45
128	Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials. Postgraduate Medicine, 2014, 126, 19-32.	2.0	27
129	Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine, 2014, 126, 66-84.	2.0	10
130	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. Postgraduate Medicine, 2014, 126, 190-204.	2.0	11
131	Dipeptidyl Peptidase 4 Inhibition and the Vascular Effects of Glucagon-Like Peptide-1 and Brain Natriuretic Peptide in the Human Forearm. Journal of the American Heart Association, 2014, 3, .	3.7	28
132	Effect of Patients' Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 1227.	5.1	158
133	Empagliflozin for the treatment of Type 2 diabetes. Expert Review of Clinical Pharmacology, 2014, 7, 271-279.	3.1	6
134	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e111543.	2.5	43
135	Incretin-based therapies in prediabetes: Current evidence and future perspectives. World Journal of Diabetes, 2014, 5, 817.	3.5	26
136	Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World Journal of Diabetes, 2014, 5, 636.	3.5	21
137	Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular Health and Risk Management, 2015, 11, 9.	2.3	9
138	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. Diabetes and Vascular Disease Research, 2014, 11, 290-293.	2.0	13
139	Typ-2-Diabetes. , 2014, , 107-202.		0
140	Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors. Pharmaceutical Regulatory Affairs: Open Access, 2014, 03, .	0.2	0
141	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World Journal of Diabetes, 2014, 5, 40.	3.5	46
142	Type 2 diabetes and cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 109-120.	2.3	42
143	Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardíaca. Revista Española De Cardiología, 2014, 67, 203-210.	1.2	13
144	Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence?. Diabetes and Metabolism, 2014, 40, 169-175.	2.9	23



#	ARTICLE	IF	CITATIONS
145	Action and therapeutic potential of oxyntomodulin. <i>Molecular Metabolism</i> , 2014, 3, 241-251.	6.5	144
146	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. <i>Diabetes and Metabolism</i> , 2014, 40, 176-185.	2.9	61
147	Comments on the ESC Guidelines on Diabetes, Prediabetes, and Cardiovascular Diseases Developed in Collaboration with the European Society for the Study of Diabetes. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 87-93.	0.6	4
148	Pancreatitis and incretin-based drugs: clarity or confusion?. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 92-93.	11.4	6
149	Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. <i>Cardiovascular Diabetology</i> , 2014, 13, 12.	6.8	22
150	Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2014, 32, 15-27.	3.3	28
151	Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. <i>Endocrine</i> , 2014, 46, 43-51.	2.3	44
152	New Developments in Diabetes Management: Medications of the 21st Century. <i>Clinical Therapeutics</i> , 2014, 36, 477-484.	2.5	27
153	Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 111-115.	11.4	36
154	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , 2014, 57, 738-745.	6.3	9
155	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	4.8	4
156	Saxagliptin: a guide to its use in type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 92-99.	0.6	1
157	Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes. <i>Advances in Therapy</i> , 2014, 31, 247-263.	2.9	9
158	Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. <i>Cardiovascular Diabetology</i> , 2014, 13, 33.	6.8	53
159	Who would really benefit from DPP-4 inhibitors?. <i>Endocrine</i> , 2014, 46, 6-7.	2.3	0
160	Effects of incretin-based therapy in patients with heart failure and myocardial infarction. <i>Endocrine</i> , 2014, 47, 21-28.	2.3	21
161	Do incretins improve endothelial function?. <i>Cardiovascular Diabetology</i> , 2014, 13, 21.	6.8	23
162	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2014, 13, 19.	6.8	56

#	ARTICLE	IF	CITATIONS
163	Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. <i>Diabetology International</i> , 2014, 5, 1-20.	1.4	3
164	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	2.9	441
165	The gutâ€“renal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014, 10, 88-103.	9.6	155
166	DPP-IV inhibitors: Beyond glycaemic control?. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 157-164.	4.9	7
167	Management of a Prediabetes Case With the DPP-4 Inhibitor Sitagliptin. <i>Annals of Pharmacotherapy</i> , 2014, 48, 811-815.	1.9	5
168	Update in Cardiology: Vascular Risk and Cardiac Rehabilitation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 203-210.	0.6	12
169	Effects of GLP-1 in the Kidney. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2014, 15, 197-207.	5.7	72
170	Cancer biology in diabetes. <i>Journal of Diabetes Investigation</i> , 2014, 5, 251-264.	2.4	25
171	Dipeptidyl peptidaseâ€4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 891-899.	4.4	43
172	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. <i>Diabetes Care</i> , 2014, 37, 1721-1728.	8.6	217
173	Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1299-1313.	1.8	24
174	Dipeptidyl Peptidaseâ€4 Inhibitors and Cardiovascular Outcomes: Metaâ€Analysis of Randomized Clinical Trials with 55,141 Participants. <i>Cardiovascular Therapeutics</i> , 2014, 32, 147-158.	2.5	111
175	Targeting inflammation in the treatment of type 2 diabetes: time to start. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 465-476.	46.4	571
176	Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 689-697.	2.6	167
177	Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans. <i>Diabetes</i> , 2014, 63, 2394-2401.	0.6	59
179	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <i>Lancet, The</i> , 2014, 383, 1068-1083.	13.7	1,230
180	Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 431-445.	1.9	16
181	Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, 142, 375-415.		437

#	ARTICLE	IF	CITATIONS
182	Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. <i>European Journal of Pharmacology</i> , 2014, 727, 8-14.	3.5	24
183	Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 223-242.	10.9	79
184	The potential for renoprotection with incretin-based drugs. <i>Kidney International</i> , 2014, 86, 701-711.	5.2	103
185	The Year in Cardiology 2013: cardiovascular disease prevention. <i>European Heart Journal</i> , 2014, 35, 307-312.	2.2	45
186	Diabetes Medications and Heart Failure. <i>Circulation</i> , 2014, 130, 1565-1567.	1.6	22
187	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 1223-1251.	5.0	23
188	Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects. <i>Drug Safety</i> , 2014, 37, 1003-1010.	3.2	10
189	Activation of glucagon-like peptide-1 receptor inhibits tumorigenicity and metastasis of human pancreatic cancer cells via $\text{PI3K}/\text{Akt}$ pathway. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 850-860.	4.4	42
190	Gliptins – do they increase cardiovascular risk or benefit?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 675-680.	2.4	17
191	Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1247-1256.	4.4	60
192	Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 353.	0.9	40
193	Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 1927-1946.	10.9	24
194	Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2014, 16, 541.	2.9	14
195	Cardiovascular Effects of Incretin Therapy in Diabetes Care. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 303-310.	1.3	9
196	AAV-Mediated Gene Therapy for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2014, 16, 434.	4.8	13
197	Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2014, 53, 773-785.	3.5	42
198	DPP-4 inhibitors: pharmacological differences and their clinical implications. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 57-68.	2.4	588
199	Sitagliptin and the risk of hospitalization for heart failure: A population-based study. <i>International Journal of Cardiology</i> , 2014, 177, 86-90.	1.7	54

#	ARTICLE	IF	CITATIONS
200	Cancers du pancréas et sécrétion des incrélines : État des lieux en 2014. <i>Medecine Des Maladies Metaboliques</i> , 2014, 8, 380-391.	0.1	0
201	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	8.6	58
204	Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 417-425.	2.0	6
205	Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors. <i>Endocrine Reviews</i> , 2014, 35, 992-1019.	20.1	439
206	Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research. <i>Diabetes Care</i> , 2014, 37, 2899-2908.	8.6	109
207	Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 225-233.	3.1	2
208	Sitagliptin Use in Patients With Diabetes and Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 573-582.	4.1	106
209	Metabolic Impairment in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1388-1400.	2.8	196
210	Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. <i>International Journal of Cardiology</i> , 2014, 177, 266-275.	1.7	32
213	Use Of Incretin-Based Therapy in Hospitalized Patients with Hyperglycemia. <i>Endocrine Practice</i> , 2014, 20, 933-944.	2.1	21
214	The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications. <i>Diabetes Care</i> , 2014, 37, 2884-2894.	8.6	138
215	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. <i>Circulation</i> , 2014, 130, 1579-1588.	1.6	594
218	Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1130-1146.	2.5	56
219	Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1613-1621.	3.8	116
220	Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E1431-E1441.	3.5	38
221	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	2.2	4,141
222	Advances in Clinical Cardiology. <i>Advances in Therapy</i> , 2014, 31, 837-860.	2.9	4
223	Recent advances in pharmacotherapy for hypertriglyceridemia. <i>Progress in Lipid Research</i> , 2014, 56, 47-66.	11.6	128

#	ARTICLE	IF	CITATIONS
224	DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovascular Diabetology, 2014, 13, 110.	6.8	107
225	GLP-1 (7â€“36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovascular Diabetology, 2014, 13, 115.	6.8	7
226	Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?. Cardiovascular Diabetology, 2014, 13, 125.	6.8	20
227	Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety, 2014, 13, 1469-1481.	2.4	15
228	Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning. Pharmacological Reviews, 2014, 66, 1142-1174.	16.0	521
229	Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus. Circulation, 2014, 129, 2705-2713.	1.6	21
231	Diabetes, incretin hormones and cardioprotection. Heart, 2014, 100, 1550-1561.	2.9	7
232	Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. Canadian Journal of Diabetes, 2014, 38, 364-371.	0.8	35
233	Do Current Clinical Trials Meet Societyâ€™s Needs?. Journal of the American College of Cardiology, 2014, 64, 1615-1628.	2.8	53
235	Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia, 2014, 57, 1320-1324.	6.3	84
236	Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Diabetology and Metabolic Syndrome, 2014, 6, 35.	2.7	16
237	Comentarios a la guÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular. Revista Espanola De Cardiologia, 2014, 67, 87-93.	1.2	15
238	Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?. JACC: Heart Failure, 2014, 2, 583-585.	4.1	23
239	Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination. Journal of Osteopathic Medicine, 2014, 114, 22-29.	0.8	8
240	GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 233-242.	5.7	21
241	Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 219-231.	5.7	10
242	Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Reviews in Endocrine and Metabolic Disorders, 2014, 15, 209-217.	5.7	12
243	Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors. Current Atherosclerosis Reports, 2014, 16, 408.	4.8	5

#	ARTICLE	IF	CITATIONS
244	Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy. Current Diabetes Reports, 2014, 14, 483.	4.2	26
245	Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. Current Hypertension Reports, 2014, 16, 455.	3.5	6
246	Extra-pancreatic effects of incretin-based therapies. Endocrine, 2014, 47, 360-371.	2.3	28
247	Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany. Diabetes Therapy, 2014, 5, 183-191.	2.5	4
248	Observational Study on Dipeptidyl Peptidase-4 Inhibitors: A Real-Life Analysis on 360 Patients from the ASL VCO Territory in Italy. Clinical Drug Investigation, 2014, 34, 513-519.	2.2	7
249	Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs, 2014, 74, 587-610.	10.9	53
250	Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovascular Diabetology, 2014, 13, 49.	6.8	86
251	On the potential of acarbose to reduce cardiovascular disease. Cardiovascular Diabetology, 2014, 13, 81.	6.8	42
252	The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. Cardiovascular Diabetology, 2014, 13, 92.	6.8	25
253	Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia. Diabetes, 2014, 63, 2188-2195.	0.6	196
254	Study to determine the durability of glycaemic control with early treatment with a vildagliptin+metformin combination regimen vs. standard-of-care metformin monotherapy—the <sc>VERIFY</sc> trial: a randomized double-blind trial. Diabetic Medicine, 2014, 31, 1178-1184.	2.3	35
255	Cardiovascular Actions of Incretin-Based Therapies. Circulation Research, 2014, 114, 1788-1803.	4.5	301
256	Newest additions to heart failure treatment. Expert Opinion on Pharmacotherapy, 2014, 15, 1849-1861.	1.8	1
257	Effects of glucagon-like peptide-1 agents on left ventricular function: Systematic review and meta-analysis. Annals of Medicine, 2014, 46, 664-671.	3.8	12
258	Complementary Approaches to Improving Glucose Control—Insulin and Incretins. The Diabetes Educator, 2014, 40, 4S-26S.	2.5	0
259	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology, 2014, 2, 843-851.	11.4	260
260	Lessons from SAVOR and EXAMINE: Some important answers, but many open questions. Journal of Diabetes and Its Complications, 2014, 28, 430-433.	2.3	13
261	Letter to the Editor. Canadian Journal of Diabetes, 2014, 38, 3-4.	0.8	0

#	ARTICLE	IF	CITATIONS
262	Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. <i>Molecular Metabolism</i> , 2014, 3, 507-517.	6.5	102
263	New and emerging regulators of intestinal lipoprotein secretion. <i>Atherosclerosis</i> , 2014, 233, 608-615.	0.8	47
264	Cardiovascular Disease in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 25-40.	3.2	43
266	Stromal derived factor 1 $\alpha$ : A chemokine that delivers a two-pronged defence of the myocardium. , 2014, 143, 305-315.		82
268	A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1041-1047.	4.4	20
269	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet, The</i> , 2014, 383, 2008-2017.	13.7	194
270	Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1001-1008.	4.4	43
271	Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 191-207.	2.2	14
272	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	1.5	6
273	Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 2305-2312.	1.6	36
274	Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: The randomized controlled Asker and BÅlrum Cardiovascular Diabetes (ABCD) study. <i>American Heart Journal</i> , 2014, 168, 280-288.e2.	2.7	14
276	Alogliptin benzoate for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 851-863.	1.8	11
277	Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. <i>Pharmaceutical Medicine</i> , 2014, 28, 109-117.	1.9	9
278	Coronary Artery Disease and Diabetes Mellitus. <i>Cardiology Clinics</i> , 2014, 32, 439-455.	2.2	135
279	Potential cardioprotective action of GLP-1: from bench to bedside. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 979-988.	3.4	11
281	Linagliptin: from bench to bedside. <i>Drug Design, Development and Therapy</i> , 2014, 8, 431.	4.3	22
282	Thérapeutique des dysosmies glycémiqes. , 2014, , 115-188.		0
283	Could Glucose Management After Acute Myocardial Infarction Cure Myocardial Damage?. <i>Circulation Journal</i> , 2014, 78, 67-68.	1.6	1



#	ARTICLE	IF	CITATIONS
284	Incretin Therapy and Heart Failure. Circulation Journal, 2014, 78, 819-824.	1.6	13
285	Saxagliptin-induced Recurrent Acute Pancreatitis. Internal Medicine, 2014, 53, 1351-1354.	0.7	11
286	Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies. Canadian Journal of Diabetes, 2015, 39, S176-S182.	0.8	2
287	EXAMINE: targeting risk and treatment in diabetes. Lancet, The, 2015, 386, 1444-1445.	13.7	0
288	Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention. Journal of Pharmacy Practice and Research, 2015, 45, 459-469.	0.8	8
289	Type 2 diabetes: recent advances in diagnosis and management. The Prescriber, 2015, 26, 15-21.	0.3	3
290	Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice, 2015, 69, 531-549.	1.7	11
291	Sitagliptin attenuates sympathetic innervation <i>via</i> modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts. Journal of Cellular and Molecular Medicine, 2015, 19, 418-429.	3.6	16
292	Incretin physiology and pathophysiology from an Asian perspective. Journal of Diabetes Investigation, 2015, 6, 495-507.	2.4	62
293	Antidiabetic Agents and Endothelial Dysfunction “Beyond Glucose Control. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 15-25.	2.5	40
294	Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial. Journal of Diabetes Investigation, 2015, 6, 692-698.	2.4	20
295	Cardiovascular effects of the incretin-based therapy: the good, the bad, or the ugly?. Journal of Diabetes Investigation, 2015, 6, 597-599.	2.4	1
296	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	30.5	1,308
297	Insulin, Other Hypoglycemic Drugs, and Glucagon. Side Effects of Drugs Annual, 2015, 37, 521-537.	0.6	1
298	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan “ 2015. Endocrine Practice, 2015, 21, 1-87.	2.1	443
299	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2015, 163, 663-672.	3.9	81
300	The Rationale for use of Incretins in the Management of new Onset Diabetes After Transplantation (NODAT). Endocrine Practice, 2015, 21, 814-822.	2.1	13
303	Empagliflozin in diabetes: A therapeutic light at the end of the cardiovascular tunnel?. Diabetes and Vascular Disease Research, 2015, 12, 394-395.	2.0	2



305	Recent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!. Practical Diabetes, 2015, 32, 319-320.	0.3	4
306	Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC Endocrine Disorders, 2015, 15, 49.	2.2	12
307	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology, 2015, 14, 57.	6.8	71
308	Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovascular Diabetology, 2015, 14, 83.	6.8	46
309	Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats. Cardiovascular Diabetology, 2015, 14, 103.	6.8	49
310	Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology, 2015, 14, 129.	6.8	66
311	New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?. Practical Diabetes, 2015, 32, 291.	0.3	0
313	Safety of antidiabetes medications: An update. Clinical Pharmacology and Therapeutics, 2015, 98, 185-195.	4.7	26
314	Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?. Clinical Pharmacology and Therapeutics, 2015, 98, 467-469.	4.7	1
315	<scp>ADVANCEâ€œCON</scp>: further support for intensive glucose control in type 2 diabetes. Practical Diabetes, 2015, 32, 6-7.	0.3	1
316	Cardiovascular risks associated with secondâ€œline oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabetic Medicine, 2015, 32, 1460-1469.	2.3	30
317	Caseâ€œcontrol study of secondâ€œline therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. Diabetes, Obesity and Metabolism, 2015, 17, 1194-1197.	4.4	6
318	Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension. Journal of Cardiovascular Pharmacology, 2015, 65, 399-405.	1.9	21
319	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clinical Pharmacology and Therapeutics, 2015, 98, 145-161.	4.7	31
320	Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs. Pharmacoepidemiology and Drug Safety, 2015, 24, 1017-1025.	1.9	30
321	Response to: â€œbaseline differences in <scp>SAVOR</scp> trialâ€œ™Ââ€œÂprespecified vs. <i>post hoc</i> analysisÂâ€œÂa potential source of bias. Diabetes, Obesity and Metabolism, 2015, 17, 1203-1204.	4.4	0
322	Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European crossâ€œsectional study. Journal of Internal Medicine, 2015, 278, 291-302.	6.0	38

#	ARTICLE	IF	CITATIONS
323	Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients. Journal of Cardiovascular Imaging, 2015, 23, 233.	0.8	2
324	Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. ClinicoEconomics and Outcomes Research, 2015, 7, 313.	1.9	6
325	Emerging Link between Diabetes and Cancer. Journal of General and Family Medicine, 2015, 16, 170-176.	0.8	0
326	Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 315.	2.4	8
327	Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?. Diabetes and Metabolism Journal, 2015, 39, 204.	4.7	2
328	Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2015, 39, 342.	4.7	17
329	Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (<i>Diabetes Metab) Tj ETQq0 0 0 0 BT /Overlock 10 Tf	4.7	1
330	Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism. Current Pharmaceutical Design, 2015, 21, 3606-3620.	1.9	60
331	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. Italian Journal of Medicine, 2015, 3, 309.	0.3	1
332	Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes. Journal of Clinical Medicine Research, 2015, 7, 211-219.	1.2	14
333	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World Journal of Diabetes, 2015, 6, 1092.	3.5	12
334	Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes and Metabolism Journal, 2015, 39, 373.	4.7	33
335	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. Journal of Clinical Medicine, 2015, 4, 1866-1889.	2.4	18
336	DPP4 in diabetes. Frontiers in Immunology, 2015, 6, 386.	4.8	324
337	The Role of Dipeptidyl Peptidase “ 4 Inhibitors in Diabetic Kidney Disease. Frontiers in Immunology, 2015, 6, 443.	4.8	35
338	Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease. Frontiers in Immunology, 2015, 6, 477.	4.8	65
339	SGLT2 inhibitors &ndash; an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 543.	2.4	51
340	Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. International Heart Journal, 2015, 56, 372-376.	1.0	10

#	ARTICLE	IF	CITATIONS
341	Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. PLoS ONE, 2015, 10, e0121988.	2.5	26
342	Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0124287.	2.5	53
343	Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. PLoS ONE, 2015, 10, e0131122.	2.5	17
344	Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach. PLoS ONE, 2015, 10, e0134971.	2.5	16
345	The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and Outcomes. Cardiac Failure Review, 2015, 1, 8.	3.0	22
346	Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database. Diabetes and Metabolism Journal, 2015, 39, 247.	4.7	22
347	Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 163.	2.4	37
348	Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes. , 2015, , .		1
349	New Insights in the Diagnosis and Treatment of Heart Failure. BioMed Research International, 2015, 2015, 1-16.	1.9	11
350	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research, 2015, 2015, 1-28.	2.3	65
351	Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?. BioMed Research International, 2015, 2015, 1-10.	1.9	42
352	Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. Journal of Diabetes Research, 2015, 2015, 1-14.	2.3	52
353	Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World Journal of Experimental Medicine, 2015, 5, 110.	1.7	27
354	Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. British Journal of Pharmacology, 2015, 172, 721-736.	5.4	21
355	DPP-4 inhibitors and risk of heart failure EXAMINED. Lancet, The, 2015, 385, 2022-2024.	13.7	21
356	Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology, 2015, 761, 109-115.	3.5	16
357	DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Contributions To Nephrology, 2015, 185, 98-115.	1.1	20
358	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet, The, 2015, 385, 2107-2117.	13.7	240

#	ARTICLE	IF	CITATIONS
359	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. <i>European Heart Journal</i> , 2015, 36, 1424-1427.	2.2	5
360	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. <i>European Heart Journal</i> , 2015, 36, 2288-2296.	2.2	210
361	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015, 163, 127-134.	3.9	162
362	Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications. <i>Current Cardiology Reports</i> , 2015, 17, 608.	2.9	2
363	Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges. <i>Current Cardiology Reports</i> , 2015, 17, 607.	2.9	24
364	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	2.7	88
365	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	27.0	2,188
366	Incretins. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 229-231.	2.8	0
367	Pharmacological Treatment and Current Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1579-1598.	4.5	87
368	Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 141-148.	2.8	16
369	Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2015, 127, 251-257.	2.0	10
370	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2345-2350.	1.6	42
371	HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2015, 14, 124.	6.8	27
372	Heart failure in SAVOR-TIMI 53: The hindsight of diabetic retinopathySAVOR-TIMI 53”ç©¶ä,çšš,â¿fè, è¿°ç«i¼šç³—â°¿ of Diabetes, 2015, 7, 304-306.		
373	Spontaneous seromuscular laceration of the sigmoid colon: a case report. <i>Clinical Case Reports</i> (discontinued), 2015, 3, 1007-1011.	0.5	1
374	NPY <sub>1</sub> and PYY <sub>1</sub> activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1528-H1542.	3.2	34
375	Design of Major Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2757-2766.	2.8	56
376	Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. <i>Advances in Therapy</i> , 2015, 32, 1065-1084.	2.9	8

#	ARTICLE	IF	CITATIONS
377	Statistical Controversies in Reporting of Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 2648-2662.	2.8	72
378	Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. BMJ Open, 2015, 5, e007959-e007959.	1.9	23
379	Causal inference methods to assess safety upper bounds in randomized trials with noncompliance. Clinical Trials, 2015, 12, 265-275.	1.6	0
380	Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes Research and Clinical Practice, 2015, 110, e13-e17.	2.8	28
381	Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetology and Metabolic Syndrome, 2015, 7, 70.	2.7	6
382	Spécificité des accidents vasculaires cérébraux chez les diabétiques. Medecine Des Maladies Metaboliques, 2015, 9, 399-405.	0.1	1
383	Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients. Medicine (United States), 2015, 94, e1128.	1.0	19
384	Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2478-2479.	27.0	17
387	Sécurité cardiovasculaire des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue. Medecine Des Maladies Metaboliques, 2015, 9, 768-775.	0.1	3
389	Obesity and Diabetes. , 2015, , .		0
390	Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!. Diabetes Care, 2015, 38, 170-175.	8.6	43
391	A review of gliptins for 2014. Expert Opinion on Pharmacotherapy, 2015, 16, 43-62.	1.8	88
392	Decreased Plasma Levels of Active Glucagon-Like Peptide-1 in Coronary Artery Disease. Journal of the American College of Cardiology, 2015, 65, 754-755.	2.8	10
393	Novedades cardiovasculares 2013/2014. Revista Clinica Espanola, 2015, 215, 33-42.	0.6	0
394	Influence of Sex on Mortality and Perioperative Outcomes in Patients Undergoing TAVR. Journal of the American College of Cardiology, 2015, 65, 755-757.	2.8	26
395	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	6.3	598
396	«Mild dysglycemia» in type 2 diabetes: to be neglected or not?. Journal of Diabetes and Its Complications, 2015, 29, 451-458.	2.3	20
397	Pharmacologic Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 540-556.	1.9	69

#	ARTICLE	IF	CITATIONS
399	Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. Expert Review of Endocrinology and Metabolism, 2015, 10, 305-317.	2.4	5
400	Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1Â·9 million people. Lancet Diabetes and Endocrinology, 2015, 3, 105-113.	11.4	838
401	Vascular Complications of Diabetes Mellitus. , 2015, , 1541-1593.		0
402	Impact of Anti-hyperglycemic Medications on Bone Health. Clinical Reviews in Bone and Mineral Metabolism, 2015, 13, 43-52.	0.8	1
403	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients WithÂHeart Failure. JACC: Heart Failure, 2015, 3, 136-145.	4.1	265
404	Cardiovascular news 2013/2014. Revista Cl&#x00ed;nica Espan&#x00f5;la, 2015, 215, 33-42.	0.5	0
405	Les nouveaux antidiab&#x00e9;tiques et le c&#x00e9;ur. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2015, 2015, 26-28.	0.0	0
406	Effect of Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin on Plasminogen Activator Inhibitor-1 in Patients With Diabetes Mellitus. American Journal of Cardiology, 2015, 115, 454-460.	1.6	16
407	Antidiabetic therapy in post kidney transplantation diabetes mellitus. Transplantation Reviews, 2015, 29, 145-153.	2.9	11
408	Dipeptidyl peptidase&#x00e9;4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 107-115.	4.4	32
409	Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety, 2015, 14, 505-524.	2.4	92
410	Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy, 2015, 16, 417-426.	1.8	35
412	Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. Diabetes Care, 2015, 38, 1058-1066.	8.6	40
413	Regional, age and sex differences in baseline characteristics of patients enrolled in the <scp>T</scp>rial <scp>E</scp>valuating <scp>C</scp>ardiovascular <scp>O</scp>utcomes with <scp>S</scp>itagliptin (<scp>TECOS</scp>). Diabetes, Obesity and Metabolism, 2015, 17, 395-402.	4.4	37
414	Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes, 2015, 64, 673-686.	0.6	165
415	Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study. Sleep and Breathing, 2015, 19, 801-808.	1.7	2
417	Welcome Reassurance About GLP-1 Drugs&#x00e9;”But They Are Still Young and Not Fully Grown. Diabetes Care, 2015, 38, 183-185.	8.6	0
418	Vascular Protection with Dipeptidyl Peptidase-IV inhibitors in Diabetes: Experimental and Clinical Therapeutics. Pharmacotherapy, 2015, 35, 277-297.	2.6	4

#	ARTICLE	IF	CITATIONS
419	Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 718-723.	4.3	35
420	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	7
421	Sitagliptin for Type 2 diabetes: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 597-610.	1.5	20
422	Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits. <i>Heart Rhythm</i> , 2015, 12, 1362-1369.	0.7	17
423	Glycemia Lowering and Risk for Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 819-825.	3.9	13
424	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <i>American Heart Journal</i> , 2015, 170, 753-759.e2.	2.7	5
425	Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?. <i>International Journal of Cardiology</i> , 2015, 184, 543-544.	1.7	5
426	DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. <i>International Journal of Cardiology</i> , 2015, 199, 163-169.	1.7	61
427	Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. <i>Vascular Pharmacology</i> , 2015, 73, 1-3.	2.1	17
428	Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death. <i>Circulation</i> , 2015, 132, 923-931.	1.6	397
429	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015, 36, 2454-2462.	2.2	94
430	Reply. <i>American Journal of Cardiology</i> , 2015, 115, 852-853.	1.6	0
431	Understanding drug preferences, different perspectives. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 978-987.	2.4	14
432	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 171-180.	2.4	24
433	Evolution of evidence-based medicine to detect evidence mutations. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 8-10.	2.0	1
434	The potential role of incretin therapy in the hospital setting. <i>Clinical Diabetes and Endocrinology</i> , 2015, 1, 4.	2.7	5
435	Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. <i>Calcified Tissue International</i> , 2015, 97, 506-515.	3.1	56
436	Emerging Diabetes Research: Prevention, Risk and Management. <i>Clinical Therapeutics</i> , 2015, 37, 1169-1171.	2.5	0



#	ARTICLE	IF	CITATIONS
437	Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 697-705.	2.6	11
438	Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism. Diabetes, 2015, 64, 2310-2318.	0.6	50
439	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. European Heart Journal, 2015, 36, 1454-1462.	2.2	106
440	The perils of surrogate endpoints. European Heart Journal, 2015, 36, 2212-2218.	2.2	61
441	Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure. International Journal of Molecular Sciences, 2015, 16, 4226-4249.	4.1	18
442	Comment on Udell et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705. Diabetes Care, 2015, 38, e88-e89.	8.6	5
443	10. Older Adults. Diabetes Care, 2015, 38, S67-S69.	8.6	37
444	Emerging treatments for post-transplantation diabetes mellitus. Nature Reviews Nephrology, 2015, 11, 465-477.	9.6	62
445	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> ). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	2.0	197
446	Commentary: Confidentiality of interim trial dataâ€”The emerging crisis. Clinical Trials, 2015, 12, 15-17.	1.6	4
447	Antidiabetic Therapy in Endâ€”Stage Renal Disease. Seminars in Dialysis, 2015, 28, 337-344.	1.3	3
448	Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 487-497.	1.4	83
449	Update on Ischemic Heart Disease and Intensive Cardiac Care. Revista Espanola De Cardiologia (English) Tj ETQq0 0.0 rgBT /Qverlock 10	0.6	3
450	The effects and safety of vildagliptin on cardiac function after acute myocardial infarction. International Journal of Cardiology, 2015, 188, 13-15.	1.7	1
451	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 670-674.	2.3	58
452	Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy, 2015, 16, 971-981.	1.8	32
453	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal, 2015, 169, 486-495.	2.7	21
454	Impact cardiovasculaire des incrÃ©tino-mimÃ©tiques chez le diabÃ©tique de type 2 : le point en 2015. Medecine Des Maladies Metaboliques, 2015, 9, 158-163.	0.1	0



#	ARTICLE	IF	CITATIONS
455	Protocolo sobre manejo de la diabetes mellitus tipo 2. FMC Formacion Medica Continuada En Atencion Primaria, 2015, 22, 9-40.	0.0	0
457	Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. European Heart Journal, 2015, 36, 1718-1727.	2.2	392
458	Medications for type 2 diabetes: how will we be treating patients in 50 years?. Diabetologia, 2015, 58, 1735-1739.	6.3	12
459	Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Research in Cardiology, 2015, 110, 20.	5.9	57
460	Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
461	Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm. American Journal of Cardiovascular Drugs, 2015, 15, 171-184.	2.2	18
462	A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy. Cardiovascular Diabetology, 2015, 14, 13.	6.8	6
463	Targeting metabolic disturbance in the diabetic heart. Cardiovascular Diabetology, 2015, 14, 17.	6.8	44
464	The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology, 2015, 14, 10.	6.8	51
465	Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve coronary haemodynamics during Exercise stress (LIONESS) crossover study. Cardiovascular Diabetology, 2015, 14, 27.	6.8	2
466	An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1287-H1297.	3.2	30
467	Pharmacological cardioprotection in diabetes. Diabetes Management, 2015, 5, 89-101.	0.5	0
468	Incretins. Handbook of Experimental Pharmacology, 2015, 233, 137-171.	1.8	45
469	Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes: a randomized, single-blinded, cross-over pilot study. Cardiovascular Diabetology, 2015, 14, 41.	6.8	43
470	Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes, Obesity and Metabolism, 2015, 17, 649-658.	4.4	20
471	Author's Reply to De Ponti et al.: Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics, 2015, 54, 449-451.	3.5	0
472	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	8.6	73
473	Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 688-699.	1.9	7

#	ARTICLE	IF	CITATIONS
474	Cardiometabolic Effects of a New Class of Antidiabetic Agents. <i>Clinical Therapeutics</i> , 2015, 37, 1178-1194.	2.5	39
475	Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs – A nested case-control study. <i>International Journal of Cardiology</i> , 2015, 178, 292-296.	1.7	26
476	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet</i> , The, 2015, 385, 2067-2076.	13.7	659
477	The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death. <i>Canadian Journal of Diabetes</i> , 2015, 39, 383-389.	0.8	27
478	Alogliptin benzoate for management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2015, 11, 229.	2.3	14
479	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, ii1-ii142.	0.7	113
481	Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1325-1333.	1.8	7
482	Impact of treatment with saxagliptin on glycaemic stability and $\beta$ -cell function in the SAVOR-TIMI 53 study. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 487-494.	4.4	33
483	Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1005-1020.	3.3	8
484	Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. <i>Diabetes and Metabolism</i> , 2015, 41, 195-201.	2.9	28
485	The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 101-114.	2.4	6
486	Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 630-638.	4.4	51
487	An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 2015, 33, 67-124.	2.9	43
488	Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 67-73.	2.0	13
489	Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. <i>Diabetes and Metabolism</i> , 2015, 41, 183-194.	2.9	121
490	Drug-subphenotype interactions for cancer in type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2015, 11, 372-379.	9.6	23
491	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 356-366.	11.4	224
492	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2015, 162, ITC1-ITC16.	3.9	74

#	ARTICLE	IF	CITATIONS
493	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research, 2015, 12, 90-100.	2.0	333
494	DPP4 in Cardiometabolic Disease. Circulation Research, 2015, 116, 1491-1504.	4.5	156
495	Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs, 2015, 75, 777-796.	10.9	24
496	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2015, 12, 154-163.	2.0	27
497	Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diabetes and Vascular Disease Research, 2015, 12, 101-110.	2.0	99
500	Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium. Journal of Molecular and Cellular Cardiology, 2015, 89, 365-375.	1.9	40
501	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. Diabetes, 2016, 65, 239-254.	0.6	41
504	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 2142-2150.	8.6	54
505	Biocompatible polymeric nanocomplexes as an intracellular stimuli-sensitive prodrug for type-2 diabetes combination therapy. Biomaterials, 2015, 73, 149-159.	11.4	26
506	RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015. International Journal of Diabetes in Developing Countries, 2015, 35, 1-71.	0.8	11
507	Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Effectiveness and Resource Allocation, 2015, 13, 12.	1.5	30
509	First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2015, 16, 2539-2547.	1.8	36
511	Angioedema induced by cardiovascular drugs: new players join old friends. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1196-1200.	5.7	44
512	Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2666-2672.	3.6	85
513	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology, 2015, 3, 697-703.	11.4	70
514	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. Circulation, 2015, 132, 691-718.	1.6	303
515	Time course and mechanisms of the antihypertensive and renal effects of liraglutide treatment. Diabetic Medicine, 2015, 32, 343-352.	2.3	61
516	¿Qué hay de nuevo en insuficiencia cardíaca en el paciente con diabetes tipo 2?. Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición, 2015, 62, 350-355.	0.8	5

#	ARTICLE	IF	CITATIONS
517	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine, 2015, 127, 463-479.	2.0	11
518	New Medications for the Treatment of Diabetes. Diabetes Technology and Therapeutics, 2015, 17, S-119-S-133.	4.4	0
519	Manuscripts Reviewed for the 2014 Yearbook. Diabetes Technology and Therapeutics, 2015, 17, S-134-S-141.	4.4	0
520	The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study. CMAJ Open, 2015, 3, E172-E181.	2.4	3
521	Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 999-1024.	1.9	65
522	Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan. Annals of Medicine, 2015, 47, 561-569.	3.8	15
523	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. Postgraduate Medicine, 2015, 127, 842-854.	2.0	5
524	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. The Diabetes Educator, 2015, 41, 19S-31S.	2.5	5
525	Saxagliptin: A Review in Type 2 Diabetes. Drugs, 2015, 75, 1783-1796.	10.9	22
526	Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17â€‰000 patients. Diabetes, Obesity and Metabolism, 2015, 17, 1085-1092.	4.4	89
528	Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. Diabetology and Metabolic Syndrome, 2015, 7, 63.	2.7	3
529	Vascular and Metabolic Implications of Novel Targeted Cancer Therapies. Journal of the American College of Cardiology, 2015, 66, 1160-1178.	2.8	157
530	Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINAâ€“T2D<sup>â„“</sup> trial. Diabetes and Vascular Disease Research, 2015, 12, 455-462.	2.0	39
531	Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study. Atherosclerosis, 2015, 242, 580-588.	0.8	26
532	Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function. International Journal of Cardiology, 2015, 197, 170-179.	1.7	19
533	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	8.6	346
534	Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. Diabetes and Vascular Disease Research, 2015, 12, 463-466.	2.0	15
535	Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings. Cardiovascular Drugs and Therapy, 2015, 29, 461-467.	2.6	22

#	ARTICLE	IF	CITATIONS
536	Metabolic abnormalities of the heart in type II diabetes. Diabetes and Vascular Disease Research, 2015, 12, 239-248.	2.0	36
537	Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective. Current Diabetes Reports, 2015, 15, 87.	4.2	25
538	Consider safety when managing co-morbid conditions in heart failure patients. Drugs and Therapy Perspectives, 2015, 31, 397-401.	0.6	0
539	Diabetes. JAMA - Journal of the American Medical Association, 2015, 314, 1052.	7.4	305
541	Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2015, 31, 1919-1931.	1.9	18
542	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	27.0	8,841
543	Making Sense of Statistics in Clinical Trial Reports. Journal of the American College of Cardiology, 2015, 66, 2536-2549.	2.8	57
544	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open, 2015, 5, e009579.	1.9	30
545	One Small Step for Empagliflozin, One Giant Leap for Diabetology. Diabetes Therapy, 2015, 6, 405-409.	2.5	7
546	EXAMINE: targeting risk and treatment in diabetes. Lancet, The, 2015, 386, 1443.	13.7	2
547	EXAMINE: targeting risk and treatment in diabetes – Authors' reply. Lancet, The, 2015, 386, 1445.	13.7	1
548	Management of Hyperglycemia in Diabetic Kidney Disease. Diabetes Spectrum, 2015, 28, 214-219.	1.0	15
549	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2015, 16, 2819-2833.	1.8	20
550	What's new in heart failure in the patient with type 2 diabetes?. Endocrinology & Nutrition (English) [TJ] ETQq1 1 0,784314 2,326 BT /Overl	0.5	2
551	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	8.6	2,326
552	Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?. Drug Safety, 2015, 38, 17-32.	3.2	23
553	DPP-4 inhibitors: focus on safety. Expert Opinion on Drug Safety, 2015, 14, 127-140.	2.4	55
554	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. International Journal of Cardiology, 2015, 181, 239-244.	1.7	88

#	ARTICLE	IF	CITATIONS
555	Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates. <i>American Journal of Pathology</i> , 2015, 185, 139-150.	3.8	16
556	Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes. <i>Journal of Cardiac Failure</i> , 2015, 21, 2-8.	1.7	33
557	Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. <i>International Journal of Cardiology</i> , 2015, 181, 200-206.	1.7	42
558	Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 149-159.	2.4	8
559	Diabetes Medications and Bone. <i>Current Osteoporosis Reports</i> , 2015, 13, 35-40.	3.6	6
560	Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1515 patients from observational studies. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 32-41.	4.4	54
561	Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment. <i>Diabetes</i> , 2015, 64, 1395-1406.	0.6	156
562	Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 50-64.	1.6	20
563	Metformin and other antidiabetic agents in renal failure patients. <i>Kidney International</i> , 2015, 87, 308-322.	5.2	112
564	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 194-202.	4.4	15
565	Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: The EASIE post-hoc analysis and extension trial. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 134-141.	2.3	5
566	Effect of Dipeptidyl Peptidase 4 Inhibition on Arterial Blood Pressure Is Context Dependent. <i>Hypertension</i> , 2015, 65, 238-249.	2.7	36
567	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 629-650.	3.0	72
568	Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 335-342.	4.4	9
569	Reducing cardiovascular risk in type 2 diabetes mellitus. <i>Medicine</i> , 2015, 43, 7-12.	0.4	1
570	Incretin-Related Drug Therapy in Heart Failure. <i>Current Heart Failure Reports</i> , 2015, 12, 24-32.	3.3	9
571	Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1-21.	3.5	86
572	Incretin-Based Therapies. <i>Medical Clinics of North America</i> , 2015, 99, 107-129.	2.5	32

#	ARTICLE	IF	CITATIONS
573	Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. <i>Endocrine</i> , 2015, 48, 461-471.	2.3	67
574	Diagnosing and Managing Diabetes in HIV-Infected Patients: Current Concepts. <i>Clinical Infectious Diseases</i> , 2015, 60, 453-462.	5.8	91
575	Concomitant Diabetes Mellitus and Heart Failure. <i>Current Problems in Cardiology</i> , 2015, 40, 7-43.	2.4	75
576	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1968-1975.	0.9	82
577	Incretin-Based Drugs and the Risk of Congestive Heart Failure. <i>Diabetes Care</i> , 2015, 38, 277-284.	8.6	44
578	Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. <i>Heart and Vessels</i> , 2015, 30, 469-476.	1.2	21
579	Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients. <i>Heart and Vessels</i> , 2015, 30, 696-701.	1.2	14
580	GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis. <i>AACE Clinical Case Reports</i> , 2016, 2, e82-e85.	1.1	1
581	Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.. <i>Colombia Medica</i> , 2016, , 109-130.	0.2	39
582	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
583	The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. <i>PLoS Medicine</i> , 2016, 13, e1002051.	8.4	57
584	The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 435.	2.0	7
585	Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials. <i>Journal of Korean Diabetes</i> , 2016, 17, 1.	0.3	0
586	Practical combination therapy based on pathophysiology of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 355-369.	2.4	16
587	Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”. <i>Current Vascular Pharmacology</i> , 2016, 14, 316-318.	1.7	2
588	Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients. <i>Italian Journal of Medicine</i> , 2016, 10, 36.	0.3	2
589	The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Journal of Korean Diabetes</i> , 2016, 17, 225.	0.3	0
590	Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 211.	4.7	22



#	ARTICLE	IF	CITATIONS
591	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clinical Pharmacology: Advances and Applications, 2016, 8, 19.	1.2	4
592	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Reports, 2016, 49, 139-148.	2.4	57
593	Diabetes Drugs and Cardiovascular Safety. Endocrinology and Metabolism, 2016, 31, 239.	3.0	12
594	Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. Hormones, 2016, 15, 170-185.	1.9	7
595	THE EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 9, 254.	0.3	5
596	The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. Gut and Liver, 2016, 10, 665-671.	2.9	19
597	Bringing patient centrality to diabetes medication access in Canada. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 599-611.	1.9	1
598	DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics. Canadian Journal of Hospital Pharmacy, 2016, 69, 253-4.	0.1	5
599	Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. Journal of Diabetes Research, 2016, 2016, 1-12.	2.3	26
600	Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS. Journal of Diabetes Research, 2016, 2016, 1-7.	2.3	4
601	Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. Mediators of Inflammation, 2016, 2016, 1-10.	3.0	138
602	Exenatide Activates the AMPK-PPAR $\alpha$ Axis to Prevent Diabetic Cardiomyocyte Apoptosis. Journal of Diabetes Research, 2016, 2016, 1-10.	2.3	17
603	Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 125.	2.4	9
604	Insulin Other Hypoglycemic Drugs. Side Effects of Drugs Annual, 2016, 38, 453-462.	0.6	0
605	Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 Pharmacology, 2016, 14, 469-473.	1.7	9
606	Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. International Journal of Molecular Sciences, 2016, 17, 1223.	4.1	37
607	Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovascular Diabetology, 2016, 15, 78.	6.8	10
608	Heart Failure as a Comorbidity of Diabetes: Role of Dipeptidyl Peptidase 4. Journal of Atherosclerosis and Thrombosis, 2016, 23, 147-154.	2.0	13



#	ARTICLE	IF	CITATIONS
609	Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. <i>BMJ</i> , The, 2016, 354, i3477.	6.0	83
610	The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0150745.	2.5	30
611	The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1001992.	8.4	101
612	Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis. <i>PLoS ONE</i> , 2016, 11, e0160436.	2.5	6
613	Update on the treatment of type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2016, 7, 354.	3.5	407
614	Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition. <i>Journal of Cardiovascular Nursing</i> , 2016, 31, 274-283.	1.1	6
615	Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients. <i>Medicine (United States)</i> , 2016, 95, e2603.	1.0	15
616	Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues. <i>Pancreas</i> , 2016, 45, 613-619.	1.1	1
617	Heart failure with multiple comorbidities. <i>Current Opinion in Cardiology</i> , 2016, 31, 209-216.	1.8	17
618	Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2016, 34, 167-175.	0.5	48
619	Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. <i>Journal of Hypertension</i> , 2016, 34, 869-876.	0.5	40
620	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 220, 595-601.	1.7	59
621	Current Therapies for the Medical Management of Diabetes. <i>Obstetrics and Gynecology</i> , 2016, 127, 780-794.	2.4	18
622	Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 333-347.	4.4	161
623	Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function. <i>Journal of Cellular Physiology</i> , 2016, 231, 756-767.	4.1	37
624	Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. <i>Diabetic Medicine</i> , 2016, 33, 621-630.	2.3	9
625	Vascular Complications of Diabetes. <i>Circulation Research</i> , 2016, 118, 1771-1785.	4.5	262
626	The EMPA-REG outcome study: critical appraisal and potential clinical implications. <i>Cardiovascular Diabetology</i> , 2016, 15, 85.	6.8	16

#	ARTICLE	IF	CITATIONS
627	Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?. International Journal of Cardiology, 2016, 220, 573-574.	1.7	7
628	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the <sc>S</sc>wedish <sc>N</sc>ational <sc>D</sc>iabetes <sc>R</sc>egister. Diabetes, Obesity and Metabolism, 2016, 18, 990-998.	4.4	44
629	Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 767-772.	2.6	10
630	A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. Journal of Molecular and Cellular Cardiology, 2016, 98, 37-47.	1.9	23
631	Adaptive Designs for Clinical Trials. New England Journal of Medicine, 2016, 375, 65-74.	27.0	335
632	Frequency of cancer events with saxagliptin in the <sc>SAVOR</sc> 53 trial. Diabetes, Obesity and Metabolism, 2016, 18, 186-190.	4.4	25
633	Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using <sc>UK</sc> primary care data linked to hospitalization and mortality records. Diabetes, Obesity and Metabolism, 2016, 18, 916-924.	4.4	12
634	An update on the "gliptins". Drug and Therapeutics Bulletin, 2016, 54, 138-141.	0.3	0
635	Vasopressin, from Regulator to Disease Predictor for Diabetes and Cardiometabolic Risk. Annals of Nutrition and Metabolism, 2016, 68, 24-28.	1.9	39
636	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology, 2016, 15, 102.	6.8	14
637	Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. Journal of Clinical Oncology, 2016, 34, 4261-4269.	1.6	163
638	More Than 7 Years of Hindsight: Revisiting the FDA's 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications. Clinical Diabetes, 2016, 34, 173-180.	2.2	31
639	An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease. SAGE Open Medicine, 2016, 4, 205031211665909.	1.8	8
640	Acute coronary syndromes and diabetes mellitus. Hellenic Journal of Cardiology, 2016, 57, 375-377.	1.0	16
649	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology, 2016, 15, 97.	6.8	49
650	Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovascular Diabetology, 2016, 15, 157.	6.8	118
652	Angioedema Due to ACE Inhibitors. Current Treatment Options in Allergy, 2016, 3, 401-415.	2.2	0
653	Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies. Current Opinion in Lipidology, 2016, 27, 484-492.	2.7	13

#	ARTICLE	IF	CITATIONS
654	Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé ?. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 574-580.	0.1	0
656	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. <i>Cell Reports</i> , 2016, 17, 2845-2856.	6.4	22
657	The year in cardiology 2015: heart failure. <i>Egyptian Heart Journal</i> , 2016, 68, 287-290.	1.2	0
658	Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study. <i>Scientific Reports</i> , 2016, 6, 30499.	3.3	11
659	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs. <i>Annals of Internal Medicine</i> , 2016, 164, 705.	3.9	91
660	Is diabetes still a state of premature cardiovascular death?. <i>Practical Diabetes</i> , 2016, 33, 285-290.	0.3	1
661	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <i>Current Diabetes Reports</i> , 2016, 16, 44.	4.2	19
662	Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 236-243.	2.0	23
663	No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?. <i>American Journal of Kidney Diseases</i> , 2016, 68, 349-352.	1.9	18
664	Insulin Signaling and Heart Failure. <i>Circulation Research</i> , 2016, 118, 1151-1169.	4.5	292
665	Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 212, 203-205.	1.7	9
666	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. <i>Canadian Journal of Diabetes</i> , 2016, 40, 193-195.	0.8	32
667	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	4.5	51
668	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016, 39, 1329-1337.	8.6	12
669	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	2.2	5,370
670	Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 867-872.	3.0	12
672	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 759-766.	2.6	18
673	Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 222, 1072-1073.	1.7	0

#	ARTICLE	IF	CITATIONS
674	Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease. International Journal of Cardiology, 2016, 218, 170-175.	1.7	13
675	Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?. Diabetes Research and Clinical Practice, 2016, 117, 28-31.	2.8	2
676	Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction â€” Long-term results of the SITAGRAMI trial. International Journal of Cardiology, 2016, 215, 441-445.	1.7	10
677	Mortality risk in admitted patients with diabetes mellitus according to treatment. Journal of Diabetes and Its Complications, 2016, 30, 1025-1031.	2.3	4
678	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. European Journal of Clinical Pharmacology, 2016, 72, 1013-1023.	1.9	13
679	NUEVOS FÁRMACOS EN DIABETES MELLITUS. Revista Médica Clínica Las Condes, 2016, 27, 235-256.	0.2	4
680	Risk of fractures and diabetes medications: a nationwide cohort study. Osteoporosis International, 2016, 27, 2709-2715.	3.1	43
681	Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. Current Heart Failure Reports, 2016, 13, 111-118.	3.3	4
682	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Clinical Therapeutics, 2016, 38, 1288-1298.	2.5	28
683	Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?. Indian Heart Journal, 2016, 68, 564-571.	0.5	15
684	Serum high-sensitivity cardiac troponin T and coronary artery calcification. Journal of Cardiovascular Computed Tomography, 2016, 10, e1.	1.3	0
685	DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes â€” A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2016, 116, 288-298.	2.8	52
686	Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapyâ€™s safety profile. Postgraduate Medicine, 2016, 128, 609-619.	2.0	17
687	Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovascular Diabetology, 2016, 15, 57.	6.8	34
688	Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. Trials, 2016, 17, 29.	1.6	11
691	Hypertension and Diabetic Nephropathy. Endocrine Development, 2016, 31, 97-107.	1.3	8
692	The metabolic vascular syndrome - guide to an individualized treatment. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 5-17.	5.7	29
693	Diabetes and oral therapies. Journal of Taibah University Medical Sciences, 2016, 11, 317-329.	0.9	25

#	ARTICLE	IF	CITATIONS
694	Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes, 2016, 65, 1714-1723.	0.6	87
696	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
697	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 380-386.	2.6	30
698	The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure. JAMA Cardiology, 2016, 1, 123.	6.1	23
699	Myocardial dysfunction and cardiovascular disease in type 2 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 271-281.	1.2	17
700	Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism: Clinical and Experimental, 2016, 65, 893-903.	3.4	30
702	Novel insight into the dangerous connection between diabetes and heart failure. Herz, 2016, 41, 201-207.	1.1	12
703	Glucose-lowering therapy in type 2 diabetes. Herz, 2016, 41, 208-216.	1.1	3
704	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care, 2016, 39, 717-725.	8.6	244
705	Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?. Diabetes Therapy, 2016, 7, 175-185.	2.5	9
706	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Research and Clinical Practice, 2016, 117, 39-47.	2.8	68
707	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. Journal of Diabetes and Its Complications, 2016, 30, 1177-1185.	2.3	15
708	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. Clinical Therapeutics, 2016, 38, 1279-1287.	2.5	18
709	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 200-205.	3.0	30
710	Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead. European Heart Journal, 2016, 37, 3201-3202.	2.2	7
711	Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 116, 171-182.	2.8	15
712	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 117-127.	5.7	5
713	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. Diabetes Care, 2016, 39, 738-742.	8.6	52

#	ARTICLE	IF	CITATIONS
715	Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. European Journal of Pharmaceutical Sciences, 2016, 89, 73-82.	4.0	14
716	DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty. Diabetes Care, 2016, 39, 735-737.	8.6	19
717	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia, 2016, 59, 1333-1339.	6.3	254
719	New strategies to tackle diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 348-354.	2.0	2
720	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. European Heart Journal, 2016, 37, 3192-3200.	2.2	142
721	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.5	13
722	Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovascular Disorders, 2016, 16, 91.	1.7	35
723	Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4205-4213.	3.6	31
724	Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 9598-9611.	2.8	26
725	SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opinion on Pharmacotherapy, 2016, 17, 2073-2084.	1.8	18
726	Antiglycemic Agents. Hospital Medicine Clinics, 2016, 5, 542-554.	0.2	0
727	Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats. Journal of Pharmacological Sciences, 2016, 132, 65-70.	2.5	16
729	Le traitement par inhibiteurs de la DPP-4 est associé à un faible risque d'hospitalisation pour insuffisance cardiaque. Medecine Des Maladies Metaboliques, 2016, 10, 89-90.	0.1	0
730	Glucagon-Like Peptide-1. JACC Basic To Translational Science, 2016, 1, 267-276.	4.1	25
731	Influencia de la diabetes mellitus y su tratamiento en pacientes con insuficiencia cardiaca por disfunción sistólica. Revista Clínica Española, 2016, 216, 506-508.	0.6	0
732	Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovascular Diabetology, 2016, 15, 133.	6.8	22
733	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	6.1	77
735	Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013-2016) analysis. Expert Opinion on Drug Safety, 2016, 15, 17-34.	2.4	6



#	ARTICLE	IF	CITATIONS
736	Ensayos clínicos de resultados de enfermedad cardiovascular en diabetes. Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición, 2016, 63, 317-319.	0.8	3
737	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. Canadian Journal of Diabetes, 2016, 40, 379-381.	0.8	1
738	Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos. Medicine, 2016, 12, 1013-1025.	0.0	0
740	Résultats de l'étude TECOS. Medecine Des Maladies Metaboliques, 2016, 10, 87-88.	0.1	0
741	Current perspectives on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2016, 15, 139.	6.8	59
742	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Current Diabetes Reports, 2016, 16, 116.	4.2	40
743	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1071-1078.	2.6	13
744	Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians. Postgraduate Medicine, 2016, 128, 822-827.	2.0	0
745	Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Therapy, 2016, 7, 725-742.	2.5	17
746	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care, 2016, 39, 1830-1845.	8.6	129
747	New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun. Revista Española De Cardiología (English Ed ), 2016, 69, 1005-1007.	0.6	0
748	Antiatherogenic and antiinflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and dipeptidyl peptidase-4 inhibitors in experimental animals. Journal of Diabetes Investigation, 2016, 7, 80-86.	2.4	44
749	DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Archives of Pharmacal Research, 2016, 39, 1114-1128.	6.3	44
750	Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy, 2016, 7, 439-454.	2.5	24
751	Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2016, 7, 387-399.	2.5	6
752	Chronic ischaemic heart disease in the elderly. Medicina Clínica (English Edition), 2016, 146, 372.e1-372.e10.	0.2	0
753	Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. Seminars in Nephrology, 2016, 36, 331-342.	1.6	15
754	Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Failure, 2016, 3, 77-85.	3.1	24

#	ARTICLE	IF	CITATIONS
755	Treatment of diabetes: Crossing to the other side. Hellenic Journal of Cardiology, 2016, 57, 304-310.	1.0	16
756	Omarigliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2016, 17, 1947-1952.	1.8	18
757	Diabetes News. Journal of Diabetes, 2016, 8, 300-304.	1.8	33
758	Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus. Internal Medicine Journal, 2016, 46, 540-549.	0.8	4
759	Novel extrapancreatic effects of incretin. Journal of Diabetes Investigation, 2016, 7, 76-79.	2.4	17
760	DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2016, 32, 391-404.	4.0	54
761	Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes/Metabolism Research and Reviews, 2016, 32, 843-857.	4.0	25
762	Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development. Diabetic Medicine, 2016, 33, 718-722.	2.3	9
763	Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes, Obesity and Metabolism, 2016, 18, 463-474.	4.4	12
764	Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. Journal of Diabetes Investigation, 2016, 7, 5-16.	2.4	40
765	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Internal Medicine, 2016, 176, 1464.	5.1	87
766	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. Diabetes, Obesity and Metabolism, 2016, 18, 1253-1262.	4.4	13
767	Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular Diabetology, 2016, 15, 123.	6.8	52
768	Glycaemic control and cardiovascular disease: is there a light at the end of the tunnel?: Table 1.. QJM - Monthly Journal of the Association of Physicians, 2016, 110, hcw141.	0.5	3
769	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications. Circulation, 2016, 134, 571-573.	1.6	16
770	Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial. Contemporary Clinical Trials Communications, 2016, 4, 46-51.	1.1	2
771	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. Current Diabetes Reports, 2016, 16, 94.	4.2	2
772	Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. Hypertension, 2016, 68, 549-551.	2.7	3



#	ARTICLE	IF	CITATIONS
773	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovascular Diabetology, 2016, 15, 111.	6.8	44
774	Cardiac implications of drugs used to treat type 2 diabetes. British Journal of Cardiac Nursing, 2016, 11, 168-172.	0.1	0
775	Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovascular Diabetology, 2016, 15, 94.	6.8	36
776	Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 733-742.	1.9	31
778	Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ, The, 2016, 353, i2231.	6.0	70
779	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	2.7	21
780	N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3437-3444.	3.6	7
781	Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models. Circulation Journal, 2016, 80, 1988-1997.	1.6	27
782	Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine, 2016, 164, 740.	3.9	509
783	Plasma Glucagon-Like Peptide-1 and Tissue Characteristics of Coronary Plaque in Non-Diabetic Acute Coronary Syndrome Patients. Circulation Journal, 2016, 80, 469-476.	1.6	4
784	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1267-1271.	3.3	8
785	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines Heart Failure registry. American Heart Journal, 2016, 182, 9-20.	2.7	115
786	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
787	Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP). Diabetes Research and Clinical Practice, 2016, 121, 146-156.	2.8	7
788	Follow the LEADER Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. Diabetes Therapy, 2016, 7, 601-609.	2.5	10
789	No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan. International Journal of Cardiology, 2016, 220, 14-20.	1.7	17
790	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. Cardiovascular Diabetology, 2016, 15, 95.	6.8	52
791	One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes, Obesity and Metabolism, 2016, 18, 1128-1133.	4.4	31

#	ARTICLE	IF	CITATIONS
792	Personalized Therapy by Phenotype and Genotype. Diabetes Care, 2016, 39, S127-S136.	8.6	13
793	Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back. Diabetes Care, 2016, 39, S146-S153.	8.6	22
794	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. Diabetes Care, 2016, 39, S154-S164.	8.6	36
795	Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	3.9	22
796	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care, 2016, 39, S210-S218.	8.6	18
797	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. Diabetes Care, 2016, 39, S244-S252.	8.6	189
798	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. Diabetes Care, 2016, 39, S187-S195.	8.6	42
799	Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis. Diabetes Care, 2016, 39, S196-S204.	8.6	37
800	Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes Care, 2016, 39, S219-S227.	8.6	10
801	Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovascular Diabetology, 2016, 15, 76.	6.8	32
802	Drugs That May Cause or Exacerbate Heart Failure. Circulation, 2016, 134, e32-69.	1.6	320
803	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 313.	7.4	329
804	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	3.9	19
806	Results from Cardiovascular Outcome Trials in Diabetes. Endocrinología y Nutrición (English) Tj ETQq1 1 0.784314 rgBT /Oyerlock 10 0.5BT	0.5	1
807	Nuevos tratamientos para la diabetes mellitus tipo 2 y enfermedad cardiovascular. La revolución ya ha empezado. Revista Espanola De Cardiologia, 2016, 69, 1005-1007.	1.2	2
808	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e535-e578.	1.6	285
809	Prevention: some important steps forward, but many unmet needs in a world with cardiovascular disease as the leading cause of death. European Heart Journal, 2016, 37, 3179-3181.	2.2	17
810	Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor. Clinica Chimica Acta, 2016, 463, 181-192.	1.1	11

#	ARTICLE	IF	CITATIONS
811	Effects of Glimepiride versus Saxagliptin on $\beta$ -Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. <i>Clinical Therapeutics</i> , 2016, 38, 2578-2588.	2.5	5
812	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 749-758.	4.4	7
813	The role of natriuretic peptides in diabetes and its complications. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1826-1832.	5.6	8
815	Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. <i>Scientific Reports</i> , 2016, 6, 29104.	3.3	52
816	Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet. <i>Current Atherosclerosis Reports</i> , 2016, 18, 79.	4.8	6
817	An update on DPP-4 inhibitors in the management of type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 409-419.	2.4	52
818	Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. <i>BMJ</i> , The, 2016, 352, i1450.	6.0	84
819	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. <i>BMJ</i> , The, 2016, 355, i5340.	6.0	13
820	Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. <i>BMJ Open</i> , 2016, 6, e012801.	1.9	44
821	Complementary Efforts Make for Efficient Research. <i>Annals of Internal Medicine</i> , 2016, 164, 771.	3.9	1
822	PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000216.	2.8	3
823	Context-dependent effects of dipeptidyl peptidase 4 inhibitors. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 26, 1.	2.0	10
824	Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visión adipoc�ntrica del abordaje de la diabetes. <i>Medicina Cl�nica</i> , 2016, 147, 8-16.	0.6	4
825	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000206.	2.8	6
826	Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists. <i>BMC Family Practice</i> , 2016, 17, 146.	2.9	3
827	Incretin-based therapies for the failing heart. <i>Cardiovascular Endocrinology</i> , 2016, 5, 86-92.	0.8	1
830	Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. <i>Medicine (United States)</i> , 2016, 95, e3995.	1.0	10
831	Diabetes medications improve cardiovascular outcomes. <i>Current Opinion in Lipidology</i> , 2016, 27, 633-635.	2.7	0

#	ARTICLE	IF	CITATIONS
832	Hyperglycemia Management In Patients With Posttransplantation Diabetes. Endocrine Practice, 2016, 22, 454-465.	2.1	17
833	The contributions of dipeptidyl peptidase IV to inflammation in heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1760-H1772.	3.2	13
836	DPP-4 inhibition improves early mortality, $\beta_2$ cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid. Diabetology and Metabolic Syndrome, 2016, 8, 16.	2.7	17
837	Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. Clinical Diabetes and Endocrinology, 2016, 2, 12.	2.7	14
838	Cardiovascular effects of anti-diabetes drugs. Expert Opinion on Drug Safety, 2016, 15, 1239-1257.	2.4	14
843	Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes?. Current Diabetes Reports, 2016, 16, 70.	4.2	13
844	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. Journal of Diabetes and Its Complications, 2016, 30, 1378-1384.	2.3	9
845	Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 7-19.	2.4	23
846	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.6	155
847	Future and emerging therapies. , 2016, , 77-92.		1
848	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology, 2016, 12, 566-592.	9.6	292
849	Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology, 2016, 783, 56-63.	3.5	24
850	GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. Expert Review of Endocrinology and Metabolism, 2016, 11, 1-8.	2.4	5
851	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diabetes and Vascular Disease Research, 2016, 13, 307-311.	2.0	6
852	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine, 2016, 54, 32-37.	2.3	1
853	Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study. Journal of Diabetes and Its Complications, 2016, 30, 1339-1346.	2.3	6
855	Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. Cardiovascular Diabetology, 2016, 15, 55.	6.8	4
856	Metabolically-inactive glucagon-like peptide-1(9â€“36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovascular Diabetology, 2016, 15, 65.	6.8	25

#	ARTICLE	IF	CITATIONS
857	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. Expert Opinion on Pharmacotherapy, 2016, 17, 1527-1538.	1.8	3
858	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. Cardiology, 2016, 135, 108-126.	1.4	5
859	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care, 2016, 39, 1267-1273.	8.6	47
860	Can a Shift in Fuel Energetics Explain the Beneficial Cardioresenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care, 2016, 39, 1115-1122.	8.6	474
861	Dipeptidyl peptidase-4 inhibitors. , 2016, , 45-60.		0
862	Optimizing management of glycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 397-411.	4.7	10
863	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	27.0	5,070
864	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
865	Cardiac and Renovascular Complications in Type 2 Diabetes “Is There Hope?”. New England Journal of Medicine, 2016, 375, 380-382.	27.0	33
867	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology, 2016, 15, 37.	6.8	148
868	Diabetes and the heart “the battle is not lost yet!”. Herz, 2016, 41, 173-174.	1.1	0
869	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
870	A Review of the Key Clinical Trials of 2015: Results and Implications. Cardiology and Therapy, 2016, 5, 109-132.	2.6	6
871	Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes/Metabolism Research and Reviews, 2016, 32, 289-296.	4.0	54
872	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
873	Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. British Journal of Pharmacology, 2016, 173, 2165-2181.	5.4	44
874	Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2016, 18, 295-299.	4.4	60
875	Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?. Diabetes, Obesity and Metabolism, 2016, 18, 641-647.	4.4	88

#	ARTICLE	IF	CITATIONS
876	Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 755-765.	4.4	26
877	Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1. <i>Journal of Diabetes</i> , 2016, 8, 63-75.	1.8	28
878	Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 41-49.	2.6	10
879	Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). <i>Diabetes Care</i> , 2016, 39, 455-464.	8.6	110
880	The year in cardiology 2015: heart failure. <i>European Heart Journal</i> , 2016, 37, 437-441.	2.2	2
881	Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. <i>Diabetes Care</i> , 2016, 39, 726-734.	8.6	72
882	Cardiovascular Effects of Incretin-Based Therapies. <i>Annual Review of Medicine</i> , 2016, 67, 245-260.	12.2	22
883	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	2.7	82
884	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	1.0	1
885	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 361-373.	2.6	37
886	Future glucose-lowering drugs for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 350-359.	11.4	80
888	Vascular Risk and Cardiac Rehabilitation 2015: A Selection of Topical Issues. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 294-299.	0.6	1
889	Coronary Artery Disease and Diabetes Mellitus. <i>Heart Failure Clinics</i> , 2016, 12, 117-133.	2.1	16
890	Copeptin predicts coronary artery disease cardiovascular and total mortality. <i>Heart</i> , 2016, 102, 127-132.	2.9	70
891	Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). <i>Diabetes Care</i> , 2016, 39, 139-148.	8.6	119
892	Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors. <i>Endocrine</i> , 2016, 53, 373-380.	2.3	6
893	Incretin-Based Therapy for Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1488-1496.	2.8	32
894	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 379-381.	11.4	6



#	ARTICLE	IF	CITATIONS
895	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 273-284.	2.6	19
897	Heart failure event definitions in drug trials in patients with type 2 diabetes. Lancet Diabetes and Endocrinology, the, 2016, 4, 294-296.	11.4	26
898	Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. International Journal of Cardiology, 2016, 212, 29-36.	1.7	47
899	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. New England Journal of Medicine, 2016, 374, 1145-1154.	27.0	191
900	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. Postgraduate Medicine, 2016, 128, 398-408.	2.0	2
901	Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. Journal of Diabetes, 2016, 8, 809-815.	1.8	10
902	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology, 2016, 15, 29.	6.8	42
903	Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes, Obesity and Metabolism, 2016, 18, 258-265.	4.4	27
905	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Review of Endocrinology and Metabolism, 2016, 11, 281-296.	2.4	0
906	Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes and Metabolism, 2016, 42, 71-76.	2.9	49
907	Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 467-473.	3.3	9
908	A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 217-232.	2.4	4
909	Type 2 Diabetes Medication Review. American Journal of the Medical Sciences, 2016, 351, 342-355.	1.1	24
910	The safety of incretin based drug treatments for type 2 diabetes. BMJ, The, 2016, 352, i801.	6.0	4
912	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, The, 2016, 352, i581.	6.0	78
913	A Comprehensive Review of Novel Drug-“Disease Models in Diabetes Drug Development. Clinical Pharmacokinetics, 2016, 55, 769-788.	3.5	10
914	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, The, 2016, 352, i610.	6.0	183
916	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes and Endocrinology, the, 2016, 4, 403-410.	11.4	133



#	ARTICLE	IF	CITATIONS
918	Carotid atherosclerosis progression and cerebrovascular events in patients with diabetes. Journal of Diabetes and Its Complications, 2016, 30, 638-643.	2.3	15
919	Sitagliptin and other “gliptins” why prescribe them?. Expert Opinion on Pharmacotherapy, 2016, 17, 757-760.	1.8	3
920	Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. International Journal of Cardiology, 2016, 211, 88-95.	1.7	66
921	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. American Heart Journal, 2016, 175, 18-27.	2.7	6
922	Comparison of Long-Term Mortality for Cardiac Diseases in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2016, 117, 1088-1094.	1.6	19
923	Treatment of diabetes and heart failure: joint forces. European Heart Journal, 2016, 37, 1535.2-1537.	2.2	12
924	Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 748-756.	3.6	65
925	DPP-4 inhibition and blood pressure lowering in perspective. Journal of Hypertension, 2016, 34, 184-187.	0.5	4
926	Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 362-369.	3.6	14
927	The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis. Renal Failure, 2016, 38, 581-587.	2.1	8
928	Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2016, 30, 189-191.	2.3	1
929	Novel Therapeutic Approaches in Diabetes. Endocrine Development, 2016, 31, 43-56.	1.3	15
930	Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovascular Diabetology, 2016, 15, 41.	6.8	58
931	Polypharmacy in the Aging Patient. JAMA - Journal of the American Medical Association, 2016, 315, 1034.	7.4	236
932	Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion. JAMA - Journal of the American Medical Association, 2016, 315, 984.	7.4	17
933	Diabetes and Risk of Arterial Stiffness: A Mendelian Randomization Analysis. Diabetes, 2016, 65, 1731-1740.	0.6	62
934	Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology, 2016, 150, 1835-1848.	1.3	71
935	Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety, 2016, 15, 697-707.	2.4	7

#	ARTICLE	IF	CITATIONS
936	The Prospective Cardioprotective Effects of DPP-4 inhibition in the ischemic myocardium. Journal of Molecular and Cellular Cardiology, 2016, 93, 44-46.	1.9	1
937	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52, 458-480.	2.3	42
938	DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2016, 91, 72-80.	1.9	42
939	Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis. Circulation: Heart Failure, 2016, 9, e002081.	3.9	39
940	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 2016, 7, 36-38.	2.4	13
941	Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat Fed Diabetic Mice. Diabetes, 2016, 65, 742-754.	0.6	82
942	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Review of Clinical Pharmacology, 2016, 9, 605-616.	3.1	3
943	8. Cardiovascular Disease and Risk Management. Diabetes Care, 2016, 39, S60-S71.	8.6	237
944	Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. Acta Diabetologica, 2016, 53, 461-468.	2.5	21
945	Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. Journal of the American Medical Directors Association, 2016, 17, 59-64.	2.5	12
946	Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. Trends in Pharmacological Sciences, 2016, 37, 207-219.	8.7	12
947	Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know. Pancreatology, 2016, 16, 10-13.	1.1	31
948	Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?. Metabolic Syndrome and Related Disorders, 2016, 14, 3-6.	1.3	2
949	Keeping Up With Safety Warnings of Oral Antidiabetic Drugs. Journal for Nurse Practitioners, 2016, 12, 61-62.	0.8	0
950	Metformin as firstline treatment for type 2 diabetes: are we sure?. BMJ, The, 2016, 352, h6748.	6.0	26
951	Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. Metabolism: Clinical and Experimental, 2016, 65, 1-11.	3.4	25
953	Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 249-264.	2.4	6
954	Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2016, 11, 21-31.	2.4	0

#	ARTICLE	IF	CITATIONS
955	An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs, 2016, 25, 145-158.	4.1	41
956	Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control. International Journal of Cardiology, 2016, 202, 415-416.	1.7	5
957	Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. Heart and Vessels, 2016, 31, 855-862.	1.2	6
958	The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice. Inflammation, 2016, 39, 413-424.	3.8	36
959	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. American Journal of Medicine, 2016, 129, 340.e1-340.e8.	1.5	34
960	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. Canadian Journal of Diabetes, 2016, 40, 50-57.	0.8	27
961	Pharmacological DPP4 inhibition for the prevention of vascular diseases. International Journal of Cardiology, 2016, 202, 49.	1.7	2
962	Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart and Vessels, 2016, 31, 1239-1246.	1.2	18
963	The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology, 2016, 202, 731-735.	1.7	19
964	Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart and Vessels, 2016, 31, 1303-1310.	1.2	32
965	Clinical use of GLP-1 agonists and DPP4 inhibitors. Pancreatology, 2016, 16, 8-9.	1.1	7
967	Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals. Journal of Clinical Epidemiology, 2016, 69, 170-173.e8.	5.0	97
968	Approach to diabetes management in patients with CVD. Trends in Cardiovascular Medicine, 2016, 26, 165-179.	4.9	38
969	Glucagon and the Glucagon-Like Peptides. , 2016, , 586-597.e5.		1
970	Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetologica, 2016, 53, 35-40.	2.5	16
971	Effects of diabetes drugs on the skeleton. Bone, 2016, 82, 93-100.	2.9	130
972	Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study. Heart and Vessels, 2016, 31, 649-654.	1.2	8
973	Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the <scp>C</scp>leveland <scp>C</scp>linic. Journal of Diabetes, 2016, 8, 279-285.	1.8	16

#	ARTICLE	IF	CITATIONS
974	Adverse Effects Associated With Newer Diabetes Therapies. <i>Journal of Pharmacy Practice</i> , 2017, 30, 238-244.	1.0	5
975	Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 64-68.	2.3	26
976	Integrated Data Analysis for Assessing Treatment Effect through Combining Information from All Sources. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 52-64.	0.8	5
978	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 375-377.	2.6	5
979	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. <i>Current Medical Research and Opinion</i> , 2017, 33, 985-992.	1.9	9
980	The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells. <i>Journal of Pharmacological Sciences</i> , 2017, 133, 42-48.	2.5	20
981	DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!. <i>Diabetes Care</i> , 2017, 40, 161-163.	8.6	33
982	Antidiabetic medications use trends in an Andalusian region from 2001 to 2014. <i>Primary Care Diabetes</i> , 2017, 11, 254-264.	1.8	6
983	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes Care</i> , 2017, 40, 494-501.	8.6	50
984	Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 261-265.	1.5	33
985	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. <i>Diabetes Research and Clinical Practice</i> , 2017, 124, 1-10.	2.8	15
986	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. <i>Cardiovascular Diabetology</i> , 2017, 16, 6.	6.8	107
988	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 18.	6.8	43
989	Sitagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 209-224.	10.9	83
990	Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1556-1570.	2.4	25
991	Is Hemoglobin A <sub>1c</sub> the Right Outcome for Studies of Diabetes?. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1017.	7.4	76
993	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 391-402.	11.4	56
994	SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 429-442.	3.1	18

#	ARTICLE	IF	CITATIONS
995	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 831-841.	4.4	75
996	Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs. <i>Journal of Diabetes Investigation</i> , 2017, 8, 633-634.	2.4	3
997	A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 13.	6.8	29
998	Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. <i>Annals of Pharmacotherapy</i> , 2017, 51, 563-569.	1.9	3
999	Recomendaciones sobre el efecto de los fármacos antidiabéticos en el hueso. <i>Endocrinología, Diabetes Y Nutrición</i> , 2017, 64, 1-6.	0.3	4
1000	Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy. <i>Vascular Medicine</i> , 2017, 22, 189-196.	1.5	26
1001	Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 138-143.	2.8	5
1002	Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. <i>Hypertension Research</i> , 2017, 40, 646-651.	2.7	34
1003	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 970-978.	4.4	17
1004	DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 22.	6.8	13
1005	Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure. <i>Heart</i> , 2017, 103, 414-420.	2.9	17
1006	The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 194-202.	4.9	34
1007	Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 27.	6.8	35
1008	Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1147-1154.	4.4	33
1009	Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 347-360.	0.8	5
1010	Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. <i>Drugs</i> , 2017, 77, 319-330.	10.9	27
1011	Type 2 diabetes. <i>Lancet, The</i> , 2017, 389, 2239-2251.	13.7	1,691
1012	Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. <i>Cardiovascular Diabetology</i> , 2017, 16, 31.	6.8	64

#	ARTICLE	IF	CITATIONS
1013	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports, 2017, 19, 25.	2.9	2
1014	Contemporary risk estimates of three HbA1c variables in relation to heart failure following diagnosis of type 2 diabetes. Heart, 2017, 103, 353-358.	2.9	8
1015	Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. Diabetes Care, 2017, 40, 702-705.	8.6	14
1016	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. International Journal of Cardiology, 2017, 241, 302-310.	1.7	20
1017	Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy. Trends in Cardiovascular Medicine, 2017, 27, 376-377.	4.9	0
1018	Hypoglycaemia manifestations and recurrent events: <sc>L</sc>essons from the <sc>SAVOR&TMI</sc> 53 outcome study. Diabetes, Obesity and Metabolism, 2017, 19, 1045-1050.	4.4	5
1019	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. Journal of Diabetes and Its Complications, 2017, 31, 1215-1221.	2.3	34
1020	Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs. American Journal of Cardiovascular Drugs, 2017, 17, 203-215.	2.2	5
1022	Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. Heart Lung and Circulation, 2017, 26, 1133-1141.	0.4	10
1023	Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	73
1024	Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. Journal of Molecular Endocrinology, 2017, 59, R1-R10.	2.5	44
1025	Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care, 2017, 40, 706-714.	8.6	152
1026	Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study. Osteoporosis International, 2017, 28, 2053-2060.	3.1	35
1027	Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Therapy, 2017, 8, 587-599.	2.5	9
1028	Incretin&Ccedil;based glucose&Ccedil;lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio&Ccedil;vascular outcome trials. Diabetes, Obesity and Metabolism, 2017, 19, 1327-1328.	4.4	17
1029	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase&Ccedil;4 inhibitor or a sulphonylurea: <sc>R</sc>esults from the <sc>OsMed H</sc>ealth&Ccedil;DB</sc> registry. Diabetes, Obesity and Metabolism, 2017, 19, 1416-1424.	4.4	18
1030	Recommendations on the effect of antidiabetic drugs in bone. Endocrinolog&Aa Diabetes Y Nutrici&A3n (English Ed ), 2017, 64, 1-6.	0.2	1
1031	DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Failure Reviews, 2017, 22, 299-304.	3.9	21



#	ARTICLE	IF	CITATIONS
1032	Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2017, 240, 414-421.	1.7	36
1033	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , 2017, 7, e014728.	1.9	10
1034	A Rock and a Hard Place. <i>Circulation</i> , 2017, 135, 1951-1955.	1.6	50
1035	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2017, 5, CD012204.	2.8	31
1036	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2263-2274.	6.1	59
1037	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. <i>CMAJ Open</i> , 2017, 5, E152-E177.	2.4	57
1038	Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action. <i>Clinical Therapeutics</i> , 2017, 39, 1064-1076.	2.5	40
1039	Are targeted therapies for diabetic cardiomyopathy on the horizon?. <i>Clinical Science</i> , 2017, 131, 897-915.	4.3	83
1040	Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 839-841.	1.8	12
1041	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. <i>Journal of Cardiology</i> , 2017, 69, 511-517.	1.9	8
1042	Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2017, 43, 1-8.	2.9	32
1043	The regulatory role of DPP4 in atherosclerotic disease. <i>Cardiovascular Diabetology</i> , 2017, 16, 76.	6.8	22
1044	Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 1869-1877.	1.9	1
1045	Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio. <i>Annals of Pharmacotherapy</i> , 2017, 51, 570-576.	1.9	10
1046	EMPA-REG OUTCOME: The Endocrinologist's Point of View. <i>American Journal of Cardiology</i> , 2017, 120, S48-S52.	1.6	2
1048	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 299-313.	2.9	28
1049	Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. <i>Diabetic Medicine</i> , 2017, 34, 1235-1243.	2.3	11
1050	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Circulation</i> , 2017, 136, 249-259.	1.6	672



#	ARTICLE	IF	CITATIONS
1051	Cardiovascular safety of noninsulin antidiabetic drugs: Facts and promises. Revista Clínica Española, 2017, 217, 473-477.	0.5	0
1052	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. Diabetes Care, 2017, 40, 813-820.	8.6	109
1053	Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care, 2017, 40, 821-831.	8.6	53
1054	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor- $\alpha$ concentrations: A systematic review and meta-analysis of controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 1458-1464.	2.3	19
1055	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. Journal of General Internal Medicine, 2017, 32, 1044-1051.	2.6	20
1056	A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Biomedicine and Pharmacotherapy, 2017, 92, 707-719.	5.6	7
1057	Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis. Value in Health, 2017, 20, 1427-1430.	0.3	21
1058	Mdivi-1 induced acute changes in the angiogenic profile after ischemia-reperfusion injury in female mice. Physiological Reports, 2017, 5, e13298.	1.7	22
1059	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. American Journal of Cardiology, 2017, 120, S28-S36.	1.6	45
1060	Novel Diabetes Drugs and the Cardiovascular Specialist. Journal of the American College of Cardiology, 2017, 69, 2646-2656.	2.8	75
1061	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends in Endocrinology and Metabolism, 2017, 28, 561-586.	7.1	31
1062	GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. Diabetes, 2017, 66, 1453-1460.	0.6	55
1063	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. American Journal of Medicine, 2017, 130, S4-S17.	1.5	83
1064	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. American Journal of Medicine, 2017, 130, S18-S29.	1.5	67
1065	Diabetes Mellitus and Heart Failure. American Journal of Medicine, 2017, 130, S40-S50.	1.5	118
1066	A review on cardiovascular effects of newer hypoglycaemic medications. Annals of Medicine, 2017, 49, 603-612.	3.8	10
1067	Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies. Pharmacological Reports, 2017, 69, 1328-1340.	3.3	49
1068	Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. Journal of Women's Health, 2017, 26, 1278-1284.	3.3	17

#	ARTICLE	IF	CITATIONS
1069	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 $\pm$ 1-67 in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1073-1081.	8.6	82
1070	EMPA-REG OUTCOME: The Endocrinologist's Point of View. <i>American Journal of Medicine</i> , 2017, 130, S51-S56.	1.5	3
1071	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Medicine</i> , 2017, 130, S30-S39.	1.5	56
1072	Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress. <i>International Journal of Cardiology</i> , 2017, 243, 413-420.	1.7	57
1073	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	2.2	11
1074	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017, 120, S17-S27.	1.6	66
1075	Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. <i>Cardiovascular Diabetology</i> , 2017, 16, 48.	6.8	28
1076	So Many Antihyperglycemics: How to Choose? A Practical Approach. <i>Canadian Journal of Diabetes</i> , 2017, 41, 469-473.	0.8	3
1077	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. <i>American Journal of Cardiology</i> , 2017, 120, S4-S16.	1.6	60
1078	Diabetes Mellitus and Heart Failure. <i>American Journal of Cardiology</i> , 2017, 120, S37-S47.	1.6	152
1079	Renal glucosuria is not associated with atherosclerotic cardiovascular disease outcome in a general Japanese community. <i>Atherosclerosis</i> , 2017, 261, 111-116.	0.8	8
1080	Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, $\beta$ -Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study. <i>Current Therapeutic Research</i> , 2017, 84, 26-31.	1.2	9
1081	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 24-33.	2.8	22
1082	Seguridad cardiovascular de los antidiabéticos no insulínicos: hechos y promesas. <i>Revista Clínica Española</i> , 2017, 217, 473-477.	0.6	1
1083	SGLT2 inhibitor/DPP-4 inhibitor combination therapy — complementary mechanisms of action for management of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 409-420.	2.0	30
1084	Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 224-237.	2.8	15
1085	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017, 241, 450-456.	1.7	36
1086	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	2.0	112

#	ARTICLE	IF	CITATIONS
1087	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 583-592.	3.3	8
1088	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clinical Pharmacology and Therapeutics, 2017, 102, 290-296.	4.7	11
1089	Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. Expert Opinion on Drug Safety, 2017, 16, 627-635.	2.4	2
1090	The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. Diabetes and Vascular Disease Research, 2017, 14, 295-303.	2.0	12
1091	Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-center, non-interventional post-authorization safety study. Diabetes, Obesity and Metabolism, 2017, 19, 1473-1478.	4.4	26
1092	Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. American Journal of Physiology - Renal Physiology, 2017, 312, F661-F670.	2.7	72
1093	Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?. Endocrine Practice, 2017, 23, 89-99.	2.1	10
1094	Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice, 2017, 23, 831-840.	2.1	11
1095	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). American Heart Journal, 2017, 187, 1-9.	2.7	49
1096	Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. Expert Opinion on Drug Safety, 2017, 16, 481-492.	2.4	6
1097	Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Annals of Internal Medicine, 2017, 166, 572.	3.9	92
1098	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. Current Diabetes Reports, 2017, 17, 21.	4.2	33
1099	Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a phase IV open-label randomized controlled study (the SMART study). Diabetes, Obesity and Metabolism, 2017, 19, 1513-1520.	4.4	24
1100	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 23.	0.9	69
1101	What would be the fate of the association between saxagliptin and heart failure admission in the SAVOR-TIMI 53 trial if appropriate statistical methods should have been applied?. Diabetes Research and Clinical Practice, 2017, 126, 320-321.	2.8	4
1102	Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged 60 years (START trial). Diabetes, Obesity and Metabolism, 2017, 19, 1188-1192.	4.4	24
1103	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 2017, 5, 333-340.	11.4	258
1104	Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction. International Journal of Cardiology, 2017, 241, 249-254.	1.7	6

#	ARTICLE	IF	CITATIONS
1105	Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction. Porto Biomedical Journal, 2017, 2, 111-114.	1.0	1
1106	Assessment of Stable Coronary Lesions. New England Journal of Medicine, 2017, 376, 1879-1881.	27.0	22
1107	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. Diabetes Technology and Therapeutics, 2017, 19, 324-327.	4.4	5
1108	Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply. JAMA Cardiology, 2017, 2, 821.	6.1	0
1109	2016 European Guidelines on cardiovascular disease prevention in clinical practice. International Journal of Behavioral Medicine, 2017, 24, 321-419.	1.7	84
1110	Transitions, Introductions, and a Notable Announcement From the US FDA in December 2016. Therapeutic Innovation and Regulatory Science, 2017, 51, 140-141.	1.6	1
1111	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. Diabetes Care, 2017, 40, 476-484.	8.6	9
1112	Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. British Journal of Pharmacology, 2017, 174, 4070-4086.	5.4	58
1113	Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research, 2017, 47, 266-280.	3.4	53
1114	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Research and Clinical Practice, 2017, 123, 199-208.	2.8	44
1115	Protocol of GLUCOSE CONTROL Safety and Efficacy in type 2 Diabetes, a NETWORK meta-analysis: <scp>GLUCOSE DINET</scp> protocol—Rational and design. Fundamental and Clinical Pharmacology, 2017, 31, 258-264.	1.9	4
1116	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. Journal of Cardiology, 2017, 69, 501-507.	1.9	28
1117	Incretin-based therapy for type 2 diabetes: A real class effect?. International Journal of Cardiology, 2017, 227, 141-142.	1.7	2
1118	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology, 2017, 13, 11-26.	9.6	398
1119	GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. Eating and Weight Disorders, 2017, 22, 231-240.	2.5	25
1120	Liquiritigenin attenuates cardiac injury induced by high fructose-feeding through fibrosis and inflammation suppression. Biomedicine and Pharmacotherapy, 2017, 86, 694-704.	5.6	43
1121	Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials. International Journal of Cardiology, 2017, 230, 324-326.	1.7	16
1122	8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40, S64-S74.	8.6	365

#	ARTICLE	IF	CITATIONS
1123	9. Cardiovascular Disease and Risk Management. Diabetes Care, 2017, 40, S75-S87.	8.6	203
1124	Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor. Journal of Cardiology, 2017, 69, 508-510.	1.9	2
1125	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.6	454
1126	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes, 2017, 35, 141-153.	2.2	1
1127	Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Bioorganic Chemistry, 2017, 75, 357-367.	4.1	21
1128	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases, 2017, 60, 422-434.	3.1	87
1129	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. Current Heart Failure Reports, 2017, 14, 445-453.	3.3	7
1130	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Advances in Experimental Medicine and Biology, 2017, 1067, 197-217.	1.6	44
1131	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	8.6	60
1132	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 1303-1316.	3.1	6
1134	The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study. Diabetes Therapy, 2017, 8, 1147-1162.	2.5	2
1135	Is the Way to Someone's Heart Through Their Stomach?. Circulation: Heart Failure, 2017, 10, .	3.9	12
1136	Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation, 2017, 136, 1548-1559.	1.6	172
1137	Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines. Diabetes Research and Clinical Practice, 2017, 134, 91-105.	2.8	32
1138	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open, 2017, 7, e018097.	1.9	38
1139	Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. Diabetes Care, 2017, 40, 1787-1789.	8.6	44
1141	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	7.1	139
1142	Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. Expert Opinion on Drug Safety, 2017, 16, 1313-1322.	2.4	10

#	ARTICLE	IF	CITATIONS
1143	The shifting paradigm in the treatment of type 2 diabetes mellitusâ€”A cardiologist's perspective. <i>Clinical Cardiology</i> , 2017, 40, 970-973.	1.8	4
1144	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , 2017, 40, 1144-1151.	8.6	50
1145	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1780-1789.e33.	2.5	33
1146	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. <i>Circulation</i> , 2017, 136, 849-870.	1.6	415
1147	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	27.0	903
1148	DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment. <i>Journal of Pharmacological Sciences</i> , 2017, 135, 29-36.	2.5	7
1149	Pharmacological management of type 2 diabetes: whatâ€™s new in 2017?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1383-1394.	3.1	19
1150	NMDAR antagonists for the treatment of diabetes mellitusâ€”Current status and future directions. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 95-106.	4.4	22
1151	Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelinâ€™s glucose-lowering effects. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	61
1152	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	27.0	1,455
1153	Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	36
1154	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017, 40, 1302-1313.	8.6	11
1155	A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1399-1405.	2.4	7
1156	Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure. <i>Biochemical Pharmacology</i> , 2017, 145, 64-80.	4.4	33
1157	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	1.7	503
1158	Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	67
1159	High glucoseâ€”induced endothelial progenitor cell dysfunction. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 381-394.	2.0	50
1160	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 67.	4.2	4



#	ARTICLE	IF	CITATIONS
1161	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care, 2017, 40, 1121-1127.	8.6	43
1163	Diabetes in the Elderly. , 2017, , 179-187.		0
1164	Individualisation du traitement de l'hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule. Medecine Des Maladies Metaboliques, 2017, 11, 2S2-2S14.	0.1	0
1165	Nouvelles études dans le diabète de type 2 : le point de vue du cardiologue. Medecine Des Maladies Metaboliques, 2017, 11, 2S43-2S48.	0.1	0
1167	Sécurité cardiovasculaire des agonistes du récepteur du glucagon-like peptide-1 et des inhibiteurs du co-transporteur sodium-glucose de type 2 : focus sur les résultats des grands essais d'intervention. Medecine Des Maladies Metaboliques, 2017, 11, 2S27-2S36.	0.1	0
1168	Effects of dipeptidyl peptidase-4 inhibitor sitagliptin on coronary atherosclerosis as assessed by intravascular ultrasound in type 2 diabetes mellitus with coronary artery disease. IJC Metabolic & Endocrine, 2017, 16, 1-9.	0.5	2
1169	Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease. Vascular Pharmacology, 2017, 96-98, 1-4.	2.1	11
1170	Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety, 2017, 16, 1133-1148.	2.4	3
1172	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgraduate Medicine, 2017, 129, 811-821.	2.0	40
1173	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety, 2017, 16, 1121-1132.	2.4	18
1174	The potential of chrysophanol in protecting against high fat-induced cardiac injury through Nrf2-regulated anti-inflammation, anti-oxidant and anti-fibrosis in Nrf2 knockout mice. Biomedicine and Pharmacotherapy, 2017, 93, 1175-1189.	5.6	45
1175	Cardiovascular disease leads to a new algorithm for diabetes treatment. Journal of Clinical Lipidology, 2017, 11, 1126-1133.	1.5	14
1176	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025.	6.1	280
1177	Dipeptidyl peptidase-4 inhibition and renoprotection. Current Opinion in Nephrology and Hypertension, 2017, 26, 56-66.	2.0	16
1178	Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1338-1346.	1.9	8
1179	Nutraceutical approaches to metabolic syndrome. Annals of Medicine, 2017, 49, 678-697.	3.8	24
1180	Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients. European Journal of Clinical Investigation, 2017, 47, 829-838.	3.4	11
1181	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes and Endocrinology, 2017, 5, 709-717.	11.4	285



#	ARTICLE	IF	CITATIONS
1182	Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice. <i>Endocrinology</i> , 2017, 158, 3592-3604.	2.8	21
1183	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1719-1727.	2.3	55
1184	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. <i>Current Geriatrics Reports</i> , 2017, 6, 175-186.	1.1	20
1185	Active Stromal Cell-Derived Factor 1 $\alpha$ and Endothelial Progenitor Cells are Equally Increased by Alogliptin in Good and Poor Diabetes Control. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2017, 10, 117955141774398.	1.9	6
1186	Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. <i>Clinical Therapeutics</i> , 2017, 39, 2438-2447.	2.5	10
1189	Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 15795.	3.3	15
1190	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. <i>Pharmaceutical Medicine</i> , 2017, 31, 399-421.	1.9	3
1191	The CANVAS trial programme raises more questions than answers. <i>Practical Diabetes</i> , 2017, 34, 232-233.	0.3	2
1192	Cardiovascular safety outcomes of new antidiabetic therapies. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 970-976.	1.0	5
1193	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 275-283.	3.3	15
1194	Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 200.	7.4	2
1195	Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice. <i>Scientific Reports</i> , 2017, 7, 1791.	3.3	15
1196	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. <i>Current Diabetes Reports</i> , 2017, 17, 64.	4.2	4
1197	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1101-1114.	1.8	12
1198	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 483-495.	1.9	35
1199	Antihyperglycemic agents and cardiovascular outcomes. <i>Current Opinion in Cardiology</i> , 2017, 32, 642-650.	1.8	2
1200	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	1.8	35
1203	Novel Therapies for Acute Kidney Injury. <i>Kidney International Reports</i> , 2017, 2, 785-799.	0.8	47

#	ARTICLE	IF	CITATIONS
1204	Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovascular Diabetology, 2017, 16, 63.	6.8	48
1205	Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. Cardiovascular Diabetology, 2017, 16, 67.	6.8	18
1206	Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction. Cardiovascular Diabetology, 2017, 16, 72.	6.8	2
1207	Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease. Renal Replacement Therapy, 2017, 3, .	0.7	0
1208	The use of incretins and fractures â€“ a meta-analysis on population-based real life data. British Journal of Clinical Pharmacology, 2017, 83, 923-926.	2.4	33
1209	Dipeptidyl peptidase-4 inhibitor approaches. Journal of Diabetes, 2017, 9, 5-7.	1.8	2
1210	Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. International Journal of Cardiology, 2017, 228, 1007-1014.	1.7	18
1211	Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine, 2017, 57, 464-473.	2.3	53
1212	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
1213	Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously. , 2017, , 251-275.		0
1214	Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy, 2017, 34, 1-40.	2.9	43
1215	A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?. International Journal of Cardiology, 2017, 228, 198-200.	1.7	9
1216	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. Clinical Therapeutics, 2017, 39, 1012-1025.	2.5	15
1217	The Central Role of Cardiovascular Safety in Drug Development and Therapeutic Use. , 2017, , 3-20.		0
1218	Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan. Pancreatology, 2017, 17, 76-82.	1.1	16
1219	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care, 2017, 40, 69-76.	8.6	205
1220	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. American Journal of Cardiovascular Drugs, 2017, 17, 83-95.	2.2	11
1221	Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgraduate Medicine, 2017, 129, 205-215.	2.0	25

#	ARTICLE	IF	CITATIONS
1222	The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 5-11.	2.1	22
1223	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 211-223.	3.3	16
1224	The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. <i>Endocrine</i> , 2017, 56, 509-520.	2.3	47
1225	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , 2017, 54, 19-36.	2.5	75
1226	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 Diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	3.8	17
1227	Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. <i>Journal of Diabetes Investigation</i> , 2017, 8, 227-234.	2.4	37
1228	SGLT2 Inhibitorsâ€”Sweet Success for Diabetic Kidney Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 7-10.	6.1	19
1229	Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. <i>Journal of Diabetes Investigation</i> , 2017, 8, 19-28.	2.4	22
1230	With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 7-8.	3.0	5
1231	Following the LEADER â€” why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 517-519.	2.3	9
1232	Cardiovascular safety trials of incretin-based drugs: What do they mean?. <i>Journal of Diabetes Investigation</i> , 2017, 8, 272-276.	2.4	7
1233	Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 284-286.	8.6	95
1234	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017, 19, 43-53.	7.1	91
1235	Cardiovascular safety of therapies for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 13-25.	2.4	7
1236	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	1.7	25
1237	A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease. <i>Hemodialysis International</i> , 2017, 21, 72-83.	0.9	19
1238	Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function. <i>Journal of Diabetes Investigation</i> , 2017, 8, 330-340.	2.4	33
1239	Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 401-411.	4.4	20

#	ARTICLE	IF	CITATIONS
1240	Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 143-155.	2.2	33
1241	Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study. <i>Journal of Cardiology</i> , 2017, 69, 518-522.	1.9	9
1242	Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 87-97.	4.4	20
1243	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	8.6	49
1244	Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis. <i>Medicine (United States)</i> , 2017, 96, e8952.	1.0	9
1246	DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring. <i>Diabetes</i> , 2018, 67, 518-531.	0.6	56
1247	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. <i>Cardiovascular Endocrinology</i> , 2018, 7, 18-23.	0.8	7
1248	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. <i>Clinical Diabetes</i> , 2017, 35, 321-328.	2.2	4
1250	Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1115-1128.	3.4	61
1251	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000400.	2.8	16
1253	Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2017, 357, j2499.	2.3	52
1254	The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). <i>Cardiovascular Diabetology</i> , 2017, 16, 125.	6.8	24
1256	Cardiovascular mortality and oral antidiabetic drugs: protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2017, 7, e017644.	1.9	0
1257	Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 974-983.	1.7	18
1258	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	3.5	4
1259	Heart failure. <i>Cardiovascular Endocrinology</i> , 2017, Publish Ahead of Print, 10-12.	0.8	2
1260	Postprandial Hyperlipidemia and Remnant Lipoproteins. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 95-109.	2.0	110
1261	Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. <i>Frontiers in Physiology</i> , 2017, 8, 15.	2.8	29

#	ARTICLE	IF	CITATIONS
1262	Effects of Incretin-Based Therapies on Diabetic Microvascular Complications. <i>Endocrinology and Metabolism</i> , 2017, 32, 316.	3.0	11
1263	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 69-79.	2.0	6
1264	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	1.9	1
1265	A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	3.0	2
1266	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure—Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry. <i>Circulation Journal</i> , 2017, 81, 1662-1669.	1.6	9
1267	Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 603-611.	2.0	5
1268	Emerging use of combination therapies for the management of type 2 diabetes &ndash; focus on saxagliptin and dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 317-332.	2.4	11
1269	Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 357.	4.7	20
1270	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1569-1576.	2.0	4
1271	Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0177646.	2.5	35
1272	Altered glucose metabolism and hypoxic response in alloxan-induced diabetic atherosclerosis in rabbits. <i>PLoS ONE</i> , 2017, 12, e0175976.	2.5	11
1273	Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. <i>BMC Geriatrics</i> , 2017, 17, 226.	2.7	38
1274	Zinc transporters and insulin resistance: therapeutic implications for type 2 diabetes and metabolic disease. <i>Journal of Biomedical Science</i> , 2017, 24, 87.	7.0	46
1275	The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction. <i>Cardiovascular Diabetology</i> , 2017, 16, 89.	6.8	33
1276	Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. <i>Cardiovascular Diabetology</i> , 2017, 16, 93.	6.8	31
1277	A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2017, 16, 112.	6.8	78
1278	Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin. <i>Cardiovascular Diabetology</i> , 2017, 16, 113.	6.8	6
1279	Updates on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 128.	6.8	45

#	ARTICLE	IF	CITATIONS
1280	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovascular Diabetology, 2017, 16, 137.	6.8	12
1282	Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovascular Diabetology, 2017, 16, 159.	6.8	44
1283	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetology and Metabolic Syndrome, 2017, 9, 53.	2.7	34
1284	Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Scientific Reports, 2017, 7, 8273.	3.3	41
1285	DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho <sup>+/+</sup> mice. Cardiovascular Diabetology, 2017, 16, 154.	6.8	20
1286	Coronary Artery Disease and Type 2 Diabetes Mellitus. International Heart Journal, 2017, 58, 475-480.	1.0	123
1288	DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction. International Heart Journal, 2017, 58, 778-786.	1.0	10
1289	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?. Annals of Translational Medicine, 2017, 5, 476-476.	1.7	4
1291	DPP-4 Inhibitors. , 2017, , 512-555.		2
1292	Dipeptidyl Peptidase-IV Inhibition for the Treatment of Cardiovascular Disease—Recent Insights Focusing on Angiogenesis and Neovascularization. Circulation Journal, 2017, 81, 770-776.	1.6	37
1293	Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?. International Journal of General Medicine, 2017, Volume 10, 23-26.	1.8	7
1294	Treatment of type 2 diabetes mellitus in the elderly. World Journal of Diabetes, 2017, 8, 278.	3.5	62
1295	Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy, 2017, Volume11, 923-937.	4.3	4
1296	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. Current Vascular Pharmacology, 2017, 16, 70-78.	1.7	6
1297	Monotherapy in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2017, 41, 349.	4.7	13
1298	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature Reviews Nephrology, 2017, 13, 605-628.	9.6	233
1299	Antihyperglycemic Medications and Cardiovascular Risk Reduction. European Endocrinology, 2017, 13, 86.	1.5	9
1300	Managing problems with medications for type 2 diabetes. Practice Nursing, 2017, 28, 148-153.	0.1	0



#	ARTICLE	IF	CITATIONS
1301	Type 2 diabetes mellitus treatment habits in a specialized care setting: the START-DIAB study. Mediterranean Journal of Nutrition and Metabolism, 2017, 10, 165-179.	0.5	2
1302	Treatment target of diabetes for prevention of coronary artery disease. Journal of the Japanese Coronary Association, 2017, 23, 170-173.	0.0	0
1303	Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice. Journal of Korean Diabetes, 2017, 18, 135.	0.3	0
1304	Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. Journal of Thoracic Disease, 2017, 9, 2124-2134.	1.4	20
1305	Treatment of type 2 diabetes mellitus in elderly patients. Revista Clínica Española, 2018, 218, 74-88.	0.5	17
1306	Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Current Medical Research and Opinion, 2018, 34, 1885-1892.	1.9	7
1307	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. International Journal of Diabetes in Developing Countries, 2018, 38, 1-115.	0.8	85
1308	The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety, 2018, 17, 387-405.	2.4	101
1309	Hormone treatments in congestive heart failure. Journal of International Medical Research, 2018, 46, 2063-2081.	1.0	11
1310	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
1311	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association, 2018, 81, 189-222.	1.4	19
1312	What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 12-14.	0.3	0
1313	The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2018, 34, 1081-1087.	1.9	4
1314	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Review of Clinical Pharmacology, 2018, 11, 411-424.	3.1	12
1315	The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	3.9	41
1316	The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies. Heart Failure Reviews, 2018, 23, 337-346.	3.9	3
1317	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
1318	Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Metabolism: Clinical and Experimental, 2018, 85, 14-22.	3.4	5



#	ARTICLE	IF	CITATIONS
1319	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Canadian Journal of Cardiology, 2018, 34, 632-643.	1.7	56
1320	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. Medicina Clínica (English Edition), 2018, 150, 275-281.	0.2	4
1321	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 137, 1060-1073.	1.6	26
1322	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgraduate Medicine, 2018, 130, 381-393.	2.0	24
1323	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	2.6	40
1324	Metabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. Diabetes, 2018, 67, 785-790.	0.6	22
1325	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones, 2018, 17, 219-229.	1.9	37
1326	Evaluación clínica y tratamiento de la diabetes en pacientes con enfermedad renal crónica. Revista Clínica Española, 2018, 218, 305-315.	0.6	2
1327	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. Annals of Vascular Diseases, 2018, 11, 2-14.	0.5	8
1328	Molecular and clinical roles of incretin-based drugs in patients with heart failure. Heart Failure Reviews, 2018, 23, 363-376.	3.9	1
1329	Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. Current Diabetes Reports, 2018, 18, 28.	4.2	8
1330	Treatment of Diabetes in People With Heart Failure. Canadian Journal of Diabetes, 2018, 42, S196-S200.	0.8	24
1331	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Canadian Journal of Diabetes, 2018, 42, S88-S103.	0.8	153
1332	Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: <scp>A</scp> disproportionality analysis among high-risk patients. Pharmacoepidemiology and Drug Safety, 2018, 27, 660-667.	1.9	12
1333	Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2018, 319, 1580.	7.4	313
1334	The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. British Journal of Clinical Pharmacology, 2018, 84, 1686-1695.	2.4	23
1335	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus. Cardiology in Review, 2018, 26, 312-320.	1.4	5
1336	Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. European Journal of Heart Failure, 2018, 20, 973-977.	7.1	26

#	ARTICLE	IF	CITATIONS
1337	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1196-1203.	8.6	6
1338	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	2.4	158
1340	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 86-98.	3.5	6
1341	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018, 41, 1285-1291.	8.6	38
1342	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. <i>Diabetic Medicine</i> , 2018, 35, 707-713.	2.3	4
1343	Leptin-Aldosterone-Nephrilysin Axis. <i>Circulation</i> , 2018, 137, 1614-1631.	1.6	163
1344	Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 279-287.	2.8	4
1345	Cardiovascular Protection in People With Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S162-S169.	0.8	44
1346	Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Therapeutics</i> , 2018, 40, 776-788.e3.	2.5	14
1347	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. <i>European Journal of Endocrinology</i> , 2018, 178, R127-R139.	3.7	52
1348	Designing Medical, Point of Care Sensors to Aid Health Care Providers in Diagnosing and Managing Diseases: Addressing Pertinent Issues and Some Contemporary Opportunities. <i>Electroanalysis</i> , 2018, 30, 310-313.	2.9	1
1349	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S-139-S-153.	4.4	3
1350	The Genetic Link Between Diabetes and Atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2018, 34, 565-574.	1.7	15
1351	Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. <i>Revista Clinica Espanola</i> , 2018, 218, 74-88.	0.6	39
1352	Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. <i>European Heart Journal</i> , 2018, 39, 2255-2262.	2.2	45
1354	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. <i>Heart Failure Reviews</i> , 2018, 23, 377-388.	3.9	16
1355	Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. <i>Current Medical Research and Opinion</i> , 2018, 34, 1005-1012.	1.9	0
1356	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 293-302.	2.4	27

#	ARTICLE	IF	CITATIONS
1357	Construction of Designer Selectable Marker Deletions with a CRISPR-Cas9 Toolbox in <i>Schizosaccharomyces pombe</i> and New Design of Common Entry Vectors. <i>G3: Genes, Genomes, Genetics</i> , 2018, 8, 789-796.	1.8	12
1358	Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. <i>Scientific Reports</i> , 2018, 8, 782.	3.3	70
1359	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. <i>Diabetologia</i> , 2018, 61, 1503-1516.	6.3	64
1360	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 559-569.	2.5	41
1361	Cardiovascular biomarkers in clinical studies of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1350-1360.	4.4	17
1362	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 81-96.	3.2	54
1363	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 137-152.	3.2	7
1364	Oxyntomodulin: Actions and role in diabetes. <i>Peptides</i> , 2018, 100, 48-53.	2.4	59
1365	Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries. <i>Journal of General Internal Medicine</i> , 2018, 33, 471-480.	2.6	14
1366	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	2.7	117
1367	Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. <i>Annals of Pharmacotherapy</i> , 2018, 52, 632-638.	1.9	7
1368	Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 73-80.	2.6	20
1369	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	3.1	80
1370	Hypertension with diabetes mellitus complications. <i>Hypertension Research</i> , 2018, 41, 147-156.	2.7	86
1371	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	94
1372	Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. <i>Postgraduate Medicine</i> , 2018, 130, 154-158.	2.0	6
1373	Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. <i>Diabetes Care</i> , 2018, 41, 219-223.	8.6	13
1374	Clinical impact of oral antidiabetic medications in heart failure patients. <i>Heart Failure Reviews</i> , 2018, 23, 325-335.	3.9	10

#	ARTICLE	IF	CITATIONS
1375	Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study. <i>Pharmacotherapy</i> , 2018, 38, 334-340.	2.6	5
1376	A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 34-46.	4.4	57
1377	Incretins: Beyond type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 59-67.	4.4	8
1378	What have we learnt from 'real world' data, observational studies and meta-analyses. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 47-58.	4.4	35
1379	Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1262-1279.	4.4	44
1380	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018, 23, 445-459.	3.9	9
1381	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. <i>International Journal of Cardiology</i> , 2018, 254, 291-296.	1.7	27
1382	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	3.2	17
1383	Antidiabéticos en prevención de ictus en pacientes con diabetes tipo 2. El punto de vista del neurólogo. <i>Medicina Clínica</i> , 2018, 150, 275-281.	0.6	5
1384	Management of diabetes in older adults. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 206-218.	2.6	47
1385	Novel therapies for diabetic kidney disease. <i>Kidney International Supplements</i> , 2018, 8, 18-25.	14.2	37
1386	Keeping the right track in the treatment of patients with type 2 diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 52-54.	7.1	2
1387	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	8.6	338
1388	Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 83-91.	1.8	12
1389	Age affects the prognostic impact of diabetes in chronic heart failure. <i>Acta Diabetologica</i> , 2018, 55, 271-278.	2.5	9
1390	Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. <i>American Journal of Medicine</i> , 2018, 131, 461-463.	1.5	5
1391	Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials. <i>American Journal of Medicine</i> , 2018, 131, e287-e289.	1.5	3
1392	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2981.	4.0	23

#	ARTICLE	IF	CITATIONS
1393	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. <i>Heart Failure Reviews</i> , 2018, 23, 469-479.	3.9	4
1394	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	2.2	16
1395	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. <i>European Heart Journal</i> , 2018, 39, 2368-2375.	2.2	34
1396	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 123-131.	1.5	0
1397	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	10.9	5
1398	Rationale, design, and baseline characteristics of the CARdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	6.8	70
1399	Effectiveness of gliclazide MR 60Âmg in the management of type 2 diabetes: analyses from the EASYDia trial. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 30.	2.7	19
1401	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. <i>Hormones</i> , 2018, 17, 83-95.	1.9	3
1402	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , 2018, 94, 26-39.	5.2	262
1403	Comparison of the Effects of Teneagliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , 2018, 40, 1-9.	0.6	2
1404	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from metaâ€ regression analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2131-2139.	4.4	14
1405	SGLT2 inhibition and heart failureâ€ current concepts. <i>Heart Failure Reviews</i> , 2018, 23, 409-418.	3.9	28
1406	A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2064-2074.	4.4	0
1407	Unexplained reciprocal regulation of diabetes and lipoproteins. <i>Current Opinion in Lipidology</i> , 2018, 29, 186-193.	2.7	17
1408	New antihyperglycaemic agents and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2018, 33, 444-454.	1.8	4
1410	Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. <i>Heart Lung and Circulation</i> , 2018, 27, 1301-1309.	0.4	3
1411	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	2.7	15
1412	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607.	3.9	6

#	ARTICLE	IF	CITATIONS
1413	Worsening Heart Failure During the Use of DPP-4 Inhibitors. JACC: Heart Failure, 2018, 6, 445-451.	4.1	63
1414	Prognostic significance of home pulse pressure for progression of diabetic nephropathy: KAMOGAWA-HBP study. Hypertension Research, 2018, 41, 363-371.	2.7	5
1415	Diabetes and Hypertension: Clinical Update. American Journal of Hypertension, 2018, 31, 515-521.	2.0	16
1416	Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. Journal of Diabetes and Its Complications, 2018, 32, 616-617.	2.3	0
1417	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. American Journal of Medicine, 2018, 131, 813-819.e5.	1.5	17
1418	Treatment with Oral Drugs. Endocrinology, 2018, , 1-44.	0.1	0
1419	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Current Diabetes Reports, 2018, 18, 27.	4.2	54
1421	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. Diabetes Therapy, 2018, 9, 851-861.	2.5	14
1422	Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis. Clinical Drug Investigation, 2018, 38, 491-501.	2.2	3
1423	New Glucose-Lowering Agents for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2018, 25, 149-157.	1.4	12
1424	The MARLINA-T2D trial: putting the results into clinical perspective. Expert Review of Endocrinology and Metabolism, 2018, 13, 173-176.	2.4	1
1425	Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, 272, 33-40.	0.8	34
1426	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2018, 71, 1379-1390.	2.8	50
1427	Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2018, 32, 113-122.	2.3	29
1428	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. Current Problems in Cardiology, 2018, 43, 68-110.	2.4	22
1429	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: perspective on glucose-lowering interventions. Diabetes, Obesity and Metabolism, 2018, 20, 238-244.	4.4	58
1430	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: review of current strategies. Journal of Diabetes, 2018, 10, 94-111.	1.8	18
1431	Do we know the true mechanism of action of the DPP-4 inhibitors?. Diabetes, Obesity and Metabolism, 2018, 20, 34-41.	4.4	89

#	ARTICLE	IF	CITATIONS
1432	SGLT2 inhibitors: are they safe?. Postgraduate Medicine, 2018, 130, 72-82.	2.0	47
1433	The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. Diabetes Care, 2018, 41, 150-155.	8.6	88
1434	Therapeutic strategies utilizing SDF-1 $\alpha$ in ischaemic cardiomyopathy. Cardiovascular Research, 2018, 114, 358-367.	3.8	36
1435	Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes. Canadian Journal of Cardiology, 2018, 34, 624-631.	1.7	11
1436	Diabetes and Cancers. , 2018, , 113-126.		2
1437	Safety of diabetes drugs in patients with heart failure. Revista Clínica Española, 2018, 218, 98-107.	0.5	0
1438	Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment. Diabetes, Obesity and Metabolism, 2018, 20, 723-729.	4.4	63
1439	Marked exercise-induced T-wave heterogeneity in symptomatic diabetic patients with nonflow-limiting coronary artery stenosis. Annals of Noninvasive Electrocardiology, 2018, 23, e12503.	1.1	5
1440	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. JACC: Heart Failure, 2018, 6, 8-17.	4.1	140
1441	Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes and Metabolism, 2018, 44, 121-128.	2.9	36
1442	The kidney and cardiovascular outcome trials. Journal of Diabetes, 2018, 10, 88-89.	1.8	37
1443	Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. Journal of Diabetes, 2018, 10, 192-199.	1.8	31
1444	Pancreatic Cancer Epidemiology and Environmental Risk Factors. , 2018, , 1-22.		1
1445	DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics. Heart Failure Reviews, 2018, 23, 355-361.	3.9	4
1446	Antidiabetic drugs and stroke risk. Current evidence. European Journal of Internal Medicine, 2018, 48, 1-5.	2.2	36
1447	Seguridad de los fármacos antidiabéticos en pacientes con insuficiencia cardíaca. Revista Clínica Española, 2018, 218, 98-107.	0.6	0
1448	Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology, 2018, 136, 280-286.	4.1	30
1449	The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 367-370.	1.2	10



#	ARTICLE	IF	CITATIONS
1450	European Society of Cardiology 2017. Journal of Diabetes, 2018, 10, 6-9.	1.8	0
1451	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	3.4	144
1452	Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2018, 52, 78-85.	1.9	6
1453	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine, 2018, 60, 224-228.	2.3	11
1454	Teneligliptin Prevents Cardiomyocyte Hypertrophy, Fibrosis, and Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats. Journal of Cardiac Failure, 2018, 24, 53-60.	1.7	8
1455	Practical strategies for improving outcomes in <scp>T2DM</scp>: <scp>T</scp>he potential role of pioglitazone and <scp>DPP4</scp> inhibitors. Diabetes, Obesity and Metabolism, 2018, 20, 786-799.	4.4	18
1456	Metformin â€” a cardiovascular moderator of DPP4 inhibitors?. Nature Reviews Endocrinology, 2018, 14, 8-9.	9.6	9
1457	Incretinâ€based therapies and risk of pancreatic cancer in patients with type 2 diabetes: <scp>A</scp> metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 910-920.	4.4	20
1458	Dose rectification of an imbalance between <scp>DPP</scp>4 and <scp>GLP</scp>â€1 ameliorates chronic stressâ€related vascular aging and atherosclerosis?. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 467-470.	1.9	7
1459	Survival in Type 1 and Type 2 Diabetes in a Population Referred for Invasive Evaluation of Coronary Disease. Cardiology, 2018, 139, 43-52.	1.4	1
1460	Role of the sodiumâ€hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 800-811.	4.4	10
1461	Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening. Journal of Molecular Graphics and Modelling, 2018, 79, 254-263.	2.4	4
1462	Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 117-125.	3.3	6
1463	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care, 2018, 41, 577-585.	8.6	25
1464	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 97-116.	3.2	5
1465	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 136, 23-31.	2.8	14
1466	Claimsâ€based studies of oral glucoseâ€lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes, Obesity and Metabolism, 2018, 20, 974-984.	4.4	63
1467	9. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€2018</i>. Diabetes Care, 2018, 41, S86-S104.	8.6	461

#	ARTICLE	IF	CITATIONS
1468	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological Research, 2018, 129, 274-294.	7.1	47
1469	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. Diabetes Care, 2018, 41, 39-48.	8.6	21
1470	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
1471	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2018, 9, 27-36.	2.5	5
1472	Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes and Metabolism, 2018, 44, 101-111.	2.9	19
1473	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (<sc>CVD&REAL Nordic</sc>) when compared with dipeptidyl peptidase-4 inhibitor therapy: <sc>A</sc> multinational observational study. Diabetes, Obesity and Metabolism, 2018, 20, 344-351.	4.4	164
1474	Oral Antidiabetic Agents and Cardiovascular Outcomes. Current Problems in Cardiology, 2018, 43, 111-126.	2.4	4
1475	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. Canadian Journal of Diabetes, 2018, 42, 325-334.	0.8	11
1476	Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	8.5	0
1478	Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?. Canadian Journal of Hospital Pharmacy, 2018, 71, .	0.1	0
1479	Effects of Cinnamomum cassia extract on oxidative stress, immunoreactivity of iNOS and impaired thoracic aortic reactivity induced by type II diabetes in rats. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	10
1481	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.	2.8	48
1482	Le mÃ©decin est-il un ingÃ©nieur, un artisan, ou un artiste ?. Medecine Des Maladies Metaboliques, 2018, 12, 232-236.	0.1	0
1483	Cardiovascular outcome trials in diabetes: what have we learnt?. Trends in Urology & Men's Health, 2018, 9, 7-12.	0.4	0
1484	OBSOLETE: Hormonal Therapy for Heart Failure. , 2018, , .		0
1485	Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl Peptidase-4 Inhibitors in Patients With Diabetes Mellitus. Circulation Journal, 2018, 82, 1996-1998.	1.6	0
1486	Role of combination therapy or coformulation products in treatment of type 2 diabetes. Pharmacy Today, 2018, 24, 50-64.	0.0	2
1488	7. Fallstricke in der pharmakologischen Therapie des Diabetes. , 2018, , 128-140.		0

#	ARTICLE	IF	CITATIONS
1490	Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2018, 33, 665-675.	1.8	7
1491	Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes. <i>Frontiers in Physiology</i> , 2018, 9, 1622.	2.8	17
1492	Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. <i>Endocrinología y Nutrición</i> (English Ed ), 2018, 65, 611-624.	0.2	4
1493	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1287-1302.	3.3	78
1494	Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 791-803.	1.9	15
1495	Incretin-based therapy for diabetic ulcers: from bench to bedside. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 989-996.	4.1	6
1496	Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. <i>Diabetes Care</i> , 2018, 41, 2603-2609.	8.6	19
1497	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	2.3	69
1499	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. <i>Frontiers in Physiology</i> , 2018, 9, 1514.	2.8	154
1500	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1629-1647.	3.0	31
1501	Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review. <i>Cells</i> , 2018, 7, 181.	4.1	10
1504	Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus-Physicians Challenge. <i>Journal of Diabetes &amp; Metabolism</i> , 2018, 09, .	0.2	1
1505	Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease. <i>Medicine (United States)</i> , 2018, 97, e13844.	1.0	4
1506	Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. <i>Clínica e Investigación en Arteriosclerosis</i> , 2018, 30, 1-19.	0.8	5
1507	Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018. <i>Endocrinología, Diabetes y Nutrición</i> , 2018, 65, 611-624.	0.3	28
1508	Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	2.3	82
1509	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <i>Indian Heart Journal</i> , 2018, 70, 915-921.	0.5	7
1510	More cardiovascular outcomes trials in people with diabetes: time to change the NICE guidelines. <i>Practical Diabetes</i> , 2018, 35, 193-194.	0.3	0

#	ARTICLE	IF	CITATIONS
1511	Updates in heart failure: what last year brought to us. ESC Heart Failure, 2018, 5, 989-1007.	3.1	10
1512	The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies. Frontiers in Cardiovascular Medicine, 2018, 5, 160.	2.4	4
1513	Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Network Open, 2018, 1, e186125.	5.9	69
1515	The past decade in type 2 diabetes and future challenges. Hormones, 2018, 17, 451-459.	1.9	8
1516	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4880.	2.3	33
1517	Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice, 2018, 24, 8-19.	2.1	1
1518	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association—European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
1519	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Current Cardiology Reports, 2018, 20, 112.	2.9	6
1520	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 327-341.	2.2	18
1521	Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm” Drugs, 2018, 78, 1567-1592.	10.9	8
1523	Glucose lowering and the kidney: are all drug classes equal?. Lancet Diabetes and Endocrinology, the, 2018, 6, 835-837.	11.4	0
1524	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 138, 2908-2918.	1.6	88
1525	Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. Journal of the American Heart Association, 2018, 7, e009379.	3.7	34
1526	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	6.3	1,002
1527	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	13.7	70
1528	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	8.6	2,190
1529	The Role of Deprescribing in Older Adults with Chronic Kidney Disease. Drugs and Aging, 2018, 35, 973-984.	2.7	42
1530	Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews, 2018, 39, 629-663.	20.1	154

#	ARTICLE	IF	CITATIONS
1531	Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3611-3619.	3.6	25
1532	Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3773-3782.	3.6	29
1533	The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2018, 38, 1089-1108.	2.2	15
1534	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
1535	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. <i>Cardiovascular Diabetology</i> , 2018, 17, 138.	6.8	104
1537	Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1760-1774.	3.0	7
1538	Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2018, 63, 106-112.	1.4	10
1539	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	2.5	23
1540	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease â€” Implications for Clinical Practice. <i>European Endocrinology</i> , 2018, 14, 40.	1.5	13
1541	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 76-84.	2.8	12
1542	Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications. , 2018, , 419-431.		0
1543	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. <i>Current Vascular Pharmacology</i> , 2018, 16, 524-527.	1.7	11
1544	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 172-179.	2.8	3
1545	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
1546	Revisiting the Diabetes-Heart Failure Connection. <i>Current Diabetes Reports</i> , 2018, 18, 134.	4.2	10
1547	Noninsulin medication therapy for hospitalized patients with diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1361-1368.	1.0	6
1548	Risk of hypoglycaemia in people aged â‰¥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2018, 72, e13240.	1.7	5
1550	Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. <i>Pharmacological Research</i> , 2018, 137, 270-279.	7.1	16

#	ARTICLE	IF	CITATIONS
1551	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome. Korean Circulation Journal, 2018, 48, 430.	1.9	0
1552	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes. JACC: Heart Failure, 2018, 6, 823-830.	4.1	33
1554	Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. BMC Pharmacology & Toxicology, 2018, 19, 58.	2.4	15
1555	The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca <sup>2+</sup> Flux and Phosphoinositide 3-Kinase $\beta$ . Diabetes, 2018, 67, 2443-2455.	0.6	8
1556	Treatment of Diabetes in Patients with Heart Failure. Current Cardiology Reports, 2018, 20, 97.	2.9	1
1557	Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care, 2018, 41, 2330-2338.	8.6	32
1558	Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. Current Diabetes Reports, 2018, 18, 92.	4.2	20
1559	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. Pharmacotherapy, 2018, 38, 739-757.	2.6	3
1560	Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study. International Journal of Cardiology, 2018, 271, 331-335.	1.7	10
1561	Glucose lowering strategies and cardiovascular disease in type 2 diabetes – teachings from the TOSCA.IT study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 722-726.	2.6	3
1563	Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. British Journal of Clinical Pharmacology, 2018, 84, 2029-2039.	2.4	29
1564	Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease. Circulation Journal, 2018, 82, 2119-2127.	1.6	6
1565	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in Therapy, 2018, 35, 939-965.	2.9	14
1566	Early and Chronic Dipeptidyl Peptidase-4 Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, .	3.7	9
1567	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. Diabetes Care, 2018, 41, 1510-1515.	8.6	30
1568	Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?. Postgraduate Medicine, 2018, 130, 461-469.	2.0	11
1569	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. Diabetes Therapy, 2018, 9, 1477-1490.	2.5	12
1570	Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Española de Diabetes (SED, 2018). Clínica e Investigación en Arteriosclerosis, 2018, 30, 137-153.	0.8	11



#	ARTICLE	IF	CITATIONS
1573	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). American Heart Journal, 2018, 203, 25-29.	2.7	29
1575	Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0197321.	2.5	20
1576	Hormonal Therapy in the Treatment of Chronic Heart Failure. , 2018, , 508-516.		1
1577	Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research, 2018, 2018, 1-7.	2.3	9
1578	2020 vision “An overview of prospects for diabetes management and prevention in the next decade. Diabetes Research and Clinical Practice, 2018, 143, 101-112.	2.8	33
1579	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. Pharmacoepidemiology and Drug Safety, 2018, 27, 857-866.	1.9	8
1580	Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Therapy, 2018, 9, 1491-1500.	2.5	11
1581	Histones and heart failure in diabetes. Cellular and Molecular Life Sciences, 2018, 75, 3193-3213.	5.4	23
1582	Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. Diabetes, Obesity and Metabolism, 2018, 20, 2653-2660.	4.4	12
1583	Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events. International Journal of Endocrinology, 2018, 2018, 1-7.	1.5	6
1584	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
1585	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. , 2018, , 431-454.		2
1586	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Research and Clinical Practice, 2018, 143, 1-14.	2.8	43
1587	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. Journal of Transplantation, 2018, 2018, 1-14.	0.5	19
1588	Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. Current Cardiology Reports, 2018, 20, 65.	2.9	7
1589	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. Current Diabetes Reports, 2018, 18, 53.	4.2	127
1590	Clinical assessment and treatment of diabetes in patients with chronic kidney disease. Revista Colombiana de Medicina, 2018, 218, 305-315.	0.5	2
1591	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. Physiology, 2018, 33, 197-210.	3.1	3



#	ARTICLE	IF	CITATIONS
1592	A practical Bayesian adaptive design incorporating data from historical controls. <i>Statistics in Medicine</i> , 2018, 37, 4054-4070.	1.6	21
1593	Cardiovascular Disease in Diabetes. , 2018, , 219-237.		0
1594	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1845-1855.	2.8	190
1595	The present and future treatment of pediatric type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 207-212.	2.4	1
1596	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1406-F1415.	2.7	22
1597	Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. <i>Cardiovascular Diabetology</i> , 2018, 17, 86.	6.8	2
1598	Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial. <i>Cardiovascular Diabetology</i> , 2018, 17, 71.	6.8	13
1599	Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea. <i>Korean Circulation Journal</i> , 2018, 48, 395.	1.9	11
1600	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 133-148.	2.4	21
1601	Myocardial considerations in type 2 diabetes: 2018. <i>Journal of Diabetes</i> , 2018, 10, 784-788.	1.8	1
1602	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. <i>Heart Lung and Circulation</i> , 2018, 27, 1123-1208.	0.4	262
1603	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , 2018, 18, 64.	4.2	27
1604	Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2018, 17, 91.	6.8	41
1605	The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 815-824.	2.4	13
1606	Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes. <i>PLoS ONE</i> , 2018, 13, e0200249.	2.5	22
1607	A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies. <i>Nutrients</i> , 2018, 10, 544.	4.1	38
1608	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	2.1	388
1609	Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 73.	6.8	117

#	ARTICLE	IF	CITATIONS
1610	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Cardiovascular Diabetology, 2018, 17, 102.	6.8	17
1611	Making sense of newer treatment options for type 2 diabetes. Internal Medicine Journal, 2018, 48, 762-769.	0.8	0
1612	DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide) Tj ETQq0.0 rgBT /Overlock 1	2.7	21
1613	Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes. Clinical and Experimental Medicine, 2018, 18, 473-480.	3.6	42
1614	Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3047.	4.0	109
1615	Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. Cardiovascular Diabetology, 2018, 17, 85.	6.8	18
1616	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care, 2018, 41, 1543-1556.	8.6	137
1617	Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Services Research, 2018, 18, 78.	2.2	21
1618	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
1619	Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study. Diabetes and Metabolism, 2018, 44, 361-367.	2.9	25
1620	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovascular Diabetology, 2018, 17, 9.	6.8	31
1621	Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovascular Diabetology, 2018, 17, 2.	6.8	22
1622	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovascular Diabetology, 2018, 17, 20.	6.8	37
1623	Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. Journal of Biological Engineering, 2018, 12, 2.	4.7	108
1624	Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetology and Metabolic Syndrome, 2018, 10, 1.	2.7	102
1626	The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovascular Diabetology, 2018, 17, 59.	6.8	23
1627	The European Medicines Agency's approval of new medicines for type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2059-2063.	4.4	17
1628	Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research, 2018, 122, 1439-1459.	4.5	220

#	ARTICLE	IF	CITATIONS
1629	The Alchemist's Nightmare. <i>Circulation</i> , 2018, 137, 2068-2073.	1.6	25
1630	Proneurotensin Predicts Cardiovascular Disease in an Elderly Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1940-1947.	3.6	21
1631	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 217-232.	1.6	52
1632	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <scp>FIGHT</scp> trial. <i>ESC Heart Failure</i> , 2018, 5, 1035-1043.	3.1	25
1633	Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. <i>Acta Diabetologica</i> , 2018, 55, 1237-1245.	2.5	17
1634	Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery. <i>Scientific Reports</i> , 2018, 8, 11820.	3.3	10
1635	The treatment of type 2 diabetes in heart failure. <i>Practical Diabetes</i> , 2018, 35, 123-126.	0.3	3
1636	Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. <i>Frontiers in Neuroscience</i> , 2018, 12, 591.	2.8	92
1637	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. <i>Endocrine Practice</i> , 2018, , .	2.1	1
1638	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	1.8	10
1639	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. <i>Diabetologia</i> , 2018, 61, 2134-2139.	6.3	50
1640	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 1-29.	0.1	0
1641	Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. <i>Diabetes and Metabolism</i> , 2018, 44, 386-392.	2.9	25
1642	Endpoints in diabetes cardiovascular outcome trials. <i>Lancet, The</i> , 2018, 391, 2412.	13.7	9
1643	Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. <i>Vascular Pharmacology</i> , 2018, 109, 17-26.	2.1	21
1644	Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. <i>Current Diabetes Reports</i> , 2018, 18, 45.	4.2	37
1645	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2018, 30, 137-153.	0.2	2
1646	Altered T�cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase�4 inhibitor: A 1�year open�label randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 375-382.	2.4	19

#	ARTICLE	IF	CITATIONS
1647	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. <i>Diabetes and Metabolism</i> , 2019, 45, 238-247.	2.9	51
1648	Cardiovascular outcomes of sodium glucose cotransporterâ2 inhibitors in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-36.	4.4	58
1649	Mechanisms and pathways of anti-inflammatory activity of DPPâ4 inhibitors in cardiovascular and renal protection. <i>Medicinal Research Reviews</i> , 2019, 39, 404-422.	10.5	57
1650	Cardiometabolic effects of antidiabetic drugs in nonâalcoholic fatty liver disease. <i>Clinical Physiology and Functional Imaging</i> , 2019, 39, 122-127.	1.2	4
1651	Effect of switching to teneligliptin from other dipeptidyl peptidaseâ4 inhibitors on glucose control and renoprotection in typeA2 diabetes patients with diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2019, 10, 706-713.	2.4	7
1652	Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of antiâdiabetic therapies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 210-217.	4.4	95
1653	Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 36-39.	3.6	13
1654	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 3-14.	4.4	39
1656	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 578-589.	7.1	43
1657	DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. <i>Basic Research in Cardiology</i> , 2019, 114, 35.	5.9	49
1658	Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?. <i>Diabetes and Metabolism</i> , 2019, 45, 501-504.	2.9	8
1659	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. <i>Cardiac Failure Review</i> , 2019, 5, 27-30.	3.0	7
1660	The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2720.	2.6	84
1661	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction. <i>Circulation</i> , 2019, 140, 1004-1014.	1.6	70
1662	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1087-1094.	2.6	19
1663	The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00076.	2.4	37
1664	Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting. <i>Diabetes Therapy</i> , 2019, 10, 1499-1507.	2.5	3
1665	Hispanic representation in diabetes cardiovascular outcomes trials. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000656.	2.8	7

#	ARTICLE	IF	CITATIONS
1666	Phosphodiesterase 5 Associates With $\beta_2$ Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts. <i>Journal of the American Heart Association</i> , 2019, 8, e012273.	3.7	30
1667	Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 435-442.	2.6	21
1669	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
1670	The future of new drugs for diabetes management. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107785.	2.8	28
1671	Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?. <i>Diabetes Therapy</i> , 2019, 10, 1625-1643.	2.5	0
1672	Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 509-523.	5.5	12
1673	Do GLP-1 RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2274-2283.	4.4	26
1674	Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2019, 19, 54.	4.2	18
1675	Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 25-31.	3.4	14
1676	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. <i>Diabetes Therapy</i> , 2019, 10, 1595-1622.	2.5	36
1677	Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study. <i>Scientific Reports</i> , 2019, 9, 10206.	3.3	3
1678	Clinical aspects of heart failure in individuals with diabetes. <i>Diabetologia</i> , 2019, 62, 1529-1538.	6.3	14
1679	Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901986012.	1.6	3
1680	Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1166-1174.	1.9	8
1681	Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-26.	4.0	388
1682	Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha. <i>Internal Medicine</i> , 2019, 58, 2773-2781.	0.7	5
1683	Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. <i>American Heart Journal</i> , 2019, 215, 178-186.	2.7	5
1684	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 38.	0.9	1

#	ARTICLE	IF	CITATIONS
1685	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. <i>Diabetic Medicine</i> , 2019, 36, 1063-1071.	2.3	8
1686	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019, 10, 376.	3.5	68
1687	Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2019, 118, S74-S82.	1.7	11
1688	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2354-2367.	4.4	22
1689	Glucocroninology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group. <i>Diabetes Therapy</i> , 2019, 10, 1577-1593.	2.5	5
1690	Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. <i>Journal of the American Heart Association</i> , 2019, 8, e012244.	3.7	8
1691	Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3152.	4.1	7
1693	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019, 152, 301-316.	0.8	1
1694	Incretin Therapies: Current Use and Emerging Possibilities. , 2019, , 515-529.		0
1695	<p><Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes</p><p><. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1783-1794.	2.4	9
1696	Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. <i>Diabetes Therapy</i> , 2019, 10, 2153-2167.	2.5	20
1697	The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 156, 107832.	2.8	2
1698	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019, 30, 847-849.	16.2	39
1699	Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107906.	2.8	1
1701	Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107909.	2.8	1
1702	Do GLP-1 Receptor Agonists Care if You Have Heart Failure?. <i>Circulation</i> , 2019, 140, 1623-1625.	1.6	1
1703	Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus. <i>Circulation Reports</i> , 2019, 1, 405-413.	1.0	19
1704	Rationale and Design of the CANONICAL Studyâ€• Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus â€•. <i>Circulation Reports</i> , 2019, 1, 347-351.	1.0	5



#	ARTICLE	IF	CITATIONS
1705	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. <i>Endocrinology &amp; Diabetes Y Nutrition</i> (English Ed ), 2019, 66, 467-468.	0.2	0
1706	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , 2019, 22, 1402-1409.	0.3	13
1707	Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e011640.	3.7	35
1708	Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, S10-S24.	0.1	6
1709	Treatment of heart failure with sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. <i>Diabetic Medicine</i> , 2019, 36, 1550-1561.	2.3	4
1710	Individually Silica-Embedded Gold Nanorod Superlattice for High Thermal and Solvent Stability and Recyclable SERS Application. <i>Advanced Materials Interfaces</i> , 2019, 6, 1900986.	3.7	8
1711	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <i>Diabetes and Metabolism</i> , 2019, 45, 409-418.	2.9	114
1712	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1733-1752.	2.5	47
1713	Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 349-357.	3.1	56
1714	The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2185-2194.	1.8	2
1715	Cardiovascular outcome trials of the newer anti-diabetic medications. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 342-348.	3.1	22
1716	Atrial Fibrillation and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1107-1115.	2.8	205
1717	Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. <i>Primary Care Diabetes</i> , 2019, 13, 485-494.	1.8	5
1718	More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. <i>Pharmacological Research</i> , 2019, 147, 104391.	7.1	37
1719	The right place for Sulphonylureas today: Part of a Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107836.	2.8	23
1720	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.	6.8	14
1721	Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107835.	2.8	8
1722	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14772.	2.3	69



#	ARTICLE	IF	CITATIONS
1723	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
1724	Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. <i>Cardiovascular Diabetology</i> , 2019, 18, 112.	6.8	109
1725	Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. <i>Journal of the Endocrine Society</i> , 2019, 3, 1784-1798.	0.2	12
1726	Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 592.	2.0	14
1727	Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107860.	2.8	11
1728	A comprehensive approach to type 2 diabetes mellitus – A recommendation document. <i>Endocrinologija Diabetes Y Nutrici3n (English Ed )</i> , 2019, 66, 443-458.	0.2	3
1729	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1155.	7.4	423
1730	Anti-Diabetic Agents and Heart Failure – Response to the CARMELINA Study –. <i>Circulation Reports</i> , 2019, 1, 4-7.	1.0	0
1731	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2019, 394, 1519-1529.	13.7	210
1732	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , 2019, 40, 1447-1467.	20.1	210
1733	A comparison of the risk of congestive heart failure-related hospitalizations in patients receiving hemodialysis and peritoneal dialysis - A retrospective propensity score-matched study. <i>PLoS ONE</i> , 2019, 14, e0223336.	2.5	17
1734	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4
1735	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. <i>Cardiovascular Diabetology</i> , 2019, 18, 130.	6.8	8
1736	DEVELOPMENT AND VALIDATION OF SENSITIVE LC-ESI-MS/MS METHOD FOR THE SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN IN HUMAN PLASMA. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 55-59.	0.3	5
1737	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
1738	Incretin Physiology and Pharmacology in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2019, 35, 341-355.	2.6	5
1739	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1073-1078.	4.4	33
1740	Management of diabetes mellitus in patients undergoing liver transplantation. <i>Pharmacological Research</i> , 2019, 141, 556-573.	7.1	23

#	ARTICLE	IF	CITATIONS
1741	Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. American Heart Journal, 2019, 211, 22-33.	2.7	34
1742	New approach to diabetes care: From blood glucose to cardiovascular disease. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 53-63.	0.2	9
1743	Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention. Mayo Clinic Proceedings, 2019, 94, 287-308.	3.0	49
1744	Dipeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 215-219.	2.6	3
1745	New Agents for the Treatment of Type 2 Diabetes. Critical Care Clinics, 2019, 35, 315-328.	2.6	13
1746	Nova abordagem para o tratamento da diabetes: da glicemia À doença cardiovascular. Revista Portuguesa De Cardiologia, 2019, 38, 53-63.	0.5	9
1747	Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016. Yonsei Medical Journal, 2019, 60, 200.	2.2	9
1748	A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2019, 149, 47-63.	2.8	13
1749	Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Primary Care Diabetes, 2019, 13, 204-211.	1.8	16
1750	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 2019, 153, 30-40.	2.8	5
1751	Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF. Canadian Journal of Physiology and Pharmacology, 2019, 97, 1053-1063.	1.4	16
1752	Empagliflozin and Heart Failure. Circulation, 2019, 139, 2831-2834.	1.6	3
1753	SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. BMC Endocrine Disorders, 2019, 19, 64.	2.2	10
1754	Clinical Use of DPP-4 Inhibitors. Frontiers in Endocrinology, 2019, 10, 389.	3.5	200
1755	Diabetes news. Journal of Diabetes, 2019, 11, 700-702.	1.8	0
1756	GLucose Control Safety & Efficacy in type 2 Diabetes, a systematic review and Network meta-analysis. PLoS ONE, 2019, 14, e0217701.	2.5	14
1757	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019, 140, e294-e324.	1.6	342
1758	Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1509-1521.	2.5	2

#	ARTICLE	IF	CITATIONS
1759	Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials. <i>Canadian Journal of Diabetes</i> , 2019, 43, 538-545.e2.	0.8	17
1760	An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 691-701.	2.4	17
1761	Ten things you should know about type 2 diabetes – Part 1. <i>Independent Nurse</i> , 2019, 2019, 23-25.	0.1	1
1762	Examining the results of cardiovascular outcome trials. <i>Practice Nursing</i> , 2019, 30, 87-90.	0.1	0
1763	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. <i>Current Diabetes Reports</i> , 2019, 19, 39.	4.2	3
1764	Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 493.	2.4	15
1765	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2240-2247.	4.4	8
1766	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2019, 42, e119-e121.	8.6	18
1767	Effects of Icosapent Ethyl on Total/Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	2.8	208
1768	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2019, 25, 584-619.	1.7	56
1769	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. <i>Journal of the American Heart Association</i> , 2019, 8, e012356.	3.7	73
1770	Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 646-651.	0.9	0
1772	Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study. <i>PLoS ONE</i> , 2019, 14, e0215248.	2.5	5
1773	Transcultural Diabetes Care in The United States – A Position Statement by the American Association of Clinical Endocrinologists. <i>Endocrine Practice</i> , 2019, 25, 729-765.	2.1	19
1774	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2019, 36, 1549-1573.	2.9	3
1775	Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 19-23.	4.4	22
1776	Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. <i>Diabetes Therapy</i> , 2019, 10, 1249-1270.	2.5	3
1777	Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1940.	4.1	24

#	ARTICLE	IF	CITATIONS
1778	<p>Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 447-455.	2.4	13
1779	Acute kidney injury with sodium-glucose co-transporter <sup>2</sup> inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1996-2000.	4.4	55
1780	DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs. Frontiers in Immunology, 2019, 10, 1050.	4.8	31
1781	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry, 2019, 65, 781-790.	3.2	8
1782	Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?. Diabetes and Vascular Disease Research, 2019, 16, 303-309.	2.0	25
1783	Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1935-1942.	3.6	7
1784	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine, 2019, 65, 15-24.	2.3	25
1785	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA - Journal of the American Medical Association, 2019, 321, 1466.	7.4	233
1786	Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes. Journal of Clinical Medicine, 2019, 8, 393.	2.4	20
1787	Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. BMC Cardiovascular Disorders, 2019, 19, 60.	1.7	16
1788	Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes, Obesity and Metabolism, 2019, 21, 1661-1667.	4.4	18
1789	Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2019, 39, 469-476.	2.2	2
1790	Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMDO Obesity) Tj ETQq0 0.4gBT / Overlock 10	2.4	20
1791	Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients. Expert Opinion on Pharmacotherapy, 2019, 20, 1037-1047.	1.8	3
1792	Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Frontiers in Endocrinology, 2019, 10, 80.	3.5	224
1793	Heart failure and diabetes: management and open issues. Herz, 2019, 44, 203-209.	1.1	2
1794	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety, 2019, 18, 241-251.	2.4	8
1795	Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials. Cardiovascular Diabetology, 2019, 18, 19.	6.8	5

#	ARTICLE	IF	CITATIONS
1796	Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. <i>BMJ Open</i> , 2019, 9, e025806.	1.9	67
1797	A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 257-265.	1.9	15
1798	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	3.6	305
1799	Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2019, 34, 80.	3.0	42
1800	Diabetic Pharmacotherapies in Kidney Disease. , 2019, , 49-74.		0
1801	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619
1803	Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 15.	2.4	30
1804	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 72-79.	0.9	9
1805	Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study. <i>Cardiovascular Diabetology</i> , 2019, 18, 28.	6.8	16
1806	Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 377-388.	4.1	12
1807	Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 299-308.	3.1	23
1808	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1165-1169.	3.3	28
1809	Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1780-1789.	4.4	31
1810	Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy. <i>Kidney International</i> , 2019, 95, 1373-1388.	5.2	27
1811	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1790-1800.	4.4	28
1813	Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2019, 18, 47.	6.8	15
1814	Heart Failure and Metabolic Factors. Updates in Hypertension and Cardiovascular Protection, 2019, , 123-133.	0.1	0
1815	Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1824-1836.	4.4	4

#	ARTICLE	IF	CITATIONS
1816	Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 271-277.	0.6	0
1817	Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. <i>Journal of General and Family Medicine</i> , 2019, 20, 129-138.	0.8	13
1819	Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. <i>Diabetes Research and Clinical Practice</i> , 2019, 150, 8-16.	2.8	90
1820	Evidence-Based Cardiovascular Risk Management in Diabetes. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 439-448.	2.2	10
1821	First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 8.	1.7	4
1822	Clinical implications of cardiovascular outcome trials in type 2 diabetes. <i>Herz</i> , 2019, 44, 192-202.	1.1	4
1823	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1277-1290.	4.4	64
1824	Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2019, 10, 429-435.	2.5	6
1825	Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. <i>EBioMedicine</i> , 2019, 41, 50-61.	6.1	26
1826	Management of hypoglycemia in older adults with type 2 diabetes. <i>Postgraduate Medicine</i> , 2019, 131, 241-250.	2.0	63
1827	Treatment of diabetes and heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 207-212.	1.8	4
1828	PDM-ProValue meets cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2019, 18, 10.	6.8	2
1830	Cardiovascular autonomic neuropathy in type 2 diabetic patients. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 56-60.	0.7	6
1831	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 45.	3.5	94
1832	Cardiovascular Protection with Anti-hyperglycemic Agents. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 249-257.	2.2	24
1833	The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2019, 35, 1283-1295.	1.9	10
1834	Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1337-1347.	2.4	23
1835	Herbal Medicine in Diabetes Mellitus with Cardiovascular Diseases. , 2019, , 139-180.		0



#	ARTICLE	IF	CITATIONS
1836	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2019, 79, 231-242.	10.9	18
1837	Nonglycemic Outcomes of Antidiabetic Medications. <i>Clinical Diabetes</i> , 2019, 37, 131-141.	2.2	1
1838	Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	4.0	18
1839	Diabetes Mellitus and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 558-568.	2.4	98
1840	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	2.1	245
1841	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, ITC65-ITC80.	3.9	46
1842	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes–2019</i>. <i>Diabetes Care</i> , 2019, 42, S103-S123.	8.6	676
1843	Documento de abordaje integral de la diabetes tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 443-458.	0.3	24
1844	Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 72, .	0.1	0
1845	Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2019, 10, 1420.	3.5	12
1846	Highlights in heart failure. <i>ESC Heart Failure</i> , 2019, 6, 1105-1127.	3.1	109
1847	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. <i>Italian Journal of Medicine</i> , 2019, 13, 205-224.	0.3	0
1848	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2019, 367, l5887.	2.3	84
1849	Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000728.	2.8	10
1850	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 721-735.	0.2	2
1851	Impact of Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control and Cardiovascular Safety with Adherence: An Overview. <i>International Journal of Diabetes and Metabolism</i> , 2019, 25, 90-99.	0.7	6
1852	Sodium Glucose Cotransporter 2 Inhibitors. <i>Circulation</i> , 2019, 140, 1703-1705.	1.6	2
1853	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.	1.2	38



#	ARTICLE	IF	CITATIONS
1854	Putting Heart (and Kidneys) Into Diabetes Care. <i>Clinical Diabetes</i> , 2019, 37, 314-315.	2.2	0
1855	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , 2019, 37, 316-337.	2.2	11
1856	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 73-80.	1.8	56
1857	Heart failure and its complications in patients with diabetes: Mounting evidence for a growing burden. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 106-113.	1.8	17
1858	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5853.	4.1	11
1859	Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-7.	2.3	6
1860	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 132.	4.2	15
1861	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	3.9	25
1862	Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 311.	1.7	5
1863	Cardioprotective diabetes drugs: what cardiologists need to know. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 96-105.	1.1	11
1864	Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes. <i>Journal of Pharmaceutical Policy and Practice</i> , 2019, 12, 30.	2.4	5
1865	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version. <i>Circulation Journal</i> , 2019, 83, 2084-2184.	1.6	446
1866	Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables. <i>Journal of Hypertension</i> , 2019, 37, 1939-1949.	0.5	7
1867	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
1868	Predictors of heart failure development in type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2019, 34, 578-583.	1.8	15
1869	Efeito da empagliflozina para a melhoria do controlo glicémico: benefício cardiovascular em doentes com DM2 e doença cardiovascular estabelecida. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 721-735.	0.5	1
1870	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. <i>Frontiers in Diabetes</i> , 2019, , 119-130.	0.4	0
1871	Physiological monitoring of the complex multimorbid heart failure patient “diabetes and monitoring glucose control. <i>European Heart Journal Supplements</i> , 2019, 21, M20-M24.	0.1	0

#	ARTICLE	IF	CITATIONS
1872	Fighting Type-2 Diabetes: Present and Future Perspectives. <i>Current Medicinal Chemistry</i> , 2019, 26, 1891-1907.	2.4	13
1873	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
1874	Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017. <i>Journal of Diabetes</i> , 2019, 11, 573-581.	1.8	15
1875	Challenges of Non-Intention-to-Treat Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 145.	7.4	40
1876	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	1.6	5
1877	Cardiovascular outcome trials of glucose-lowering medications: an update. <i>Diabetologia</i> , 2019, 62, 357-369.	6.3	67
1878	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 605-617.	2.5	50
1879	Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation Research</i> , 2019, 124, 121-141.	4.5	411
1880	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
1881	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
1882	Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 644-654.	3.0	15
1883	Diabetes: the place of new therapies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880759.	3.2	10
1884	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	7.4	830
1885	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 78-86.	1.7	22
1886	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 854-865.	4.4	6
1887	Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure. <i>Circulation</i> , 2019, 139, 362-365.	1.6	14
1888	Future perspectives of the pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 129-143.	3.1	29
1889	Improving Drug Use and Dosing in Chronic Kidney Disease. , 2019, , 250-272.e5.		0

#	ARTICLE	IF	CITATIONS
1890	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1081-1087.	4.4	39
1891	All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes. <i>BMC Endocrine Disorders</i> , 2019, 19, 3.	2.2	6
1892	Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study. <i>Clinical Therapeutics</i> , 2019, 41, 118-127.e0.	2.5	1
1893	Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes. <i>Frontiers in Physiology</i> , 2018, 9, 1857.	2.8	75
1894	Publications Simultaneous With Meeting Presentation. <i>Circulation</i> , 2019, 139, 307-309.	1.6	3
1895	Diabetic cardiomyopathy. <i>Heart</i> , 2019, 105, 337-345.	2.9	60
1896	Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 110-121.	2.9	42
1897	Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2019, 35, 77-91.	1.7	17
1898	Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. <i>Journal of Cardiology</i> , 2019, 73, 28-32.	1.9	19
1899	Unstable Angina and Non-ST Elevation Myocardial Infarction. <i>Contemporary Cardiology</i> , 2019, , 233-259.	0.1	0
1900	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.1	0
1901	Medications for the Treatment of Type II Diabetes. , 2019, , 101-106.		0
1902	Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?. <i>Annals of Pharmacotherapy</i> , 2019, 53, 510-522.	1.9	6
1903	The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2019, 10, 119-134.	2.5	4
1904	Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 106-114.	11.4	54
1905	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin+Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	1.6	21
1906	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 41-63.	9.4	23
1907	Cardiovascular outcome trials in type 2 diabetes: A critical analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 300-305.	3.6	1

#	ARTICLE	IF	CITATIONS
1908	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	13.7	73
1909	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. <i>Diabetic Medicine</i> , 2019, 36, 718-725.	2.3	46
1910	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019, 123, 145-152.	1.6	25
1911	Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: Data from the FAST-MI 2005 registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 218-230.	1.0	13
1912	Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 333-353.	5.4	25
1913	Alogliptin and Glimepiride Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 215-219.	1.2	7
1914	Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 237-242.	3.3	2
1915	CD26 and Asthma: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 139-160.	6.5	37
1916	National Trends in Diabetes Medication Use in the United States: 2008 to 2015. <i>Journal of Pharmacy Practice</i> , 2020, 33, 433-442.	1.0	27
1917	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. <i>Acta Cardiologica</i> , 2020, 75, 211-217.	0.9	3
1918	Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. <i>Journal of Diabetes Investigation</i> , 2020, 11, 110-124.	2.4	8
1919	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. <i>European Heart Journal</i> , 2020, 41, 1764-1774.	2.2	11
1920	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. <i>Canadian Journal of Diabetes</i> , 2020, 44, 103-110.	0.8	2
1921	A LEADER in the management of type 2 diabetes and cardiorenal disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 978-984.	0.8	2
1922	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. <i>Journal of Medical Economics</i> , 2020, 23, 193-203.	2.1	17
1923	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2020, 36, 209-211.	1.9	3
1924	Comorbidities and comedications as confounders of cardioprotection? "Does it matter in the clinical setting?". <i>British Journal of Pharmacology</i> , 2020, 177, 5252-5269.	5.4	90
1925	Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 6-15.	4.4	36

#	ARTICLE	IF	CITATIONS
1926	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
1927	Management of Comorbidities in Heart Failure. , 2020, , 687-696.e2.		0
1928	From pump to sink: The hydraulic connection of type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107772.	2.8	0
1929	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. Nephrology Dialysis Transplantation, 2020, 35, 2103-2111.	0.7	20
1930	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
1931	Anabolic Deficiencies in Heart Failure. Heart Failure Clinics, 2020, 16, 11-21.	2.1	3
1932	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. Primary Care Diabetes, 2020, 14, 193-212.	1.8	7
1933	Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example. Value in Health, 2020, 23, 217-226.	0.3	6
1934	Glucose-dependent insulintropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	2.4	27
1935	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Diabetology International, 2020, 11, 129-141.	1.4	17
1936	Optimization of the benzamide fragment targeting the S2â€² site leads to potent dipeptidyl peptidase-IV inhibitors. Bioorganic Chemistry, 2020, 94, 103366.	4.1	7
1937	Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics. Postgraduate Medicine, 2020, 132, 109-125.	2.0	9
1938	Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Medical Journal of Australia, 2020, 212, 133-139.	1.7	14
1939	The EMPagliflozin compaRative effectiveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinology, Diabetes and Metabolism, 2020, 3, e00103.	2.4	18
1940	Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective doseâ€‘escalating trial. British Journal of Clinical Pharmacology, 2020, 86, 979-990.	2.4	6
1941	Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovascular Diabetology, 2020, 19, 1.	6.8	121
1942	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. Diabetes Therapy, 2020, 11, 369-386.	2.5	48
1943	Myocardial infarction in type 2 diabetes using sodiumâ€‘glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. Current Medical Research and Opinion, 2020, 36, 403-409.	1.9	11

#	ARTICLE	IF	CITATIONS
1944	Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction. Hypertension, 2020, 75, 150-162.	2.7	18
1945	Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. Journal of Cardiovascular Medicine, 2020, 21, 21-26.	1.5	10
1946	Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e012940.	3.7	48
1947	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	7.1	131
1948	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism: Clinical and Experimental, 2020, 103, 154031.	3.4	12
1949	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension, 2020, 38, 377-386.	0.5	7
1951	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2020, 22, 699-704.	4.4	75
1952	Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system. Pharmacological Research, 2020, 151, 104578.	7.1	10
1953	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials. International Journal of Environmental Research and Public Health, 2020, 17, 155.	2.6	4
1954	Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovascular Diabetology, 2020, 19, 160.	6.8	20
1955	Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research. Frontiers in Pharmacology, 2020, 11, 561494.	3.5	21
1956	Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 28-42.	1.5	8
1957	The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review. Current Therapeutic Research, 2020, 93, 100596.	1.2	19
1959	Addressing Comorbidities in Heart Failure. Heart Failure Clinics, 2020, 16, 441-456.	2.1	13
1960	Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in $\alpha$ -Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3497-3506.	2.4	1
1961	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. Current Diabetes Reports, 2020, 20, 63.	4.2	4
1962	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism: Clinical and Experimental, 2020, 111, 154343.	3.4	36
1964	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2020, 21, 2101-2114.	1.8	3



#	ARTICLE	IF	CITATIONS
1965	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4811.	4.1	20
1966	Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE. <i>Diabetic Medicine</i> , 2020, 37, 593-601.	2.3	3
1967	A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study). <i>Scientific Reports</i> , 2020, 10, 19033.	3.3	0
1968	Contemporary Management of Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2020, 43, 2895-2903.	8.6	20
1969	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 172, 541.	3.9	53
1970	Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?. <i>Diabetes and Metabolism</i> , 2021, 47, 101209.	2.9	5
1971	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. <i>Frontiers in Endocrinology</i> , 2020, 11, 599355.	3.5	12
1972	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. <i>Pharmaceuticals</i> , 2020, 13, 427.	3.8	14
1973	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 823-836.	2.0	1
1974	Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 602251.	2.4	11
1975	Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. <i>Annals of Internal Medicine</i> , 2020, 173, 813-821.	3.9	60
1976	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. <i>Cardiology in Review</i> , 2020, 28, 219-235.	1.4	6
1977	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	2.4	159
1978	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 1-122.	0.8	16
1979	Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseases. <i>International Journal of Cardiology</i> , 2020, 307, 87-93.	1.7	2
1980	New model of integrated care for uncontrolled type 2 diabetes in a retrospective, underserved adult population in the USA: a study protocol for an effectiveness and cost-effectiveness analysis. <i>BMJ Open</i> , 2020, 10, e038084.	1.9	1
1982	Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2350.	2.4	1
1983	Antidiabetic drugs and blood pressure changes. <i>Pharmacological Research</i> , 2020, 161, 105108.	7.1	11



#	ARTICLE	IF	CITATIONS
1984	Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 488.	7.4	391
1985	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	1.4	266
1987	Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist. Current Cardiology Reports, 2020, 22, 105.	2.9	3
1988	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	3.6	6
1989	Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring. Diabetes Therapy, 2020, 11, 2945-2958.	2.5	5
1990	Challenges and Strategies for Inpatient Diabetes Management in Older Adults. Diabetes Spectrum, 2020, 33, 227-235.	1.0	5
1991	Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis. Cardiovascular Diabetology, 2020, 19, 177.	6.8	9
1992	<p>Randomized Study Comparing Vildagliptin vs Glimepiride on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3221-3229.	2.4	3
1993	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2020</i>. Diabetes Care, 2020, 43, S111-S134.	8.6	421
1994	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. BMJ Open, 2020, 10, e034883.	1.9	2
1995	Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012â€”2018. BMJ Open Diabetes Research and Care, 2020, 8, e001279.	2.8	41
1996	Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults. Clinical Medicine Insights: Endocrinology and Diabetes, 2020, 13, 117955142094223.	1.9	13
1997	Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. Diabetes Care, 2020, 43, 2614-2623.	8.6	9
1998	Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: A methodologic systematic review using the case study of DPP â€4 inhibitors and cardiovascular outcomes. Pharmacoepidemiology and Drug Safety, 2020, 29, 939-950.	1.9	10
1999	Cardiovascular safety outcomes of onceâ€”weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 61-72.	1.5	9
2000	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, The, 2020, 370, m3342.	6.0	70
2001	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 187-210.	3.0	10
2002	Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. BMC Nephrology, 2020, 21, 402.	1.8	11

#	ARTICLE	IF	CITATIONS
2003	Diabetes, pre-diabetes and cardiovascular diseases in light of the 2019 ESC Guidelines. <i>Studia Medyczne</i> , 2020, 36, 148-155.	0.1	0
2004	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	2.8	2
2005	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2020, 10, 12837.	3.3	4
2006	Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 642-653.	9.6	162
2007	Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. <i>Diabetes Care</i> , 2020, 43, 2859-2869.	8.6	68
2008	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. <i>Canadian Journal of Diabetes</i> , 2020, 44, 575-591.	0.8	98
2009	Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 68.	2.4	19
2010	Non-Insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
2012	Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. <i>Diabetes Care</i> , 2020, 43, 2785-2795.	8.6	26
2013	Repurposing Antidiabetic Drugs for Cardiovascular Disease. <i>Frontiers in Physiology</i> , 2020, 11, 568632.	2.8	25
2014	Novel therapeutic agents for the treatment of diabetic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1277-1293.	4.1	11
2015	Metformin in Pulmonary Hypertension in Left Heart Disease. <i>Frontiers in Medicine</i> , 2020, 7, 425.	2.6	7
2016	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5756.	4.1	6
2017	Effects of Epeleuton, a Novel Synthetic Second-Generation $\omega$ 3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. <i>Journal of the American Heart Association</i> , 2020, 9, e016334.	3.7	17
2018	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. <i>Internal Medicine Journal</i> , 2022, 52, 841-847.	0.8	5
2019	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 212.	6.8	3
2020	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 603247.	2.8	11
2021	Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 530160.	3.9	10

#	ARTICLE	IF	CITATIONS
2022	Diabetic cardiomyopathy. Revista Clínica Española, 2022, 222, 100-111.	0.5	11
2023	Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study. Acta Diabetologica, 2020, 57, 1181-1192.	2.5	16
2025	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	8.6	92
2026	Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies. Diabetes Research and Clinical Practice, 2020, 164, 108199.	2.8	5
2027	What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Therapy, 2020, 11, 1381-1395.	2.5	4
2028	Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1670-1677.	4.4	9
2029	Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovascular Diabetology, 2020, 19, 55.	6.8	27
2030	Should Baseline Hemoglobin A1c or Dose of SGLT2i Guide Treatment With SGLT2i Versus DPP4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review. Journal of Clinical Pharmacology, 2020, 60, 980-991.	2.0	1
2031	Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	0
2032	Refocusing on the Primary Prevention of Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	7
2033	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 2020, 8, 418-435.	11.4	105
2034	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	1.4	5
2035	Advances in the management of diabetes: therapies for type 2 diabetes. Postgraduate Medical Journal, 2020, 96, 610-618.	1.8	11
2036	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism: Clinical and Experimental, 2020, 109, 154295.	3.4	18
2037	Consenso de expertos sobre la insuficiencia cardiaca con fracción de eyección reducida: más allá de las guías. Revista Española De Cardiología Suplementos, 2020, 20, 1-46.	0.2	2
2038	Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovascular Diabetology, 2020, 19, 95.	6.8	16
2039	The treatment of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research, 2020, 160, 105018.	7.1	5
2040	Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2020, 12, 45.	2.7	10

#	ARTICLE	IF	CITATIONS
2041	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3025-3035.	3.6	22
2042	A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3076-3087.	3.6	65
2043	Type 2 diabetes mellitus management in patients with chronic kidney disease: an update. Hormones, 2020, 19, 467-476.	1.9	6
2044	Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. Diabetes, Obesity and Metabolism, 2020, 22, 1847-1856.	4.4	6
2045	Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Medicine, 2020, 18, 165.	5.5	13
2046	Cancer Biology and Prevention in Diabetes. Cells, 2020, 9, 1380.	4.1	39
2047	Diabetes and coronary artery disease: not just a risk factor. Heart, 2020, 106, 1357-1364.	2.9	13
2048	Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovascular Diabetology, 2020, 19, 89.	6.8	20
2049	Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy, 2020, 11, 1645-1666.	2.5	27
2050	Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetology International, 2020, 11, 245-251.	1.4	13
2051	Cardiometabolic Medicine: Development of a New Subspecialty. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2095-2104.	3.6	15
2052	Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2020, 11, 288.	3.5	13
2053	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology, 2020, 8, 606-615.	11.4	67
2054	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opinion on Pharmacotherapy, 2020, 21, 1565-1577.	1.8	13
2055	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 162, 108112.	2.8	21
2056	Toxicity of Metformin and Hypoglycemic Therapies. Advances in Chronic Kidney Disease, 2020, 27, 18-30.	1.4	16
2057	A randomized, open-label, active comparator trial assessing the effects of 26-weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	4.4	13
2058	DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide) Tj ETQq 1.7 0.7843 14 rgBT	1.7	14

#	ARTICLE	IF	CITATIONS
2059	Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Review of Clinical Pharmacology, 2020, 13, 461-468.	3.1	12
2060	Noninsulin Therapy for Diabetes. Physician Assistant Clinics, 2020, 5, 153-165.	0.1	0
2061	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	2.8	53
2062	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Research and Care, 2020, 8, e000943.	2.8	15
2063	Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. International Journal of Molecular Sciences, 2020, 21, 2275.	4.1	21
2064	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 912.	2.4	27
2065	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, Obesity and Metabolism, 2020, 22, 1243-1262.	4.4	13
2066	Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial. Postgraduate Medicine, 2020, 132, 314-319.	2.0	0
2067	Effectiveness of sodium-glucose cotransporter 2 inhibitors on ischaemic heart disease. Diabetes, Obesity and Metabolism, 2020, 22, 1197-1206.	4.4	6
2068	Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 233.	5.1	7
2069	Approximate Bayesian Bootstrap procedures to estimate multilevel treatment effects in observational studies with application to type 2 diabetes treatment regimens. Statistical Methods in Medical Research, 2020, 29, 3362-3380.	1.5	2
2070	Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment. Diabetology International, 2020, 11, 252-260.	1.4	4
2071	Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. Journal of Comparative Effectiveness Research, 2020, 9, 781-794.	1.4	11
2072	Pleiotropic effects of anti-diabetic drugs: A comprehensive review. European Journal of Pharmacology, 2020, 884, 173349.	3.5	19
2073	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular Diabetology, 2020, 19, 107.	6.8	18
2074	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association, 2020, 83, 587-621.	1.4	7
2075	DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database. Lancet Diabetes and Endocrinology, the, 2020, 8, 365-367.	11.4	15
2076	Diabetes and Heart Failure. Clinics in Geriatric Medicine, 2020, 36, 447-455.	2.6	5

#	ARTICLE	IF	CITATIONS
2077	Primary Care Physiciansâ€™ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey. <i>Advances in Therapy</i> , 2020, 37, 3630-3639.	2.9	5
2078	The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 988-996.	4.4	11
2079	GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 193-212.	1.6	24
2080	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108054.	2.8	10
2081	Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo. <i>Cardiology</i> , 2020, 145, 370-374.	1.4	9
2082	Impact on guidelines: The general practitioner point of view. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108091.	2.8	4
2083	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseaseâ€”A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1509.	4.1	29
2084	Manage cardiovascular risk in patients with type 2 diabetes by using agents with proven cardiovascular benefits. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 181-185.	0.6	0
2085	Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. , 2020, 209, 107503.		136
2086	Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c<6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2020, 19, 21.	6.8	12
2087	MÃ©dicaments hypoglycÃ©mifiants dans le diabÃ©te de type 2 et nÃ©phroprotection: un nouvel axe thÃ©rapeutique?. <i>Medicine Des Maladies Metaboliques</i> , 2020, 14, 77-84.	0.1	0
2088	MiocardioopatÃ©a diabÃ©tica. <i>Revista Clinica Espanola</i> , 2022, 222, 100-111.	0.6	11
2089	Effect of hyperglycaemia and diabetes on acute myocardial ischaemiaâ€”reperfusion injury and cardioprotection by ischaemic conditioning protocols. <i>British Journal of Pharmacology</i> , 2020, 177, 5312-5335.	5.4	68
2090	&p&gt;Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence&p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 161-174.	2.4	105
2091	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
2092	Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 604-615.	3.1	6
2093	Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 640-644.	1.6	0
2094	Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease. <i>Cell Proliferation</i> , 2020, 53, e12763.	5.3	65



#	ARTICLE	IF	CITATIONS
2095	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	2.8	58
2096	Safety And Efficacy Of Dpp-4 Inhibitors For The Management Of Hospitalized General Medicine And Surgery Patients with Type 2 Diabetes. Endocrine Practice, 2020, 26, 722-728.	2.1	16
2097	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ, The, 2020, 369, m1186.	6.0	63
2098	Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. Journal of the American College of Cardiology, 2020, 75, 1956-1974.	2.8	48
2099	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. Advances in Experimental Medicine and Biology, 2020, 1307, 129-152.	1.6	31
2100	Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2020, 1307, 7-27.	1.6	11
2101	Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. Drugs and Aging, 2020, 37, 399-409.	2.7	20
2102	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
2103	Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. Atherosclerosis, 2020, 300, 10-18.	0.8	6
2104	Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 265-272.	3.6	18
2105	Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. Expert Opinion on Drug Safety, 2020, 19, 625-631.	2.4	8
2106	Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 32-45.	4.4	29
2107	Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 33-42.	4.4	7
2108	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	4.4	27
2109	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. Diabetes Care, 2020, 43, 1326-1335.	8.6	41
2110	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Frontiers in Endocrinology, 2020, 11, 178.	3.5	137
2111	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€” 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	2.1	410
2112	Cardiovascular protection with sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism, 2020, 22, 1481-1495.	4.4	17



#	ARTICLE	IF	CITATIONS
2114	Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications. <i>Endocrine Reviews</i> , 2020, 41, .	20.1	314
2115	Drug discovery approaches targeting the incretin pathway. <i>Bioorganic Chemistry</i> , 2020, 99, 103810.	4.1	11
2117	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154242.	3.4	17
2118	Risk stratification tools for heart failure in the diabetes clinic. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1070-1079.	2.6	7
2119	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 187-199.	1.5	1
2120	Second revolution in cardiovascular prevention. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 327-336.	1.4	6
2121	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
2122	Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2020, 13, 117955142091297.	1.9	48
2123	A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. <i>Trials</i> , 2020, 21, 315.	1.6	21
2124	Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research. <i>Frontiers in Endocrinology</i> , 2020, 11, 133.	3.5	8
2125	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , 2020, 9, 947.	2.4	85
2126	Sodium-glucose cotransporter-2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 67-73.	2.4	7
2127	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <i>Primary Care Diabetes</i> , 2021, 15, 31-51.	1.8	27
2128	Changing Fields-Diabetes Medications Invading the Cardiovascular Space. <i>Current Problems in Cardiology</i> , 2021, 46, 100736.	2.4	1
2129	The role of Dipeptidyl Peptidase-4 in cutaneous disease. <i>Experimental Dermatology</i> , 2021, 30, 304-318.	2.9	28
2130	Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor) Tj ETQq1 1.0,784314,rgBT /Over 2.2 23	2.2	23
2131	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 322, 183-190.	1.7	31
2132	Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. <i>Heart Failure Reviews</i> , 2021, 26, 437-450.	3.9	5

#	ARTICLE	IF	CITATIONS
2133	Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. European Journal of Preventive Cardiology, 2021, 28, 8-17.	1.8	4
2134	Dipeptidyl peptidaseâ€4 inhibitor treatment and the risk of bullous pemphigoid and skinâ€related adverse events: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2021, 37, e3391.	4.0	13
2135	Effect of dipeptidyl peptidaseâ€4 inhibitors on complement activation. Diabetes/Metabolism Research and Reviews, 2021, 37, e3385.	4.0	4
2136	Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidaseâ€4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients. Clinical Pharmacology and Therapeutics, 2021, 109, 772-781.	4.7	1
2137	Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis. Primary Care Diabetes, 2021, 15, 227-233.	1.8	0
2138	Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies. Maturitas, 2021, 143, 118-126.	2.4	11
2139	GLP-1 receptor agonists in the treatment of type 2 diabetes â€“ state-of-the-art. Molecular Metabolism, 2021, 46, 101102.	6.5	518
2140	Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. Internal and Emergency Medicine, 2021, 16, 895-903.	2.0	6
2141	SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. Journal of Diabetes and Its Complications, 2021, 35, 107761.	2.3	3
2142	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
2143	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
2144	The effects of dipeptidyl peptidaseâ€4 inhibitors on kidney outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 763-773.	4.4	12
2145	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (<sc>TRSâ€HF<sub>DM</sub></sc>) in patients in the <sc>ACCORD</sc> trial. Diabetes, Obesity and Metabolism, 2021, 23, 782-790.	4.4	19
2146	Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015. Primary Care Diabetes, 2021, 15, 323-331.	1.8	5
2147	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology, 2021, 17, 227-244.	9.6	87
2148	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
2149	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€2021</i>. Diabetes Care, 2021, 44, S125-S150.	8.6	359
2150	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. Circulation, 2021, 143, 1002-1013.	1.6	174

#	ARTICLE	IF	CITATIONS
2151	External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 971-979.	4.4	2
2152	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. <i>Diabetology International</i> , 2021, 12, 1-51.	1.4	6
2153	FDA's New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory Science. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1-5.	1.6	7
2154	Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. <i>Acta Diabetologica</i> , 2021, 58, 39-46.	2.5	13
2155	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. <i>Primary Care Diabetes</i> , 2021, 15, 59-68.	1.8	9
2156	Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. <i>Thrombosis and Haemostasis</i> , 2021, 121, 106-108.	3.4	2
2157	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. <i>Clinical Diabetes</i> , 2021, 39, 105-116.	2.2	0
2158	The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes. <i>Endocrine</i> , 2021, 71, 47-58.	2.3	2
2159	Lower cardiorenal risk with <sc>sodium-glucose</sc> cotransporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 75-85.	4.4	43
2160	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLAREâ€TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	4.4	28
2161	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 101-108.	4.9	5
2162	Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials. <i>Current Cardiology Reviews</i> , 2021, 16, 253-257.	1.5	2
2163	Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2). <i>Advances in Therapy</i> , 2021, 38, 1514-1535.	2.9	1
2164	Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110206.	3.2	8
2165	Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110269.	2.5	1
2167	Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. <i>Protein and Cell</i> , 2022, 13, 336-359.	11.0	74
2168	Impact of peroxisome proliferator-activated receptor-Î± on diabetic cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2021, 20, 2.	6.8	58
2169	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 660.	4.1	15

#	ARTICLE	IF	CITATIONS
2170	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. Journal of Lipid and Atherosclerosis, 2021, 10, 210.	3.5	3
2171	Diabetes mellitus and atrial fibrillationâ€”Untying the Gordian Knot. , 2021, , 95-121.		1
2172	Targeting <scp>AGEâ€RAGE</scp> signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats. Drug Development Research, 2021, 82, 589-597.	2.9	4
2173	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	2.9	6
2175	DPP-IV Inhibitorâ€”Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110330.	0.6	1
2176	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	6.0	322
2177	Diabetes and Heart Failure. Cardiovascular Prevention and Pharmacotherapy, 2021, 3, 21.	0.1	0
2178	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
2179	A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis. Critical Reviews in Food Science and Nutrition, 2022, 62, 4095-4151.	10.3	19
2180	Effect of Tenueligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea. Endocrinology and Metabolism, 2021, 36, 70-80.	3.0	4
2181	Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. Journal of Clinical Medicine, 2021, 10, 505.	2.4	6
2182	Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 1232-1241.	4.4	5
2183	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	4.4	4
2184	Renoprotective Effects of DPP-4 Inhibitors. Antioxidants, 2021, 10, 246.	5.1	15
2185	The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathyâ€”A Review. Journal of Clinical Medicine, 2021, 10, 705.	2.4	9
2186	DPP4 Activity, Hyperinsulinemia, and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1553-1565.	3.6	20
2187	Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart, 2021, 107, 1032-1038.	2.9	90
2188	A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovascular Diabetology, 2021, 20, 32.	6.8	34

#	ARTICLE	IF	CITATIONS
2189	Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 17.	2.7	2
2190	Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 565-573.	2.4	14
2191	Are restricted mean survival time methods especially useful for noninferiority trials?. <i>Clinical Trials</i> , 2021, 18, 188-196.	1.6	7
2192	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. <i>EClinicalMedicine</i> , 2021, 32, 100739.	7.1	36
2193	Diabetes Management in Patients with Heart Failure. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 158-172.	4.7	9
2194	Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats. <i>Journal of the American Heart Association</i> , 2021, 10, e020088.	3.7	1
2195	Toward a broader view of mechanisms of drug cardiotoxicity. <i>Cell Reports Medicine</i> , 2021, 2, 100216.	6.5	44
2196	Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation. <i>PLoS ONE</i> , 2021, 16, e0248577.	2.5	6
2197	Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3279-3291.	2.4	2
2198	Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset. <i>Diabetes Therapy</i> , 2021, 12, 1209-1226.	2.5	2
2199	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	6.8	9
2200	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. <i>Current Drug Safety</i> , 2021, 16, 32-51.	0.6	1
2201	Diabetes and Stroke. <i>Journal of Korean Diabetes</i> , 2021, 22, 26-37.	0.3	1
2202	Effect of metformin on outcomes of catheter ablation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1232-1239.	1.7	17
2203	Glucose-Lowering Medications and Cardiovascular Outcomes. <i>Current Cardiology Reports</i> , 2021, 23, 24.	2.9	2
2204	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. <i>Cardiac Failure Review</i> , 2021, 7, e04.	3.0	7
2205	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <i>European Cardiology Review</i> , 2021, 16, e11.	2.2	2
2206	Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-10.	2.3	8

#	ARTICLE	IF	CITATIONS
2207	DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. American Journal of Physiology - Renal Physiology, 2021, 320, F505-F517.	2.7	7
2208	Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital. Chinese Medical Journal, 2021, 134, 1317-1323.	2.3	28
2209	Cardiovascular Safety and Sclerostin Inhibition. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1845-1853.	3.6	26
2210	Diabetes and Heart Failure. Journal of Korean Diabetes, 2021, 22, 12-20.	0.3	0
2211	Use of diabetes medications in traditional Medicare and Medicare Advantage. American Journal of Managed Care, 2021, 27, e80-e88.	1.1	4
2212	Blood glucose, antidiabetic drugs, and risk of stroke. Precision and Future Medicine, 2021, 5, 13-20.	1.6	0
2213	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 2021, 21, 15.	4.2	78
2214	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. Cardiovascular Research, 2022, 118, 686-715.	3.8	24
2215	Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology, 2021, 87, 3938-3948.	2.4	0
2217	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1612-1624.	3.3	14
2218	Anti-Diabetic Drugs in Cardiovascular Disease. Korean Journal of Medicine, 2021, 96, 85-91.	0.3	2
2219	Causes and Risk Factors for Death in Diabetes. Journal of the American College of Cardiology, 2021, 77, 1837-1840.	2.8	22
2220	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 384, 1248-1260.	27.0	60
2221	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	6.8	28
2222	Rol de nuevos fármacos antidiabéticos en prevención cardiovascular e insuficiencia cardíaca. Clínica E Investigación En Arteriosclerosis, 2021, 33, 314-322.	0.8	0
2224	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14.	2.4	6
2225	New antidiabetic therapy and HFpEF: light at the end of tunnel?. Heart Failure Reviews, 2022, 27, 1137-1146.	3.9	16
2226	Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Research and Care, 2021, 9, e001313.	2.8	15



#	ARTICLE	IF	CITATIONS
2227	Chronic kidney disease in patients with diabetes mellitus. <i>Endocrine Connections</i> , 2021, 10, R151-R159.	1.9	12
2228	Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress. <i>International Heart Journal</i> , 2021, 62, 470-478.	1.0	5
2229	Heart failure at the crossroads of cardiology and diabetology. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108844.	2.8	0
2230	Interpretación de los ensayos clínicos sobre efectos cardiovasculares de los fármacos hipoglucemiantes en personas con diabetes tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 741-750.	0.3	0
2231	Heart failure subtypes: Pathophysiology and definitions. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108815.	2.8	9
2232	Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1128-1135.	2.4	8
2233	Recent advances in new-onset diabetes mellitus after kidney transplantation. <i>World Journal of Diabetes</i> , 2021, 12, 541-555.	3.5	4
2235	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. <i>International Journal of Cardiology</i> , 2021, 330, 23-29.	1.7	6
2236	CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology. <i>Cancers</i> , 2021, 13, 2191.	3.7	20
2237	Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 464-472.	4.7	4
2238	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 670155.	3.5	27
2239	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.2	0
2240	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.8	9
2241	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 103.	6.8	3
2242	Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—The role of the GLP-1 receptor. <i>British Journal of Pharmacology</i> , 2022, 179, 659-676.	5.4	28
2243	DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells. <i>European Heart Journal</i> , 2021, 42, 2935-2951.	2.2	24
2244	Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1840-1849.	1.8	6
2245	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100933.	7.1	67

#	ARTICLE	IF	CITATIONS
2246	Evidence-based use of newer agents in type 2 diabetes. Journal of Prescribing Practice, 2021, 3, 224-234.	0.1	1
2247	Interdisciplinary assessment and diagnostic algorithm: The role of the diabetologist. Diabetes Research and Clinical Practice, 2021, 176, 108850.	2.8	2
2248	Heart failure management; a perspective from diabetes care. Diabetes Research and Clinical Practice, 2021, 176, 108849.	2.8	1
2249	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. Current Cardiology Reports, 2021, 23, 75.	2.9	6
2250	The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLoS ONE, 2021, 16, e0252711.	2.5	5
2251	Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression. Journal of Clinical Medicine, 2021, 10, 2871.	2.4	10
2252	Dipeptidyl Peptidase 4 Inhibitor, an Update. Journal of Korean Diabetes, 2021, 22, 91-96.	0.3	0
2253	The effects of antidiabetic agents on heart failure. Netherlands Heart Journal, 2022, 30, 65-75.	0.8	2
2254	Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. Diabetes, Obesity and Metabolism, 2021, 23, 2035-2047.	4.4	7
2255	The year 2020 in Atherosclerosis. Atherosclerosis, 2021, 326, 35-44.	0.8	1
2256	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. Journal of Atherosclerosis and Thrombosis, 2021, 28, 563-572.	2.0	1
2257	Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia, 2021, 64, 1949-1962.	6.3	29
2258	Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption. International Journal of Molecular Sciences, 2021, 22, 6578.	4.1	13
2259	Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis. JACC Basic To Translational Science, 2021, 6, 527-542.	4.1	6
2260	Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure. International Heart Journal, 2021, 62, 885-890.	1.0	7
2261	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. Journal of Cardiac Failure, 2021, 27, 1447-1455.	1.7	14
2262	Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology, 2021, 26, 4534.	1.4	1
2264	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34

#	ARTICLE	IF	CITATIONS
2265	Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options. Medical Herald of the South of Russia, 2021, 12, 6-15.	0.4	1
2266	Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. CKJ: Clinical Kidney Journal, 2022, 15, 5-13.	2.9	10
2267	Successful glucose lowering therapy triumphs in heart failure. EClinicalMedicine, 2021, 37, 100996.	7.1	1
2268	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs, 2021, 81, 1373-1379.	10.9	13
2269	Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach. Current Drug Therapy, 2021, 16, 184-203.	0.3	1
2270	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	0.8	45
2271	A Practical Review of Diabetes Mellitus Type 2 Treatment in Primary Care. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2021, .	0.6	2
2272	Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovascular Diabetology, 2021, 20, 139.	6.8	13
2273	Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus. International Heart Journal, 2021, 62, 843-849.	1.0	2
2274	Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System. Clinical Therapeutics, 2021, 43, 1336-1355.	2.5	3
2275	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	3.8	23
2276	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
2277	Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study. Scientific Reports, 2021, 11, 16637.	3.3	2
2278	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-13.	1.8	2
2279	Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies. Clinical Pharmacology and Therapeutics, 2021, , .	4.7	3
2280	Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectrum, 2021, 34, 217-224.	1.0	0
2281	Promoting analysis of real-world data: Prospects for preventive cardiology in Japan. Global Health & Medicine, 2021, 3, 203-213.	1.4	0
2282	Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism, 2021, 23, 2207-2214.	4.4	22

#	ARTICLE	IF	CITATIONS
2283	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. <i>Diabetes Spectrum</i> , 2021, 34, 248-256.	1.0	1
2284	Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2021, 2, .	0.8	5
2285	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.2	5,558
2286	Recent therapeutic targets in diabetic nephropathy. <i>International Journal of Clinical Practice</i> , 2021, 75, e14650.	1.7	5
2287	Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging. <i>Frontiers in Endocrinology</i> , 2021, 12, 731273.	3.5	8
2288	Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet. <i>Frontiers in Nutrition</i> , 2021, 8, 688540.	3.7	16
2289	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	3.3	6
2290	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	1.8	220
2291	Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. <i>European Journal of Pharmacology</i> , 2021, 907, 174320.	3.5	4
2292	Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2945-2958.	2.6	1
2293	Incretinâ€Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 272-282.	4.7	7
2294	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 29-42.	1.8	4
2296	Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. <i>Cardiovascular Diabetology</i> , 2021, 20, 175.	6.8	6
2297	Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. <i>Diabetologia</i> , 2021, 64, 2773-2778.	6.3	7
2298	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2745-2755.	2.6	21
2299	Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109069.	2.8	4
2300	Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Postgraduate Medicine</i> , 2021, 133, 1-11.	2.0	3
2301	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	8.6	13

#	ARTICLE	IF	CITATIONS
2302	Prevention of Diabetes Macrovascular Complications and Heart Failure. Endocrinology and Metabolism Clinics of North America, 2021, 50, 415-430.	3.2	3
2303	Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study. Diabetes Research and Clinical Practice, 2021, 179, 108999.	2.8	4
2304	Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR. Kidney International Reports, 2021, 6, 2415-2424.	0.8	8
2305	Evolving Concepts of Type 2 Diabetes Management. Medical Clinics of North America, 2021, 105, 955-966.	2.5	3
2306	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. Current Diabetes Reports, 2021, 21, 41.	4.2	15
2307	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs – A systematic review. Current Diabetes Reviews, 2021, 17, .	1.3	0
2308	2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	1.5	1
2309	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	1.7	60
2310	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291.	1.6	80
2311	Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Medicine, 2021, 3, 1065-1073.	2.0	14
2312	Role of diabetes in stroke: Recent advances in pathophysiology and clinical management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	4.0	10
2313	Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128270.	2.2	1
2314	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. Current Vascular Pharmacology, 2021, 19, 487-498.	1.7	1
2315	Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies. Primary Care Diabetes, 2021, 15, 761-771.	1.8	5
2316	Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation. Atherosclerosis, 2021, 335, 16-22.	0.8	10
2317	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	3.2	3
2318	Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. Physiological Reviews, 2021, 101, 1745-1807.	28.8	150
2319	Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry, 2021, 225, 113765.	5.5	8

#	ARTICLE	IF	CITATIONS
2320	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. , 2021, 228, 107920.		20
2321	The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta Diabetologica, 2021, 58, 633-641.	2.5	2
2322	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098022.	3.2	58
2323	Hipoglucemiantes y riesgo cardiovascular. FMC Formacion Medica Continuada En Atencion Primaria, 2021, 28, 4-13.	0.0	0
2324	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	2.8	15
2325	Type 2 Diabetes Mellitus. , 2021, , .		0
2326	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	8.2	102
2327	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2018, 3, 155.	6.1	78
2328	Concept End Points Informing Design Considerations for Confirmatory Clinical Trials in Osteoarthritis. Arthritis Care and Research, 2022, 74, 1154-1162.	3.4	14
2329	Diabetes in China and the Western Pacific Region. , 2017, , 63-83.		3
2330	Antidiabetika. , 2015, , 399-424.		1
2331	Antidiabetika. , 2017, , 299-315.		1
2332	Antidiabetika. , 2019, , 471-490.		1
2333	Falsely Accused? Insufficient Evidence to Conclude that Sitagliptin is a Cause of Chronic Cough. Lung, 2020, 198, 271-273.	3.3	7
2334	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2a,, Trial). Rationale, Design, and Baseline Characteristics of the Study Population. Cardiovascular Drugs and Therapy, 2019, 33, 547-555.	2.6	3
2336	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	4.1	47
2337	The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure. Journal of Pharmacological Sciences, 2017, 135, 164-173.	2.5	14
2339	AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Bioscience Reports, 2019, 39, .	2.4	43



#	ARTICLE	IF	CITATIONS
2340	Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure. <i>Clinical Science</i> , 2020, 134, 1081-1094.	4.3	7
2342	Diabetes management in older people: a focus on cardiovascular risk reduction. <i>Postgraduate Medicine</i> , 2017, 129, 169-177.	2.0	3
2343	Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 85-93.	4.1	12
2344	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 605-613.	3.1	5
2346	Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. <i>Diabetic Medicine</i> , 2020, 37, 1418-1426.	2.3	13
2347	Design and baseline characteristics of participants in the <sc>Researching cardiovascular </sc>events with a <sc>Weekly </sc>IN</sc>cretin in <sc>Diabetes </sc>(REWIND</sc>) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 42-49.	4.4	160
2348	Drugs for type 2 diabetes: role in the regulation of bone metabolism. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 130-4.	1.0	21
2349	Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e017260.	1.9	17
2350	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. <i>Journal of Clinical Investigation</i> , 2017, 127, 83-93.	8.2	127
2351	Cardiovascular outcome trials of diabetes drugs: lessons learned. <i>Journal of Clinical Investigation</i> , 2018, 128, 893-896.	8.2	9
2352	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. <i>Circulation Journal</i> , 2019, 83, 1085-1196.	1.6	324
2353	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes – A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. <i>Circulation Journal</i> , 2020, 85, 82-125.	1.6	16
2354	New hypoglycemic agents and the kidney: what do the major trials tell us?. <i>F1000Research</i> , 2018, 7, 1844.	1.6	2
2355	Positioning Metabolism as a Central Player in the Diabetic Heart. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 92.	3.5	7
2356	No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. <i>World Journal of Clinical Cases</i> , 2020, 8, 5576-5588.	0.8	26
2357	Antidiabetic agents in patients with hepatic impairment. <i>World Journal of Meta-analysis</i> , 2019, 7, 380-388.	0.1	7
2358	Comparing the incidence of major cardiovascular events and severe microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>World Journal of Meta-analysis</i> , 2020, 8, 400-410.	0.1	2
2359	Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review. <i>PLoS ONE</i> , 2014, 9, e90963.	2.5	9

#	ARTICLE	IF	CITATIONS
2360	Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes. PLoS ONE, 2014, 9, e103217.	2.5	40
2361	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0153502.	2.5	6
2362	Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells. PLoS ONE, 2017, 12, e0180393.	2.5	13
2363	Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway. PLoS ONE, 2017, 12, e0182422.	2.5	17
2364	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	1.9	16
2365	Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials). Diabetes Mellitus, 2016, 19, 221-228.	1.9	3
2366	Association of Whole Blood Viscosity With Metabolic Syndrome in Type 2 Diabetic Patients: Independent Association With Post-Breakfast Triglyceridemia. Journal of Clinical Medicine Research, 2017, 9, 332-338.	1.2	11
2367	Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. Journal of Clinical Medicine Research, 2017, 9, 745-753.	1.2	30
2368	Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study. Journal of Clinical Medicine Research, 2017, 9, 802-808.	1.2	5
2369	New Therapeutic Strategies for Type 2 Diabetes<sup>CME</sup>. Methodist DeBakey Cardiovascular Journal, 2021, 14, 281.	1.0	8
2370	Series: Cardiovascular outcome trials for diabetes drugs Sitagliptin and TECOS. British Journal of Diabetes, 2020, 20, 55-57.	0.2	1
2371	Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial. Endocrine Connections, 2019, 8, 318-325.	1.9	10
2372	Sodiumâ€“Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. Cardiac Failure Review, 2019, 5, 169-172.	3.0	1
2373	TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?. Russian Journal of Cardiology, 2018, , 79-91.	1.4	6
2374	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	1.4	229
2375	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	1.4	32
2376	Do glucagonomas always produce glucagon?. Bosnian Journal of Basic Medical Sciences, 2016, 16, 1-7.	1.0	14
2377	Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin â€“ Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. European Endocrinology, 2017, 13, 62.	1.5	4

#	ARTICLE	IF	CITATIONS
2378	The Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors “Real-world Data. European Endocrinology, 2018, 14, 17.	1.5	26
2380	What's next after metformin? focus on sulphonylurea: add-on or combination therapy. Pharmacy Practice, 2015, 13, 606-606.	1.5	8
2381	Optimal therapy of type 2 diabetes: a controversial challenge. Aging, 2014, 6, 187-206.	3.1	41
2382	Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget, 2016, 7, 62687-62696.	1.8	10
2383	Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget, 2017, 8, 53028-53040.	1.8	17
2384	Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. Oncotarget, 2018, 9, 8898-8910.	1.8	11
2385	Anti-diabetic agents and heart health: how to use new diabetes medications in a global strategy for the prevention of cardiovascular complications in type 2 diabetes. Annals of Translational Medicine, 2018, 6, 195-195.	1.7	5
2386	A 7.0“7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus. Annals of Translational Medicine, 2019, 7, S122-S122.	1.7	3
2387	Diabetes and Vascular Disease: Is It All About Glycemia?. Current Pharmaceutical Design, 2019, 25, 3112-3127.	1.9	14
2388	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design, 2020, 26, 5911-5932.	1.9	8
2389	Protective Effects of Incretin Against Age-Related Diseases. Current Drug Delivery, 2019, 16, 793-806.	1.6	6
2390	Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure. Current Topics in Medicinal Chemistry, 2019, 19, 1850-1866.	2.1	6
2391	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry, 2019, 19, 1818-1849.	2.1	22
2392	Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall. Current Vascular Pharmacology, 2018, 17, 6-15.	1.7	12
2393	Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology, 2019, 17, 411-420.	1.7	22
2394	Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?. Current Vascular Pharmacology, 2020, 18, 148-157.	1.7	10
2395	Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection. Current Diabetes Reviews, 2020, 16, 869-873.	1.3	2
2396	Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials. Current Diabetes Reviews, 2020, 16, 917-921.	1.3	2

#	ARTICLE	IF	CITATIONS
2397	Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?. <i>Current Diabetes Reviews</i> , 2020, 17, e122820189511.	1.3	3
2398	Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 70-78.	4.5	54
2399	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	8.6	44
2400	Nocturnal Hypoglycemia in Type 2 Diabetes. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2018, 25, 99-103.	0.3	1
2401	Editorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2018, 25, 123-130.	0.3	4
2402	Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. <i>Clinical and Investigative Medicine</i> , 2014, 37, 172.	0.6	15
2403	The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. , 2018, 2, .		5
2404	Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-218.	2.8	62
2405	Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea. <i>International Journal of Heart Failure</i> , 2019, 1, 25.	2.7	22
2406	Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 9090-7.	3.3	36
2407	Drug induced acute pancreatitis: Does it exist?. <i>World Journal of Gastroenterology</i> , 2014, 20, 16529.	3.3	56
2408	COVID-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	1.8	14
2409	Treatment of diabetic kidney disease: current and future targets. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 622-630.	1.7	30
2410	Monotherapy in patients with type 2 diabetes mellitus. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 959-966.	1.7	5
2411	Newer oral and noninsulin therapies to treat type 2 diabetes mellitus. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S18-S26.	1.3	5
2412	Diabetes medications and cardiovascular outcome trials: Lessons learned. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 759-767.	1.3	13
2413	Type 2 diabetes: Evolving concepts and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 494-504.	1.3	5
2414	Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 67.	4.7	8

#	ARTICLE	IF	CITATIONS
2415	A low-carbohydrate survey: Evidence for sustainable metabolic syndrome reversal. Journal of Insulin Resistance, 2016, 1, .	1.3	3
2416	Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review. Indian Journal of Endocrinology and Metabolism, 2016, 20, 32.	0.4	4
2417	Efficacy and safety of teneligliptin. Indian Journal of Endocrinology and Metabolism, 2017, 21, 11.	0.4	13
2418	Noncardiac pulmonary edema induced by sitagliptin treatment. Journal of Family Medicine and Primary Care, 2014, 3, 456.	0.9	5
2419	A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors. Indian Journal of Endocrinology and Metabolism, 2018, 22, 689.	0.4	19
2420	SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins. Indian Journal of Endocrinology and Metabolism, 2019, 23, 175.	0.4	2
2421	Cardiovascular effects of sodium glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2019, 23, 150.	0.4	1
2422	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.4	85
2423	Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism, 2019, 23, 128.	0.4	12
2424	Liraglutide and Insulin are Associated with a Decreased Risk of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients. Journal of Diabetes & Metabolism, 2014, 05, .	0.2	1
2425	Hospitalisation Due to Heart Failure with Gliptins and Universal Label Change (FDA)-Still Justified? A Meta-Analysis of 5 Cardiovascular Outcomes Trials. Journal of Diabetes & Metabolism, 2018, 9, .	0.2	2
2426	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. World Journal of Diabetes, 2019, 10, 490-510.	3.5	56
2427	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future. World Journal of Diabetes, 2019, 10, 446-453.	3.5	17
2428	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World Journal of Diabetes, 2014, 5, 165.	3.5	16
2429	Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World Journal of Diabetes, 2015, 6, 1186.	3.5	9
2430	Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World Journal of Diabetes, 2015, 6, 840.	3.5	23
2431	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	3.2	251
2432	Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. Swiss Medical Weekly, 2016, 146, w14282.	1.6	8

#	ARTICLE	IF	CITATIONS
2433	Identification of biomarkers and mechanisms of diabetic cardiomyopathy using microarray data. Cardiology Journal, 2020, 27, 807-816.	1.2	8
2435	Optimal utilisation of sulphonylureas in resource-constrained settings : review article. Cardiovascular Journal of Africa, 2014, 25, 83-85.	0.4	8
2436	Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. Journal of Stroke, 2019, 21, 139-150.	3.2	8
2437	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.8	102
2438	Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of Obesity and Metabolic Syndrome, 2019, 28, 254-261.	3.6	13
2439	Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Drugs in Context, 2016, 5, 1-10.	2.2	4
2440	Management of type 2 diabetes: consensus of diabetes organizations. Drugs in Context, 2020, 9, 1-25.	2.2	19
2441	Improvement of Cardiac Fibrosis Biomarkers through Inflammation Inhibition by Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Administration in Metabolic Syndrome Rat Model. F1000Research, 0, 10, 1013.	1.6	0
2442	Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2021, 13, 117.	2.7	1
2443	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. JAMA Internal Medicine, 2021, 181, 1575.	5.1	28
2444	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	6.8	31
2445	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	2.8	28
2446	Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World Journal of Cardiology, 2021, 13, 585-592.	1.5	20
2447	Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway. Biochemistry and Cell Biology, 2022, 100, 9-16.	2.0	11
2448	Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice, 2022, 183, 109080.	2.8	12
2449	One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British Journal of Clinical Pharmacology, 2022, 88, 1598-1612.	2.4	4
2450	Gut Hormones and the Vascular System. , 2013, , 1-11.		0
2451	The prediction and assessment of cardiovascular and renal disease in type 2 diabetes. A current review. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2013, 20, 427-434.	0.3	1



#	ARTICLE	IF	CITATIONS
2452	Antidiabetika. , 2014, , 393-418.		1
2453	Vascular Complications of Diabetes Mellitus. , 2014, , 1-65.		0
2454	Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. European Endocrinology, 2014, 10, 117.	1.5	3
2455	Recent Medical Treatment of Diabetes Mellitus : Prevention and Cardiovascular Complications. The Japanese Journal of Rehabilitation Medicine, 2014, 51, 547-550.	0.0	0
2456	Diabetische Folgeerkrankungen. , 2014, , 239-296.		0
2457	Dipeptidyl Peptidase-4 Inhibitor. Korean Journal of Medicine, 2014, 87, 1.	0.3	1
2458	Glucagon-like Peptide-1 Suppresses the Proliferation and Migration of Vascular Smooth Muscle Cells: Implications for Preventive Effects on Atherosclerosis. The Showa University Journal of Medical Sciences, 2014, 26, 191-199.	0.1	0
2459	Alogliptin. Pharma-Kritik (discontinued), 2014, 36, .	0.0	0
2461	Individualizing treatment of type 2 diabetes. Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2014, 4, 56.	0.1	1
2462	The fibrin network in diabetes: its role in thrombosis risk. Polish Archives of Internal Medicine, 2014, 124, 617-627.	0.4	5
2463	Why are we doing cardiovascular outcome trials in type 2 diabetes?. Cleveland Clinic Journal of Medicine, 2014, 81, 665-671.	1.3	0
2464	Methodological challenges to control for immortal time bias in addressing drug effects in type 2 diabetes. World Journal of Methodology, 2015, 5, 122.	3.5	1
2465	Cardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?. Journal of Diabetes Research & Clinical Metabolism, 2015, 4, 3.	0.2	0
2466	Gut Hormones and the Vascular System. , 2015, , 4695-4703.		0
2467	Hyp-O-besity: Unmet Challenge in Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. Journal of Diabetes & Metabolism, 2015, 06, .	0.2	0
2468	SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS. Farmakoekonomika, 2015, 8, 55-61.	1.2	0
2469	Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). Diabetes Mellitus, 2015, 18, 5-23.	1.9	13
2470	Influence of Fixed Combination of Metformin SR and Glimepiride on Carbohydrate, Lipid Metabolism and Arterial Wall Stiffness in Patients with Diabetes Mellitus Type 2. МÃ-Ã¼narodnij EndokrinologÃ-Ã-nij Å½urnal, 2016, .	0.4	0

#	ARTICLE	IF	CITATIONS
2471	Limitaciones más frecuentes en los ensayos clínicos con Asignación Aleatoria (ECA) en el Área de medicina interna. Revista Med, 2015, 23, 35.	0.1	2
2472	Antidiabetika. , 2016, , 301-318.		0
2473	Diabetes in the Elderly. , 2016, , 1-9.		1
2474	Cardiac Metabolism and Energetic Control. , 2016, , 97-134.		0
2475	What news brought last year on oral antidiabetic drugs?. Interni Medicina Pro Praxi, 2016, 18, 14-18.	0.0	0
2476	Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Medical Weekly, 2016, 146, w14295.	1.6	7
2479	New peroral antidiabetic drugs and heart failure. Interni Medicina Pro Praxi, 2016, 18, 78-82.	0.0	0
2480	Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes. Cleveland Clinic Journal of Medicine, 2016, 83, S11-S17.	1.3	0
2481	Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. Diabetes Mellitus, 2016, 19, 229-236.	1.9	1
2482	Antidiabetic drugs of interest. Interni Medicina Pro Praxi, 2016, 18, 125-129.	0.0	0
2483	Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Risk in Patients with Diabetes: Fact or Fiction?. IOSR Journal of Pharmacy, 2016, 06, 01-07.	0.1	0
2484	EMPA-REG OUTCOME and reduction of the risk of heart failure in patients with diabetes. Interni Medicina Pro Praxi, 2016, 18, 163-167.	0.0	1
2485	Diabetes type 2 diabetes in the elderly “ solved and unsolved questions. Diabetes Mellitus, 2016, 19, 322-330.	1.9	3
2486	Novelty in treatment of Type 2 diabetes by oral antidiabetic drugs. Medicina Pro Praxi, 2016, 13, 168-170.	0.0	0
2487	Glucose lowering therapy of type 2 diabetes “ the art of possible. Clinical Endocrinology and Endocrine Surgery, 2016, .	0.1	0
2488	Heart Failure and Chronic Kidney Disease in Type 2 Diabetes. Journal of Interdisciplinary Medicine, 2016, 1, 252-258.	0.1	3
2489	Neuere Antidiabetika im Vergleich. Pharma-Kritik (discontinued), 2016, 38, .	0.0	1
2490	Glycemic Control and Diabetes Macroangiopathy. International Journal of Medicine and Surgery, 2017, 4, 21-25.	0.0	0

#	ARTICLE	IF	CITATIONS
2491	Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis. Indian Journal of Endocrinology and Metabolism, 2017, 21, 4.	0.4	5
2492	Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure. Indian Journal of Endocrinology and Metabolism, 2017, 21, 618.	0.4	2
2493	Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes. Journal of Korean Diabetes, 2017, 18, 7.	0.3	0
2494	Role of Proteases in Diabetes Mellitus. , 2017, , 515-533.		0
2495	Perspectives on medical treatment of type 2 diabetes mellitus. Journal of the Japanese Coronary Association, 2017, 23, 113-116.	0.0	0
2496	3. Antidiabetic Agents. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 216-225.	0.0	0
2497	Management of Diabetes in Elderly. International Journal of Medicine and Surgery, 2017, 4, 26-33.	0.0	0
2498	Diabetic Nephropathy: Where do we Stand. Urology & Nephrology Open Access Journal, 2017, 4, .	0.1	0
2499	Diabetology: a field of new possibilities. Interni Medicina Pro Praxi, 2017, 19, 54-56.	0.0	0
2500	Protective Effect of Anti-diabetic Drugs on Cardiovascular Diseases. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1029-1036.	0.0	0
2501	Cardio Vascular Outcomes Trials (CVOTs) with Anti-Hyperglycemic Agents: Demystifying Statistical Complexities. Journal of Diabetes, Metabolic Disorders & Control, 2017, 4, .	0.1	2
2502	Herzinsuffizienz und Diabetes. Klinikarzt, 2017, 46, 318-323.	0.0	0
2504	The Current Role of Glucose Control Medications in Primary and Secondary Prevention for Cardiovascular Disease. MOJ Gerontology & Geriatrics, 2017, 2, .	0.1	0
2505	Second line therapy in type 2 diabetes: legacy effect activation. Diabetes Mellitus, 2017, 20, 356-362.	1.9	1
2506	Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world. Annals of Translational Medicine, 2017, 5, 474-474.	1.7	0
2507	CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Meditsinskiy Sovet, 2017, , 32-37.	0.5	1
2508	A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES. Meditsinskiy Sovet, 2017, , 38-43.	0.5	1
2509	Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2018, 5, 5-15.	0.7	7

#	ARTICLE	IF	CITATIONS
2510	Antidiabetika. , 2018, , 353-368.		0
2511	Fall 71: SpÄtschÄden â€“ 49 Jahre, â™€, DM Typ 2, Progression der Niereninsuffizienz. , 2018, , 285-287.		0
2512	Fall 40: Therapie â€“ 60 Jahre, â™€, PrÄdiabetes, metabolisches Syndrom, Äœbergewicht. , 2018, , 157-159.		0
2513	Enfoque terapÄutico de la diabetes mellitus tipo 2 en adultos. MÄs allÄ de una meta glucÄmica. Medicina UPB, 2018, 37, 36-46.	0.1	1
2514	Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Journal of Clinical Medicine Research, 2018, 10, 796-797.	1.2	1
2515	Diabetes and the Cardiovascular System. Endocrinology, 2018, , 131-159.	0.1	0
2516	Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes. AIMS Medical Science, 2018, 5, 67-79.	0.4	1
2517	Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism. Journal of Lipid and Atherosclerosis, 2018, 7, 21.	3.5	0
2518	Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift. US Cardiology Review, 2018, 12, 46-50.	0.5	0
2519	A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018). Vnitri Lekarstvi, 2018, 64, 405-426.	0.2	0
2520	The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials. Annals of Translational Medicine, 2018, 6, 194-194.	1.7	1
2521	2. Incretin Based Treatments and SGLT2 in Patients with Diabetic Kidney Disease. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 841-847.	0.0	0
2524	Vildagliptina en pacientes diabÄticos tipo 2 con riesgo cardiovascular o compromiso renal. RevisiÄn de literatura. Revista Cuarzo, 2018, 24, 28-45.	0.1	0
2525	Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure. Methodist DeBakey Cardiovascular Journal, 2021, 14, 257.	1.0	1
2526	Heart failure in diabetes: From an increased risk to a treatment target. Diabetes Mellitus, 2018, 21, 399-403.	1.9	1
2527	Le seuil du Â« p Â» statistique Ä 0,05 est-il fiable ou non ? Telle est la question. Medecine Des Maladies Metaboliques, 2018, 12, 671-678.	0.1	0
2528	Current situation analysis of diabetic home care patients. Ä°stanbul Kuzey Klinikleri, 2019, 7, 140-145.	0.3	1
2529	Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study. Journal of Clinical Medicine Research, 2019, 11, 15-20.	1.2	0

#	ARTICLE	IF	CITATIONS
2530	Diabetes and Cardiovascular Disease. , 2019, , 709-730.		1
2531	Approach to the treatment of diabetes in the elderly. Sisli Etfal Hastanesi Tip Bulteni, 2019, 53, 96-102.	0.3	3
2532	Th��rapeutique des d��sordres glyc��miques. , 2019, , 141-252.		0
2533	Effets des traitements anti-hyperglyc��miants sur les complications cardiovasculaires et r��nales du patient diab��tique de type 2 : le��sons des grands essais d'intervention. , 2019, , 283-295.		0
2535	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
2536	7. Diabetes and Heart Failure: How to Treat Doubles Dangers. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 147a-147a.	0.0	0
2537	3. Recent Progress in the Treatment of Type 2 Diabetes. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 460-467.	0.0	0
2538	New perspectives on oral antidiabetics therapy. Farmacist Ro, 2019, 187 (2), 25-28.	0.0	0
2539	A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus. Vnitri Lekarstvi, 2019, 65, 289-294.	0.2	2
2540	Diabetes Mellitus and Chronic Heart Failure. Vnitri Lekarstvi, 2019, 65, 307-313.	0.2	0
2541	Oral Hypoglycemics in Patients with type 2 Diabetes and Peripheral Artery Disease. Canadian Journal of General Internal Medicine, 2019, 14, 13-17.	0.2	1
2542	Series: Cardiovascular outcome trials for diabetes drugs Saxagliptin and SAVOR-TIMI 53. British Journal of Diabetes, 2019, 19, 34-36.	0.2	1
2543	Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. Diabetes Mellitus, 2019, 22, 159-164.	1.9	1
2545	Pharmacotherapy of Diabetes Focused on Stroke. Journal of the Korean Neurological Association, 2019, 37, 235-250.	0.1	3
2546	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. Endocrinologia, Diabetes Y Nutrici��n, 2019, 66, 467-468.	0.3	0
2547	7. Diabetes and Heart Failure: How to Treat Doubles Dangers. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1902-1911.	0.0	0
2548	A modern view on the mechanisms of diabetic cardiomyopathy development and the its modification options. Russian Journal of Cardiology, 2019, , 142-147.	1.4	3
2549	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	1.4	6

#	ARTICLE	IF	CITATIONS
2550	Series: Cardiovascular outcome trials for diabetes drugs Alogliptin and EXAMINE. British Journal of Diabetes, 2019, 19, 133-135.	0.2	0
2551	Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5: a retrospective cohort study. Sao Paulo Medical Journal, 2019, 137, 523-529.	0.9	3
2552	(New antidiabetics and cardiovascular safety in the light of clinical trials). Cor Et Vasa, 2019, 61, 588-598.	0.1	0
2553	Cardiovascular Risk Factors: It's Time to Focus on Variability!. Journal of Lipid and Atherosclerosis, 2020, 9, 255.	3.5	11
2554	Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis. Indian Journal of Endocrinology and Metabolism, 2020, 24, 143.	0.4	0
2555	The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. Diabetes Mellitus, 2019, 22, 461-466.	1.9	1
2557	Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema. Ophthalmic Surgery Lasers and Imaging Retina, 2020, 51, 226-234.	0.7	3
2558	Efecto de terapias farmacológicas para el control glicémico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares. Revista Colombiana De Nefrología, 2020, 7, 44-59.	0.1	1
2559	Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review). МАНРодний Ендокринологічний Журнал, 2020, 16, 237-244.	0.4	1
2560	Incretin-based treatment of diabetes and cardiovascular complications. Vnitri Lekarstvi, 2020, 66, 74-80.	0.2	0
2563	Management of the heart failure patient in the primary care setting. Singapore Medical Journal, 2020, 61, 225-229.	0.6	5
2564	Dipeptidyl peptidase 4 inhibitors in modern domestic practice. Meditsinskiy Sovet, 2020, , 14-18.	0.5	1
2565	Series: Cardiovascular outcome trials for diabetes drugs Lixisenatide and ELIXA. British Journal of Diabetes, 2020, 20, 52-54.	0.2	0
2566	ASSOCIATION BETWEEN DIABETICS AND INTESTINAL CANCER WITH THE RISK OF MUTATION IN CD38 GENE IN IRANIAN POPULATION. Arquivos De Gastroenterologia, 2020, 57, 137-143.	0.8	3
2567	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.8	6
2568	Reverse remodeling in diabetic cardiomyopathy: the role of extracellular matrix. Minerva Cardiology and Angiology, 2022, 70, .	0.7	3
2569	Overview of Type 2 Diabetes Drugs on the Market. Journal of Biosciences and Medicines, 2020, 08, 1-14.	0.2	2
2570	Pharmacotherapy for patients with diabetes mellitus. Journal of the Korean Medical Association, 2020, 63, 766-775.	0.3	0



#	ARTICLE	IF	CITATIONS
2571	Liraglutid in diabetic patients in LEADER study - is there any benefit in patients with heart failure?. Klinicka Farmakologie A Farmacie, 2020, 34, 168-170.	0.2	0
2572	&lt;p&gt;Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial&lt;/p&gt;. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4993-5001.	2.4	5
2573	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.1	1
2574	Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER. British Journal of Diabetes, 2020, 20, 142-144.	0.2	0
2575	(Dapagliflozin and heart failure). Cor Et Vasa, 2020, 62, 618-623.	0.1	2
2576	Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. Endocrine Practice, 2020, 26, 1486-1496.	2.1	4
2577	Diabetes and Cardiovascular Disease. Current Pharmaceutical Design, 2020, 26, 5909-5910.	1.9	0
2578	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Current Pharmaceutical Design, 2020, 26, 5953-5968.	1.9	4
2579	The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. Journal of the Endocrine Society, 2021, 5, bvaa193.	0.2	4
2580	Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME. British Journal of Diabetes, 2020, 20, 138-141.	0.2	1
2581	Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents. Diabetes Mellitus, 2019, 22, 467-472.	1.9	0
2582	Standard Pharmacological Treatment of Diabetes Based on the Guidelines. Stroke Revisited, 2021, , 179-187.	0.2	0
2583	Dipeptidyl Peptidase-4 Inhibitors. Stroke Revisited, 2021, , 143-154.	0.2	0
2584	Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control. Clinical Medicine Insights: Endocrinology and Diabetes, 2021, 14, 117955142110516.	1.9	13
2585	Antidiabetika. , 2020, , 339-358.		0
2586	Modifiable factors related to 7-year renal outcomes in subjects with type 2 diabetes and chronic kidney disease stage 3. Journal of Postgraduate Medicine, 2020, 66, 187-193.	0.4	1
2587	Cardiovascular Impact of Newer Diabetes Medications. , 2020, , 735-745.		0
2588	Diabetes and the Cardiovascular System. Endocrinology, 2020, , 131-159.	0.1	0

#	ARTICLE	IF	CITATIONS
2589	The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection. <i>Arhiv Za Farmaciju</i> , 2020, 70, 198-223.	0.5	0
2590	In-patient management of hyperglycemia during COVID-19 pandemic. <i>Apollo Medicine</i> , 2020, .	0.0	0
2591	Treatment of Diabetes and Heart Failure. , 2020, , 719-733.		0
2592	Diabetes and Treatments. , 2020, , 705-717.		2
2593	Effects of empagliflozin and vildagliptin on structural and functional parameters in patients with type 2 diabetes. <i>Arterial Hypertension (Russian Federation)</i> , 2020, 25, 622-629.	0.4	0
2594	Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 308-317.	1.5	1
2596	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021, 20, 218.	6.8	38
2597	Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 177-186.	4.4	11
2599	Actualización del efecto de los antihiperlipemiantes en la función renal en diabetes mellitus tipo 2. <i>Acta Medica Costarricense</i> , 2018, 60, .	0.1	0
2601	Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease. <i>PLoS ONE</i> , 2020, 15, e0240141.	2.5	6
2602	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	1.8	0
2603	Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus. <i>Turkish Journal of Internal Medicine</i> , 0, , .	0.6	0
2604	DYDA 2TM trial: unveil the linagliptin innocence. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 5-7.	1.8	0
2605	Vascular repair strategies in type 2 diabetes: novel insights. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 374-86.	1.7	7
2606	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 617-23.	0.4	6
2607	Acute myocardial infarction associated to DPP-4 inhibitors. <i>Heart, Lung and Vessels</i> , 2014, 6, 180-6.	0.4	4
2608	Cardiovascular safety profile of currently available diabetic drugs. <i>Ochsner Journal</i> , 2014, 14, 616-32.	1.1	37
2609	DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 471-8.	1.7	13

#	ARTICLE	IF	CITATIONS
2610	Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. American Journal of Translational Research (discontinued), 2016, 8, 2450-8.	0.0	14
2611	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Hippokratia, 2015, 19, 195-9.	0.3	9
2612	Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. Colombia Medica, 2016, 47, 109-31.	0.2	11
2613	Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study. American Journal of Cardiovascular Disease, 2016, 6, 153-162.	0.5	3
2614	PURLs: Need an add-on to metformin? Consider this. Journal of Family Practice, 2017, 66, 42-44.	0.2	0
2615	Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?. Canadian Journal of Hospital Pharmacy, 2018, 71, 282-285.	0.1	0
2616	Cardiovascular outcomes and safety with antidiabetic drugs. International Journal of Health Sciences, 2018, 12, 70-83.	0.4	5
2617	New Pharmacologic Agents for Diabetes Treatment. Missouri Medicine, 2016, 113, 361-366.	0.3	1
2618	The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Biological and Applied Environmental Research: an Open Access Peer Reviewed Journal, 2018, 2, .	0.3	11
2619	Newer Oral Antihyperglycemics: From to. Canadian Journal of Hospital Pharmacy, 2019, 72, 385-387.	0.1	0
2620	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	1.9	3
2621	Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors. Canadian Family Physician, 2020, 66, 341-346.	0.4	0
2622	3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy. Annals of Translational Medicine, 2020, 8, 1345.	1.7	2
2623	The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study. Indian Journal of Pharmacology, 2021, 53, 229-233.	0.7	1
2624	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	4.4	17
2626	Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article. Cureus, 2021, 13, e19398.	0.5	4
2628	Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Science Translational Medicine, 2021, 13, eabf7084.	12.4	28
2629	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). PLoS ONE, 2021, 16, e0259372.	2.5	6

2631	Incretins in the Therapy of Diabetic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 12312.	4.1	4
------	--	-----	---

#	ARTICLE	IF	CITATIONS
2649	DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. <i>Hypertension</i> , 2022, 79, 827-835.	2.7	6
2650	Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis" Journal of Lipid and Atherosclerosis, 2022, 11, 89.	3.5	2
2651	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. <i>Biomolecules</i> , 2022, 12, 176.	4.0	20
2652	Glucose-dependent insulintropic polypeptide and tissue inflammation: Implications for atherogenic cardiovascular disease. <i>European Journal of Inflammation</i> , 2022, 20, 205873922110704.	0.5	0
2653	Therapeutic Advances in Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2022, 11, 378.	2.4	49
2654	Bone fragility in diabetes: novel concepts and clinical implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 207-220.	11.4	123
2656	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, C100000000000000001040.	1.6	193
2657	Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862110723.	2.4	7
2658	Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 49-62.	4.7	7
2659	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	7.1	820
2660	Cardiovascular outcomes associated with prescription of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 928-937.	4.4	2
2661	Does diabetes increase the risk of cardiovascular events in patients with negative treadmill stress echocardiography?. <i>Endocrine Journal</i> , 2022, 69, 785-796.	1.6	1
2662	Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. <i>World Journal of Diabetes</i> , 2022, 13, 85-96.	3.5	14
2663	The gut hormone glucose-dependent insulintropic polypeptide is downregulated in response to myocardial injury. <i>Cardiovascular Diabetology</i> , 2022, 21, 18.	6.8	0
2664	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. <i>Heart Failure Reviews</i> , 2022, , .	3.9	0
2665	The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF). <i>Primary Care Diabetes</i> , 2022, 16, 135-141.	1.8	3
2666	Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies. <i>Primary Care Diabetes</i> , 2022, 16, 207-210.	1.8	1
2667	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 281-295.	2.4	35

#	ARTICLE	IF	CITATIONS
2668	Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues. <i>Biomolecules</i> , 2022, 12, 272.	4.0	11
2669	Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 561-569.	2.6	28
2670	Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India. <i>Cureus</i> , 2022, 14, e22141.	0.5	0
2671	Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. <i>ESC Heart Failure</i> , 2022, 9, 1388-1399.	3.1	20
2672	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109231.	2.8	4
2673	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S144-S174.	8.6	282
2675	Prescription of DPP4 inhibitors: indication and effect on glycosylated hemoglobin in a primary care institution of Colombia. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.2	0
2677	Capillaries as a Therapeutic Target for Heart Failure. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 971-988.	2.0	4
2678	Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model. <i>Medicine (United States)</i> , 2022, 101, e28823.	1.0	5
2679	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. <i>Primary Care Diabetes</i> , 2022, 16, 223-244.	1.8	15
2680	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. <i>Minerva Cardiology and Angiology</i> , 2022, , .	0.7	5
2681	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. <i>Current Cardiology Reports</i> , 2022, 24, 567-576.	2.9	2
2682	Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study. <i>PLoS ONE</i> , 2022, 17, e0262831.	2.5	4
2684	Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 30.	2.7	4
2685	Team-based strategies to prevent heart failure. <i>Current Opinion in Cardiology</i> , 2022, Publish Ahead of Print, .	1.8	0
2686	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. <i>European Journal of Internal Medicine</i> , 2022, 97, 78-85.	2.2	2
2687	Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102437.	3.6	2
2688	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e10.	3.0	0



#	ARTICLE	IF	CITATIONS
2689	Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis. <i>BMJ Open</i> , 2022, 12, e045966.	1.9	4
2690	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	4.1	16
2691	Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 818537.	3.5	2
2692	Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis. <i>Endocrine Practice</i> , 2022, 28, 333-341.	2.1	10
2693	Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis. <i>Scientific Reports</i> , 2022, 12, 5129.	3.3	7
2694	Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i+DPP4i in the Indian Diabetes Setting. <i>Diabetes Therapy</i> , 2022, 13, 1097-1114.	2.5	9
2695	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3587.	4.1	48
2696	Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2022, 13, 816588.	3.5	10
2697	Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2022, Publish Ahead of Print, .	2.7	6
2698	Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs. <i>Korean Journal of Internal Medicine</i> , 2022, , .	1.7	3
2699	Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. <i>Cardiovascular Research</i> , 2023, 119, 668-690.	3.8	11
2700	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
2701	Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis. <i>Current Problems in Cardiology</i> , 2023, 48, 101194.	2.4	5
2702	Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1114-1121.	2.4	7
2703	Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. <i>Medical Hypotheses</i> , 2022, 162, 110804.	1.5	0
2705	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 636-642.	1.5	3
2706	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes. <i>Endocrinology &amp; Diabetes Y Nutrici3n (English Ed )</i> , 2021, 68, 741-750.	0.2	0
2707	Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e12.	0.5	2

#	ARTICLE	IF	CITATIONS
2709	Type 2 diabetes mellitus and chronic heart failure: new treatment strategies. <i>Cardiosomatics</i> , 2021, 12, 234-238.	0.4	1
2710	Angioedema associated with dipeptidyl peptidase-IV inhibitors. <i>Clinical and Molecular Allergy</i> , 2021, 19, 24.	1.8	8
2711	The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-7.	2.3	1
2712	Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. <i>Journal of Translational Medicine</i> , 2021, 19, 520.	4.4	15
2713	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. <i>Russian Journal of Cardiology</i> , 2022, 26, 4807.	1.4	0
2714	Cardiovascular outcomes of type 2 diabetic patients treated with DPP-4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice. <i>Scientific Reports</i> , 2021, 11, 23826.	3.3	1
2716	Diabetes Medications and Cardiovascular Disease Prevention. <i>Korean Journal of Family Practice</i> , 2022, 12, 61-71.	0.3	0
2717	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	1.2	40
2718	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	1.2	27
2719	New Approaches to Diabetic Nephropathy from Bed to Bench. <i>Biomedicines</i> , 2022, 10, 876.	3.2	4
2720	Anabolic Deficiencies in Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, 149-159.	2.2	1
2743	Achieving coronary plaque regression: a decades-long battle against coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2022, , 1-15.	1.5	1
2744	Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. <i>BMJ</i> , The, 2022, 376, e067731.	6.0	14
2745	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	1.9	5
2747	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 617.	0.4	8
2750	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	3.3	16
2751	Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. <i>JACC: Heart Failure</i> , 2022, 10, 404-414.	4.1	15
2752	Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 1201-1211.	1.8	1

#	ARTICLE	IF	CITATIONS
2753	Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opinion on Pharmacotherapy, 2022, 23, 791-803.	1.8	5
2754	Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Failure, 2022, 9, 2500-2510.	3.1	12
2755	Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage. Minerva Cardiology and Angiology, 2022, 70, .	0.7	6
2756	Efficacy of linagliptin on cardiovascular risk and cardiometabolic parameters in Thai patients with type 2 diabetes mellitus: A real-world observational study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102498.	3.6	3
2757	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice, 2022, 188, 109927.	2.8	18
2758	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular Diabetology, 2022, 21, 74.	6.8	82
2760	Exposure-Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies. Frontiers in Endocrinology, 2022, 13, .	3.5	3
2761	Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics, 2022, 14, 1180.	4.5	0
2762	Validation of the WATCH-DM and TRS-HF <sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	3.7	10
2763	Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovascular Diabetology, 2014, 13, 154.	6.8	0
2764	Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. PLoS ONE, 2022, 17, e0269970.	2.5	2
2765	Re- adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clinical Cardiology, 0, , .	1.8	2
2766	Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open, 2022, 12, e057977.	1.9	8
2767	Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a <sc>UK</sc> clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 2138-2147.	4.4	4
2768	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype. Aging Clinical and Experimental Research, 2022, 34, 1949-1967.	2.9	11
2770	Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. International Journal of Cardiology, 2022, 364, 104-111.	1.7	7
2771	Diabetes: how to manage cardiovascular risk in secondary prevention patients. Drugs in Context, 0, 11, 1-12.	2.2	1
2772	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Journal of Diabetes Investigation, 2022, 13, 1472-1488.	2.4	2

#	ARTICLE	IF	CITATIONS
2773	Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 0, , e068882.	6.0	13
2774	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7261.	4.1	4
2777	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <i>Endocrinology and Metabolism</i> , 2022, 37, 415-429.	3.0	3
2778	Series: Cardiovascular outcome trials for diabetes drugs. Linagliptin, CARMELINA and CAROLINA. <i>British Journal of Diabetes</i> , 2022, 22, 42-46.	0.2	0
2780	Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
2781	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	1.2	5
2782	Therapeutic Perspectives of CD26 Inhibitors in Immune-Mediated Diseases. <i>Molecules</i> , 2022, 27, 4498.	3.8	7
2783	Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study. <i>Journal of General Internal Medicine</i> , 0, , .	2.6	0
2784	Efficacy and safety of <sc>DBPR108</sc> (prusogliptin) as an addâ€on to metformin therapy in patients with type 2 diabetes: A 24â€week, multiâ€centre, randomized, doubleâ€blind, placeboâ€controlled, superiority, phase <sc>III</sc> clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2232-2240.	4.4	3
2785	Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone. <i>Biomedicines</i> , 2022, 10, 1573.	3.2	4
2786	Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy. <i>Diabetes Care</i> , 0, , .	8.6	3
2787	Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure. <i>Life Sciences</i> , 2022, 305, 120757.	4.3	5
2788	An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. <i>Current Medical Research and Opinion</i> , 0, , 1-19.	1.9	0
2789	Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 4333.	2.4	3
2790	The effect of trajectory of serum uric acid on survival and renal outcomes in patients with stage 3 chronic kidney disease. <i>Medicine (United States)</i> , 2022, 101, e29589.	1.0	0
2791	The Evaluation of the Obstetric Outcomes in Re-Pregnancy after Recovery from Peripartum Cardiomyopathy. <i>Pakistan Biomedical Journal</i> , 0, , 223-226.	0.1	0
2792	Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
2793	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	2.1	146

#	ARTICLE	IF	CITATIONS
2794	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	18
2795	Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. Journal of Clinical Medicine, 2022, 11, 4660.	2.4	6
2796	Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study. Journal of Clinical Medicine, 2022, 11, 4988.	2.4	2
2797	A polygenic risk score predicts atrial fibrillation in cardiovascular disease. European Heart Journal, 2023, 44, 221-231.	2.2	21
2798	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Military Medical Research, 2022, 9, .	3.4	4
2799	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. , 2022, , 211-225.		0
2800	Dipeptidyl Peptidase IV Inhibitors and the Risk of Mycobacterial Pulmonary Infections in Type 2 Diabetes Mellitus. SSRN Electronic Journal, 0, , .	0.4	0
2801	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
2802	Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies. , 2022, 1, .		1
2803	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , .		0
2804	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (United States), 2022, 101, e30072.	1.0	2
2805	Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2. CES Medicina, 2022, 36, 81-105.	0.1	0
2806	Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3022-3034.	3.6	5
2807	Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes. International Journal of Cardiology, 2022, , .	1.7	1
2808	The dual role of empagliflozin: Cardio renal protection in T2DM patients. Annals of Medicine and Surgery, 2022, 81, .	1.1	2
2809	Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. Cardiovascular Research, 2023, 119, 1130-1145.	3.8	6
2810	External validation and extension of the <scp>TIMI</scp> risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2023, 25, 229-237.	4.4	3
2811	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences, 2022, 23, 10882.	4.1	9

#	ARTICLE	IF	CITATIONS
2812	Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Scientific Reports, 2022, 12, .	3.3	3
2813	Stroke genetics informs drug discovery and risk prediction across ancestries. Nature, 2022, 611, 115-123.	27.8	143
2814	DPP4 as a Potential Candidate in Cardiovascular Disease. Journal of Inflammation Research, 0, Volume 15, 5457-5469.	3.5	10
2815	Effects of DPP-4 inhibitors on brain natriuretic peptide, neurotensin, glucagon like peptide-1, substance P levels and global longitudinal strain measurements in type 2 diabetes mellitus patients. Journal of Health Sciences and Medicine, 2022, 5, 1424-1430.	0.1	0
2816	Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Annales D'Endocrinologie, 2023, 84, 57-68.	1.4	2
2817	Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 192, 110094.	2.8	0
2818	Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis. British Journal of Pharmacology, 2023, 180, 2846-2861.	5.4	4
2819	Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study. Cardiovascular Diabetology, 2022, 21, .	6.8	1
2821	Evaluating gliclazide for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2022, 23, 1869-1877.	1.8	2
2822	Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
2823	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1957-1974.	1.8	0
2824	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. Biochemical Pharmacology, 2022, 206, 115304.	4.4	5
2825	Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism: Clinical and Experimental, 2022, 137, 155332.	3.4	35
2827	Synthesis of new sulphonate derivatives containing adamantane and 4-chlorophenyl moieties as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors. Journal of Molecular Structure, 2023, 1274, 134494.	3.6	0
2828	Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. Circulation, 2023, 147, 212-222.	1.6	11
2829	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. Journal of Personalized Medicine, 2022, 12, 1915.	2.5	2
2830	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. Journal of Pharmacy Practice, 2024, 37, 410-414.	1.0	1
2831	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 639-648.	4.4	3



#	ARTICLE	IF	CITATIONS
2832	Meta-analysis of numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. ESC Heart Failure, 2023, 10, 552-567.	3.1	3
2833	Low soluble dipeptidyl Peptidase-4 levels during acute myocardial infarction and decreased endogenous glucagon like Peptide-1 response are associated with adverse long-term cardiovascular outcome and mortality: A pilot study. European Journal of Clinical Investigation, 2023, 53, .	3.4	0
2835	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53.	1.0	0
2836	Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. Journal of Diabetes and Its Complications, 2023, 37, 108362.	2.3	5
2837	Corrigendum to "Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes" [Biochem. Pharmacol. 206 (2022) 115304]. Biochemical Pharmacology, 2023, 207, 115349.	4.4	0
2838	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023, 19, 151-163.	9.6	21
2839	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. Frontiers in Cardiovascular Drug Discovery, 2022, , 191-229.	0.0	0
2840	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Therapy, 0, , .	2.5	0
2841	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. European Heart Journal Supplements, 2022, 24, L29-L37.	0.1	0
2842	Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning. Pharmacological Reviews, 2023, 75, 159-216.	16.0	29
2843	Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent. British Journal of Diabetes, 2022, 22, 87-94.	0.2	0
2844	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. Diabetes Care, 2023, 46, S158-S190.	8.6	156
2845	Therapeutics in Metabolic Diseases. Advances in Experimental Medicine and Biology, 2023, , 255-273.	1.6	0
2846	Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?. Pharmacology Research and Perspectives, 2022, 10, .	2.4	3
2847	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetology International, 2023, 14, 1-14.	1.4	8
2848	Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System. Diabetes Care, 0, , .	8.6	0
2849	Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study. Diabetology and Metabolic Syndrome, 2022, 14, .	2.7	1
2850	Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World Journal of Diabetes, 0, 13, 1168-1183.	3.5	0



#	ARTICLE	IF	CITATIONS
2851	Renal outcomes with sodium-glucose cotransporters 2 inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
2852	Diabetes medication following heart transplantation: a focus on novel cardioprotective therapiesâ€”a joint review from endocrinologists and cardiologists. <i>Acta Diabetologica</i> , 2023, 60, 471-480.	2.5	1
2853	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
2854	A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2023, 14, 151-164.	2.4	15
2855	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. <i>JACC Asia</i> , 2023, 3, 93-104.	1.5	8
2856	Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumâ€”glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 301-310.	3.0	4
2857	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. <i>Contemporary Cardiology</i> , 2023, , 67-138.	0.1	0
2858	Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	0
2860	Control of Blood Glucose and Cardiovascular Risk Profile. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 451-469.	0.1	0
2861	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2023, 43, 1-7.	2.1	3
2863	Dipeptidyl Peptidase 4/Midlineâ€”1 Axis Promotes T Lymphocyte Motility in Atherosclerosis. <i>Advanced Science</i> , 2023, 10, .	11.2	2
2864	Longitudinal HbA1c trajectory modelling reveals the association of HbA1c and risk of hospitalization for heart failure for patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2023, 18, e0275610.	2.5	1
2865	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 10-26.	4.7	4
2866	Individual or familial diabetes in relation to eight cardiovascular diseases: A two-sample Mendelian randomization study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 883-891.	2.6	1
2867	Advances in contemporary medical management to treat patients with heart failure. <i>Current Opinion in Cardiology</i> , 2023, 38, 136-142.	1.8	4
2868	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. <i>International Journal of Heart Failure</i> , 2023, 5, 1.	2.7	2
2869	Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for postâ€”transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation. <i>Clinical Transplantation</i> , 2023, 37, .	1.6	5
2871	Atrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?. <i>Journal of Clinical Medicine</i> , 2023, 12, 2868.	2.4	2

#	ARTICLE	IF	CITATIONS
2873	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. Diabetes, Obesity and Metabolism, 2023, 25, 3-14.	4.4	4
2874	Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model. European Journal of Pharmacology, 2023, 948, 175673.	3.5	0
2875	Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs, 2022, 31, 1311-1320.	4.1	3
2876	Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the <sc>CAROLINA</sc> cardiovascular outcome trial. Diabetes, Obesity and Metabolism, 0, , .	4.4	1
2877	Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 139-150.	0.9	0
2878	Vascular ageing: moving from bench towards bedside. European Journal of Preventive Cardiology, 2023, 30, 1101-1117.	1.8	25
2879	Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA<sub>1c</sub> Levels. JAMA Internal Medicine, 2023, 183, 242.	5.1	17
2881	Long-term increase in fasting blood glucose is associated with increased risk of sudden cardiac arrest. Cardiovascular Diabetology, 2023, 22, .	6.8	0
2882	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research, 2023, 2023, 1-11.	2.3	0
2883	Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis. Metabolism Open, 2023, 17, 100236.	2.9	6
2884	Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment. Journal of Clinical Pharmacology, 2023, 63, 848-858.	2.0	2
2885	Safety and cardiometabolic efficacy of novel antidiabetic drugs. Expert Opinion on Drug Safety, 2023, 22, 119-124.	2.4	1
2886	Paradigm shift of the medical care in diabetes. Nihon Ika Daigaku Igakkai Zasshi, 2023, 19, 32-41.	0.0	0
2887	Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk. Nutrients, 2023, 15, 1384.	4.1	0
2888	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovascular Diabetology, 2023, 22, .	6.8	4
2889	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovascular Diabetology, 2023, 22, .	6.8	4
2890	Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care, 2023, 46, 967-977.	8.6	6
2891	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 117-167.	0.1	0

#	ARTICLE	IF	CITATIONS
2892	A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	3
2893	Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts. <i>FASEB Journal</i> , 2023, 37, .	0.5	1
2894	Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. <i>Internal and Emergency Medicine</i> , 2023, 18, 1049-1063.	2.0	1
2895	Medications to Avoid When Treating Heart Failure. , 2023, , 285-306.		0
2896	Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. , 2023, , 365-396.		0
2897	Embedding guidelines into clinical practice. <i>Practical Diabetes</i> , 2023, 40, 28.	0.3	0
2898	Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). <i>Swiss Medical Weekly</i> , 2023, 153, 40060.	1.6	5
2899	Avoiding and managing the side effects of type 2 diabetes treatments. <i>Journal of Prescribing Practice</i> , 2023, 5, 158-165.	0.1	0
2900	Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy. <i>Journal of Insulin Resistance</i> , 2023, 6, .	1.3	0
2901	Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials. <i>Endocrine Practice</i> , 2023, 29, 509-516.	2.1	2
2902	Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	42
2903	Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease. <i>World Journal of Diabetes</i> , 0, 14, 352-363.	3.5	0
2904	A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 33-47.	4.4	0
2905	Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 1043-1054.	2.4	4
2906	Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The <sc>gemia€heart</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2181-2190.	4.4	0
2907	Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2023, 28, 107424842311622.	2.0	0
2908	Treatment of type 2 diabetes patients with heart conditions. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 255-265.	2.4	9
2911	Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2023, 2023, 1-9.	1.3	0

#	ARTICLE	IF	CITATIONS
2912	Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose-Lowering Drugs: A Meta-Analysis of Randomized Outcome Trials. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.7	1
2913	Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis. <i>Journal of Diabetes Investigation</i> , 2023, 14, 844-855.	2.4	2
2914	American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. <i>Endocrine Practice</i> , 2023, 29, 305-340.	2.1	46
2915	Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes. <i>Annals of Internal Medicine</i> , 2023, 176, 751-760.	3.9	4
2916	DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	10
2917	Effects of <scp>DPP</scp>-4 inhibitors, <scp>GLP</scp>-1 receptor agonists, <scp>SGLT</scp>-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analysis-driven approach. <i>Diabetic Medicine</i> , 0, , .	2.3	2
2918	Incretin Therapies: Current Use and Emerging Possibilities. , 2023, , 565-580.		0
2919	Diabetes and Cardiovascular Disease. , 2023, , 813-835.		0
2920	Diabetes Management in the United States. , 2023, , 309-328.		0
2921	A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy – A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9760.	4.1	4
2922	Aspects of the safety of hypoglycemic drugs according to the results of clinical trials. , 2023, 1, 63-74.		0
2923	Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	1.7	2
2924	Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2023, 12, 3925.	2.4	3
2925	Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review. <i>Biomedicine and Pharmacotherapy</i> , 2023, 165, 115032.	5.6	5
2926	Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2023, 81, 2391-2402.	2.8	2
2927	Assessment of the patient with heart failure symptoms and risk factors: A guide for the non-cardiologist. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 15-25.	4.4	1
2929	Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110798.	2.8	0
2930	Endocrine. , 2023, , 107-203.		0

#	ARTICLE	IF	CITATIONS
2931	Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. <i>Biomolecules</i> , 2023, 13, 752.	4.0	7
2932	Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment. <i>World Journal of Diabetes</i> , 0, 14, 512-527.	3.5	5
2933	Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. <i>European Heart Journal</i> , 2023, 44, 2216-2230.	2.2	8
2934	Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-19.	3.5	2
2935	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. <i>Contemporary Cardiology</i> , 2023, , 1043-1070.	0.1	0
2936	Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110742.	2.8	1
2937	Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM. <i>Contemporary Cardiology</i> , 2023, , 895-921.	0.1	0
2938	Predicting and preventing heart failure in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2023, 11, 607-624.	11.4	4
2940	Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease. <i>Pharmaceutics</i> , 2023, 15, 1858.	4.5	2
2941	Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection. <i>Journal of Korean Diabetes</i> , 2023, 24, 59-65.	0.3	0
2942	Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2023, 29, 1844-1862.	1.9	2
2944	The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists. , 0, , .		0
2945	2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	2
2946	Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. <i>Lancet Diabetes and Endocrinology</i> , the, 2023, 11, 644-656.	11.4	14
2947	Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients. <i>Heart and Vessels</i> , 0, , .	1.2	1
2948	Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2023, 46, 1807-1815.	8.6	4
2949	Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease-Pathophysiology and Translational Therapeutic Approaches. <i>Biomedicines</i> , 2023, 11, 2284.	3.2	0
2950	Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. <i>Diabetologia</i> , 2023, 66, 1832-1845.	6.3	3

#	ARTICLE	IF	CITATIONS
2951	2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal, 2023, 44, 4043-4140.	2.2	88
2952	Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes. The Cochrane Library, 2023, 2023, .	2.8	0
2953	Diabetes mellitus treatment. , 2023, , .		0
2954	Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 3560-3577.	4.4	3
2955	Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus. Journal of Diabetes, 0, , .	1.8	0
2956	The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?. American Journal of Cardiovascular Drugs, 0, , .	2.2	1
2957	Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study. Scientific Reports, 2023, 13, .	3.3	0
2958	Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 2023, 66, 1820-1831.	6.3	3
2959	Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?. Future Cardiology, 2023, 19, 301-312.	1.2	0
2960	Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262, 717-752.	1.9	2
2961	Measuring the Uptake of Pharmacoepidemiologic Research Through Qualitative Analysis of Citations: A Case Study from a Canadian Network of Researchers. Science and Technology Libraries, 0, , 1-16.	1.8	0
2962	Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial. BMC Medicine, 2023, 21, .	5.5	0
2963	The effect of Dipeptidyl peptidase 4 (DPP-4) inhibitors on hemoglobin level in diabetic kidney disease: A retrospective cohort study. Medicine (United States), 2023, 102, e34538.	1.0	0
2964	Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase). Expert Opinion on Drug Safety, 2024, 23, 247-255.	2.4	0
2965	Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus. Journal of Infection and Public Health, 2023, 16, 1709-1715.	4.1	0
2966	Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial. Diabetes, Obesity and Metabolism, 2023, 25, 3671-3681.	4.4	0
2967	Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI. Acta Diabetologica, 0, , .	2.5	0
2968	Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. Journal of the Royal Society of Medicine, 0, , .	2.0	3



#	ARTICLE	IF	CITATIONS
2969	Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease. Movement Disorders Clinical Practice, 2023, 10, 1659-1665.	1.5	1
2970	Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours. Frontiers in Endocrinology, 0, 14, .	3.5	0
2971	Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years. Presse Medicale, 2023, 52, 104178.	1.9	0
2974	Stratified analysis in comparative effectiveness studies that emulate randomized trials. Pharmacoepidemiology and Drug Safety, 2024, 33, .	1.9	0
2975	Management of Type 2 Diabetes Mellitus. , 0, , .		0
2976	The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists. Journal of Osteopathic Medicine, 2024, 124, 127-135.	0.8	0
2977	Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4. Biomedicines, 2023, 11, 3032.	3.2	0
2978	Diabetes Mellitus in Acute Coronary Syndrome. Life, 2023, 13, 2226.	2.4	0
2979	Rethinking the Impact and Management of Diabetes in Heart Failure Patients. Current Heart Failure Reports, 0, , .	3.3	0
2980	The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells. Biomedicines, 2023, 11, 3051.	3.2	1
2981	Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema. Cureus, 2023, , .	0.5	0
2982	Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes and Endocrinology, the, 2023, 11, 894.	11.4	0
2983	Drug Therapies for Diabetes. International Journal of Molecular Sciences, 2023, 24, 17147.	4.1	1
2984	10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetesâ€”2024</i>. Diabetes Care, 2024, 47, S179-S218.	8.6	8
2985	Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date. Expert Opinion on Pharmacotherapy, 2023, 24, 1937-1947.	1.8	0
2986	Expedient Synthesis of 6-Functionalized Azabicyclo[4.1.0]heptane Derivatives. ChemistrySelect, 2023, 8, .	1.5	0
2987	Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of <sc>SAVORâ€”TIMI</sc> 53, <sc>DECLAREâ€”TIMI</sc> 58 and <sc>CAMELLIAâ€”TIMI</sc> 61. European Journal of Heart Failure, 0, , .	7.1	1
2989	Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials. Journal of Nephrology, 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
2990	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
2991	Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review. Diabetologia, 2024, 67, 443-458.	6.3	0
2992	Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights. International Journal of Molecular Sciences, 2024, 25, 804.	4.1	1
2993	National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus. Diabetes Mellitus, 2023, 26, 619-625.	1.9	0
2998	Prusogliptin (<scp>DBPR108</scp>) monotherapy in treatmentâ€naÃve patients with type 2 diabetes: A randomized, doubleâ€blind, active and placeboâ€controlled, phase 3 study. Diabetes, Obesity and Metabolism, 2024, 26, 1321-1332.	4.4	0
2999	The entero-insular axis and metabolic syndrome. , 2024, , 173-186.		0
3000	Effect of Anagliptin on Vascular Injury in the Femoral Artery of Type 2 Diabetic Rats. Biological and Pharmaceutical Bulletin, 2024, 47, 204-212.	1.4	0
3001	Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-NaÃve Type 2 Diabetes Mellitus Patients. Diabetes and Metabolism Journal, 2024, 48, 253-264.	4.7	0
3002	A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications. European Journal of Medicinal Chemistry, 2024, 267, 116185.	5.5	0
3004	Natriuretic peptidesÂ€“Â€Biomarker companions through thick and thin. European Journal of Heart Failure, 2024, 26, 270-273.	7.1	0
3005	AntidiabÃ©ticos NÃ£o InsulÃ©nicos na Abordagem da Hiperglicemia nos Doentes Hospitalizados por DoenÃ§a Aguda NÃ£o CrÃ©tica. Acta Medica Portuguesa, 2024, 37, 207-214.	0.4	0
3006	Emerging role of antidiabetic drugs in cardiorenal protection. Frontiers in Pharmacology, 0, 15, .	3.5	0
3007	Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovascular Diabetology, 2024, 23, .	6.8	0
3008	Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiology, 2024, 9, 385.	6.1	0
3010	A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications. Heliyon, 2024, 10, e26863.	3.2	0
3011	Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies. Acta Diabetologica, 0, , .	2.5	0
3012	Cancer biology in diabetes update: Focusing on antidiabetic drugs. Journal of Diabetes Investigation, 2024, 15, 525-540.	2.4	0
3013	<scp>DPP</scp>â€4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. Physiological Reports, 2024, 12, .	1.7	0

#	ARTICLE	IF	CITATIONS
3014	Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors. Journal of Inflammation Research, 0, Volume 17, 1897-1917.	3.5	0
3015	CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovascular Diabetology, 2024, 23, .	6.8	0
3016	JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease. Circulation Journal, 2024, 88, 763-842.	1.6	0
3017	Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2024, 13, 1797.	2.4	0